#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=The major depressive disorder GWAS-supported variant rs10514299 in TMEM161B-MEF2C predicts putamen activation during reward processing in alcohol dependence
#Text=Alcohol dependence (AD) frequently co-occurs with major depressive disorder (MDD).
1-1	0-3	The	_
1-2	4-9	major	_
1-3	10-20	depressive	_
1-4	21-29	disorder	_
1-5	30-44	GWAS-supported	_
1-6	45-52	variant	_
1-7	53-63	rs10514299	_
1-8	64-66	in	_
1-9	67-81	TMEM161B-MEF2C	_
1-10	82-90	predicts	_
1-11	91-98	putamen	_
1-12	99-109	activation	_
1-13	110-116	during	_
1-14	117-123	reward	_
1-15	124-134	processing	_
1-16	135-137	in	_
1-17	138-145	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]
1-18	146-156	dependence	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]
1-19	157-164	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]
1-20	165-175	dependence	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]
1-21	176-177	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]
1-22	177-179	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]
1-23	179-180	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[2]
1-24	181-191	frequently	_
1-25	192-201	co-occurs	_
1-26	202-206	with	_
1-27	207-212	major	_
1-28	213-223	depressive	_
1-29	224-232	disorder	_
1-30	233-234	(	_
1-31	234-237	MDD	_
1-32	237-238	)	_
1-33	238-239	.	_

#Text=While this comorbidity is associated with an increase in disease burden, worse treatment outcomes, and greater economic costs, the underlying neurobiology remains poorly understood.
2-1	240-245	While	_
2-2	246-250	this	_
2-3	251-262	comorbidity	_
2-4	263-265	is	_
2-5	266-276	associated	_
2-6	277-281	with	_
2-7	282-284	an	_
2-8	285-293	increase	_
2-9	294-296	in	_
2-10	297-304	disease	_
2-11	305-311	burden	_
2-12	311-312	,	_
2-13	313-318	worse	_
2-14	319-328	treatment	_
2-15	329-337	outcomes	_
2-16	337-338	,	_
2-17	339-342	and	_
2-18	343-350	greater	_
2-19	351-359	economic	_
2-20	360-365	costs	_
2-21	365-366	,	_
2-22	367-370	the	_
2-23	371-381	underlying	_
2-24	382-394	neurobiology	_
2-25	395-402	remains	_
2-26	403-409	poorly	_
2-27	410-420	understood	_
2-28	420-421	.	_

#Text=A recent large-scale GWAS of MDD has identified a locus in the TMEM161B-MEF2C region (rs10514299) as a novel risk variant; however, the biological relevance of this variant has not yet been studied.
3-1	422-423	A	_
3-2	424-430	recent	_
3-3	431-442	large-scale	_
3-4	443-447	GWAS	_
3-5	448-450	of	_
3-6	451-454	MDD	_
3-7	455-458	has	_
3-8	459-469	identified	_
3-9	470-471	a	_
3-10	472-477	locus	_
3-11	478-480	in	_
3-12	481-484	the	_
3-13	485-499	TMEM161B-MEF2C	_
3-14	500-506	region	_
3-15	507-508	(	_
3-16	508-518	rs10514299	_
3-17	518-519	)	_
3-18	520-522	as	_
3-19	523-524	a	_
3-20	525-530	novel	_
3-21	531-535	risk	_
3-22	536-543	variant	_
3-23	543-544	;	_
3-24	545-552	however	_
3-25	552-553	,	_
3-26	554-557	the	_
3-27	558-568	biological	_
3-28	569-578	relevance	_
3-29	579-581	of	_
3-30	582-586	this	_
3-31	587-594	variant	_
3-32	595-598	has	_
3-33	599-602	not	_
3-34	603-606	yet	_
3-35	607-611	been	_
3-36	612-619	studied	_
3-37	619-620	.	_

#Text=Given previous reports of disrupted reward processing in both AD and MDD, we hypothesized that rs10514299 would be associated with differences in striatal BOLD responses during reward/loss anticipation in AD.
4-1	621-626	Given	_
4-2	627-635	previous	_
4-3	636-643	reports	_
4-4	644-646	of	_
4-5	647-656	disrupted	_
4-6	657-663	reward	_
4-7	664-674	processing	_
4-8	675-677	in	_
4-9	678-682	both	_
4-10	683-685	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
4-11	686-689	and	_
4-12	690-693	MDD	_
4-13	693-694	,	_
4-14	695-697	we	_
4-15	698-710	hypothesized	_
4-16	711-715	that	_
4-17	716-726	rs10514299	_
4-18	727-732	would	_
4-19	733-735	be	_
4-20	736-746	associated	_
4-21	747-751	with	_
4-22	752-763	differences	_
4-23	764-766	in	_
4-24	767-775	striatal	_
4-25	776-780	BOLD	_
4-26	781-790	responses	_
4-27	791-797	during	_
4-28	798-804	reward	_
4-29	804-805	/	_
4-30	805-809	loss	_
4-31	810-822	anticipation	_
4-32	823-825	in	_
4-33	826-828	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
4-34	828-829	.	_

#Text=DNA samples from 45 recently detoxified patients with AD and 45 healthy controls (HC) were genotyped for rs10514299.
5-1	830-833	DNA	_
5-2	834-841	samples	_
5-3	842-846	from	_
5-4	847-849	45	_
5-5	850-858	recently	_
5-6	859-869	detoxified	_
5-7	870-878	patients	_
5-8	879-883	with	_
5-9	884-886	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
5-10	887-890	and	_
5-11	891-893	45	_
5-12	894-901	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]
5-13	902-910	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]
5-14	911-912	(	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]
5-15	912-914	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]
5-16	914-915	)	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]
5-17	916-920	were	_
5-18	921-930	genotyped	_
5-19	931-934	for	_
5-20	935-945	rs10514299	_
5-21	945-946	.	_

#Text=Participants performed the Monetary Incentive Delay task in a 3-Tesla MRI scanner.
6-1	947-959	Participants	_
6-2	960-969	performed	_
6-3	970-973	the	_
6-4	974-982	Monetary	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]
6-5	983-992	Incentive	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]
6-6	993-998	Delay	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]
6-7	999-1003	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]
6-8	1004-1006	in	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]
6-9	1007-1008	a	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]
6-10	1009-1010	3	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]
6-11	1010-1011	-	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]
6-12	1011-1016	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]
6-13	1017-1020	MRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]
6-14	1021-1028	scanner	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]
6-15	1028-1029	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[4]

#Text=Effects of rs10514299 on striatal activation during anticipation of high/low reward/loss were investigated.
7-1	1030-1037	Effects	_
7-2	1038-1040	of	_
7-3	1041-1051	rs10514299	_
7-4	1052-1054	on	_
7-5	1055-1063	striatal	_
7-6	1064-1074	activation	_
7-7	1075-1081	during	_
7-8	1082-1094	anticipation	_
7-9	1095-1097	of	_
7-10	1098-1102	high	_
7-11	1102-1103	/	_
7-12	1103-1106	low	_
7-13	1107-1113	reward	_
7-14	1113-1114	/	_
7-15	1114-1118	loss	_
7-16	1119-1123	were	_
7-17	1124-1136	investigated	_
7-18	1136-1137	.	_

#Text=Furthermore, we examined associations between rs10514299 and lifetime AD diagnosis in two independent clinical samples [NIAAA: n = 1858 (1123 cases, 735 controls); SAGE: n = 3838 (1848 cases, 1990 controls)], as well as its association with depression severity in a subsample of individuals with a lifetime AD diagnosis (n = 953).
8-1	1138-1149	Furthermore	_
8-2	1149-1150	,	_
8-3	1151-1153	we	_
8-4	1154-1162	examined	_
8-5	1163-1175	associations	_
8-6	1176-1183	between	_
8-7	1184-1194	rs10514299	_
8-8	1195-1198	and	_
8-9	1199-1207	lifetime	_
8-10	1208-1210	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
8-11	1211-1220	diagnosis	_
8-12	1221-1223	in	_
8-13	1224-1227	two	_
8-14	1228-1239	independent	_
8-15	1240-1248	clinical	_
8-16	1249-1256	samples	_
8-17	1257-1258	[	_
8-18	1258-1263	NIAAA	_
8-19	1263-1264	:	_
8-20	1265-1266	n	_
8-21	1267-1268	=	_
8-22	1269-1273	1858	_
8-23	1274-1275	(	_
8-24	1275-1279	1123	_
8-25	1280-1285	cases	_
8-26	1285-1286	,	_
8-27	1287-1290	735	_
8-28	1291-1299	controls	_
8-29	1299-1300	)	_
8-30	1300-1301	;	_
8-31	1302-1306	SAGE	_
8-32	1306-1307	:	_
8-33	1308-1309	n	_
8-34	1310-1311	=	_
8-35	1312-1316	3838	_
8-36	1317-1318	(	_
8-37	1318-1322	1848	_
8-38	1323-1328	cases	_
8-39	1328-1329	,	_
8-40	1330-1334	1990	_
8-41	1335-1343	controls	_
8-42	1343-1344	)	_
8-43	1344-1345	]	_
8-44	1345-1346	,	_
8-45	1347-1349	as	_
8-46	1350-1354	well	_
8-47	1355-1357	as	_
8-48	1358-1361	its	_
8-49	1362-1373	association	_
8-50	1374-1378	with	_
8-51	1379-1389	depression	_
8-52	1390-1398	severity	_
8-53	1399-1401	in	_
8-54	1402-1403	a	_
8-55	1404-1413	subsample	_
8-56	1414-1416	of	_
8-57	1417-1428	individuals	_
8-58	1429-1433	with	_
8-59	1434-1435	a	_
8-60	1436-1444	lifetime	_
8-61	1445-1447	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
8-62	1448-1457	diagnosis	_
8-63	1458-1459	(	_
8-64	1459-1460	n	_
8-65	1461-1462	=	_
8-66	1463-1466	953	_
8-67	1466-1467	)	_
8-68	1467-1468	.	_

#Text=Patients carrying the T allele showed significantly greater putamen activation during anticipation of high reward (p = 0.014), low reward (at trend-level; p = 0.081), high loss (p = 0.024), and low loss (p = 0.046) compared to HCs.
9-1	1469-1477	Patients	_
9-2	1478-1486	carrying	_
9-3	1487-1490	the	_
9-4	1491-1492	T	_
9-5	1493-1499	allele	_
9-6	1500-1506	showed	_
9-7	1507-1520	significantly	_
9-8	1521-1528	greater	_
9-9	1529-1536	putamen	_
9-10	1537-1547	activation	_
9-11	1548-1554	during	_
9-12	1555-1567	anticipation	_
9-13	1568-1570	of	_
9-14	1571-1575	high	_
9-15	1576-1582	reward	_
9-16	1583-1584	(	_
9-17	1584-1585	p	_
9-18	1586-1587	=	_
9-19	1588-1593	0.014	_
9-20	1593-1594	)	_
9-21	1594-1595	,	_
9-22	1596-1599	low	_
9-23	1600-1606	reward	_
9-24	1607-1608	(	_
9-25	1608-1610	at	_
9-26	1611-1622	trend-level	_
9-27	1622-1623	;	_
9-28	1624-1625	p	_
9-29	1626-1627	=	_
9-30	1628-1633	0.081	_
9-31	1633-1634	)	_
9-32	1634-1635	,	_
9-33	1636-1640	high	_
9-34	1641-1645	loss	_
9-35	1646-1647	(	_
9-36	1647-1648	p	_
9-37	1649-1650	=	_
9-38	1651-1656	0.024	_
9-39	1656-1657	)	_
9-40	1657-1658	,	_
9-41	1659-1662	and	_
9-42	1663-1666	low	_
9-43	1667-1671	loss	_
9-44	1672-1673	(	_
9-45	1673-1674	p	_
9-46	1675-1676	=	_
9-47	1677-1682	0.046	_
9-48	1682-1683	)	_
9-49	1684-1692	compared	_
9-50	1693-1695	to	_
9-51	1696-1699	HCs	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
9-52	1699-1700	.	_

#Text=Association analyses in the NIAAA sample showed a trend-level relationship between rs10514299 and a lifetime AD diagnosis in the European American subgroup (odds ratio = 0.82, p = 0.09).
10-1	1701-1712	Association	_
10-2	1713-1721	analyses	_
10-3	1722-1724	in	_
10-4	1725-1728	the	_
10-5	1729-1734	NIAAA	_
10-6	1735-1741	sample	_
10-7	1742-1748	showed	_
10-8	1749-1750	a	_
10-9	1751-1762	trend-level	_
10-10	1763-1775	relationship	_
10-11	1776-1783	between	_
10-12	1784-1794	rs10514299	_
10-13	1795-1798	and	_
10-14	1799-1800	a	_
10-15	1801-1809	lifetime	_
10-16	1810-1812	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
10-17	1813-1822	diagnosis	_
10-18	1823-1825	in	_
10-19	1826-1829	the	_
10-20	1830-1838	European	_
10-21	1839-1847	American	_
10-22	1848-1856	subgroup	_
10-23	1857-1858	(	_
10-24	1858-1862	odds	_
10-25	1863-1868	ratio	_
10-26	1869-1870	=	_
10-27	1871-1875	0.82	_
10-28	1875-1876	,	_
10-29	1877-1878	p	_
10-30	1879-1880	=	_
10-31	1881-1885	0.09	_
10-32	1885-1886	)	_
10-33	1886-1887	.	_

#Text=This finding was not replicated in the SAGE sample.
11-1	1888-1892	This	_
11-2	1893-1900	finding	_
11-3	1901-1904	was	_
11-4	1905-1908	not	_
11-5	1909-1919	replicated	_
11-6	1920-1922	in	_
11-7	1923-1926	the	_
11-8	1927-1931	SAGE	_
11-9	1932-1938	sample	_
11-10	1938-1939	.	_

#Text=In the NIAAA sample, the T allele was significantly associated with greater depression symptom severity in individuals with a lifetime AD diagnosis (β = 1.25, p = 0.02); this association was driven by the African American ancestry subgroup (β = 2.11, p = 0.008).
12-1	1940-1942	In	_
12-2	1943-1946	the	_
12-3	1947-1952	NIAAA	_
12-4	1953-1959	sample	_
12-5	1959-1960	,	_
12-6	1961-1964	the	_
12-7	1965-1966	T	_
12-8	1967-1973	allele	_
12-9	1974-1977	was	_
12-10	1978-1991	significantly	_
12-11	1992-2002	associated	_
12-12	2003-2007	with	_
12-13	2008-2015	greater	_
12-14	2016-2026	depression	_
12-15	2027-2034	symptom	_
12-16	2035-2043	severity	_
12-17	2044-2046	in	_
12-18	2047-2058	individuals	_
12-19	2059-2063	with	_
12-20	2064-2065	a	_
12-21	2066-2074	lifetime	_
12-22	2075-2077	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
12-23	2078-2087	diagnosis	_
12-24	2088-2089	(	_
12-25	2089-2090	β	_
12-26	2091-2092	=	_
12-27	2093-2097	1.25	_
12-28	2097-2098	,	_
12-29	2099-2100	p	_
12-30	2101-2102	=	_
12-31	2103-2107	0.02	_
12-32	2107-2108	)	_
12-33	2108-2109	;	_
12-34	2110-2114	this	_
12-35	2115-2126	association	_
12-36	2127-2130	was	_
12-37	2131-2137	driven	_
12-38	2138-2140	by	_
12-39	2141-2144	the	_
12-40	2145-2152	African	_
12-41	2153-2161	American	_
12-42	2162-2170	ancestry	_
12-43	2171-2179	subgroup	_
12-44	2180-2181	(	_
12-45	2181-2182	β	_
12-46	2183-2184	=	_
12-47	2185-2189	2.11	_
12-48	2189-2190	,	_
12-49	2191-2192	p	_
12-50	2193-2194	=	_
12-51	2195-2200	0.008	_
12-52	2200-2201	)	_
12-53	2201-2202	.	_

#Text=We show for the first time that the previously identified MDD risk variant rs10514299 in TMEM161B-MEF2C predicts neuronal correlates of reward processing in an AD phenotype, possibly explaining part of the shared pathophysiology and comorbidity between the disorders.
13-1	2203-2205	We	_
13-2	2206-2210	show	_
13-3	2211-2214	for	_
13-4	2215-2218	the	_
13-5	2219-2224	first	_
13-6	2225-2229	time	_
13-7	2230-2234	that	_
13-8	2235-2238	the	_
13-9	2239-2249	previously	_
13-10	2250-2260	identified	_
13-11	2261-2264	MDD	_
13-12	2265-2269	risk	_
13-13	2270-2277	variant	_
13-14	2278-2288	rs10514299	_
13-15	2289-2291	in	_
13-16	2292-2306	TMEM161B-MEF2C	_
13-17	2307-2315	predicts	_
13-18	2316-2324	neuronal	_
13-19	2325-2335	correlates	_
13-20	2336-2338	of	_
13-21	2339-2345	reward	_
13-22	2346-2356	processing	_
13-23	2357-2359	in	_
13-24	2360-2362	an	_
13-25	2363-2365	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
13-26	2366-2375	phenotype	_
13-27	2375-2376	,	_
13-28	2377-2385	possibly	_
13-29	2386-2396	explaining	_
13-30	2397-2401	part	_
13-31	2402-2404	of	_
13-32	2405-2408	the	_
13-33	2409-2415	shared	_
13-34	2416-2431	pathophysiology	_
13-35	2432-2435	and	_
13-36	2436-2447	comorbidity	_
13-37	2448-2455	between	_
13-38	2456-2459	the	_
13-39	2460-2469	disorders	_
13-40	2469-2470	.	_

#Text=Introduction
#Text=Alcohol dependence (AD) is a chronically relapsing disorder, characterized by a pattern of compulsive drinking that is maintained despite negative health, social, or occupational consequences.
14-1	2471-2483	Introduction	_
14-2	2484-2491	Alcohol	_
14-3	2492-2502	dependence	_
14-4	2503-2504	(	_
14-5	2504-2506	AD	_
14-6	2506-2507	)	_
14-7	2508-2510	is	_
14-8	2511-2512	a	_
14-9	2513-2524	chronically	_
14-10	2525-2534	relapsing	_
14-11	2535-2543	disorder	_
14-12	2543-2544	,	_
14-13	2545-2558	characterized	_
14-14	2559-2561	by	_
14-15	2562-2563	a	_
14-16	2564-2571	pattern	_
14-17	2572-2574	of	_
14-18	2575-2585	compulsive	_
14-19	2586-2594	drinking	_
14-20	2595-2599	that	_
14-21	2600-2602	is	_
14-22	2603-2613	maintained	_
14-23	2614-2621	despite	_
14-24	2622-2630	negative	_
14-25	2631-2637	health	_
14-26	2637-2638	,	_
14-27	2639-2645	social	_
14-28	2645-2646	,	_
14-29	2647-2649	or	_
14-30	2650-2662	occupational	_
14-31	2663-2675	consequences	_
14-32	2675-2676	.	_

#Text=Prevalence rates in the United States of America range from 4.1% in women to 7.8% in men.
15-1	2677-2687	Prevalence	_
15-2	2688-2693	rates	_
15-3	2694-2696	in	_
15-4	2697-2700	the	_
15-5	2701-2707	United	_
15-6	2708-2714	States	_
15-7	2715-2717	of	_
15-8	2718-2725	America	_
15-9	2726-2731	range	_
15-10	2732-2736	from	_
15-11	2737-2741	4.1%	_
15-12	2742-2744	in	_
15-13	2745-2750	women	_
15-14	2751-2753	to	_
15-15	2754-2758	7.8%	_
15-16	2759-2761	in	_
15-17	2762-2765	men	_
15-18	2765-2766	.	_

#Text=The etiology of AD is intricate with biological, environmental, and cognitive contributing factors.
16-1	2767-2770	The	_
16-2	2771-2779	etiology	_
16-3	2780-2782	of	_
16-4	2783-2785	AD	_
16-5	2786-2788	is	_
16-6	2789-2798	intricate	_
16-7	2799-2803	with	_
16-8	2804-2814	biological	_
16-9	2814-2815	,	_
16-10	2816-2829	environmental	_
16-11	2829-2830	,	_
16-12	2831-2834	and	_
16-13	2835-2844	cognitive	_
16-14	2845-2857	contributing	_
16-15	2858-2865	factors	_
16-16	2865-2866	.	_

#Text=AD frequently co-occurs with major depressive disorder (MDD).
17-1	2867-2869	AD	_
17-2	2870-2880	frequently	_
17-3	2881-2890	co-occurs	_
17-4	2891-2895	with	_
17-5	2896-2901	major	_
17-6	2902-2912	depressive	_
17-7	2913-2921	disorder	_
17-8	2922-2923	(	_
17-9	2923-2926	MDD	_
17-10	2926-2927	)	_
17-11	2927-2928	.	_

#Text=In one study, 20.48% of individuals who met DSM-IV criteria for AD also met criteria for MDD in the previous 12 months, indicating that the odds of MDD are 3.7 times greater for individuals with relative to those without a diagnosis of AD.
18-1	2929-2931	In	_
18-2	2932-2935	one	_
18-3	2936-2941	study	_
18-4	2941-2942	,	_
18-5	2943-2949	20.48%	_
18-6	2950-2952	of	_
18-7	2953-2964	individuals	_
18-8	2965-2968	who	_
18-9	2969-2972	met	_
18-10	2973-2979	DSM-IV	_
18-11	2980-2988	criteria	_
18-12	2989-2992	for	_
18-13	2993-2995	AD	_
18-14	2996-3000	also	_
18-15	3001-3004	met	_
18-16	3005-3013	criteria	_
18-17	3014-3017	for	_
18-18	3018-3021	MDD	_
18-19	3022-3024	in	_
18-20	3025-3028	the	_
18-21	3029-3037	previous	_
18-22	3038-3040	12	_
18-23	3041-3047	months	_
18-24	3047-3048	,	_
18-25	3049-3059	indicating	_
18-26	3060-3064	that	_
18-27	3065-3068	the	_
18-28	3069-3073	odds	_
18-29	3074-3076	of	_
18-30	3077-3080	MDD	_
18-31	3081-3084	are	_
18-32	3085-3088	3.7	_
18-33	3089-3094	times	_
18-34	3095-3102	greater	_
18-35	3103-3106	for	_
18-36	3107-3118	individuals	_
18-37	3119-3123	with	_
18-38	3124-3132	relative	_
18-39	3133-3135	to	_
18-40	3136-3141	those	_
18-41	3142-3149	without	_
18-42	3150-3151	a	_
18-43	3152-3161	diagnosis	_
18-44	3162-3164	of	_
18-45	3165-3167	AD	_
18-46	3167-3168	.	_

#Text=Subclinical levels of depressive symptoms are experienced by an even larger percentage of patients with AD (80%).
19-1	3169-3180	Subclinical	_
19-2	3181-3187	levels	_
19-3	3188-3190	of	_
19-4	3191-3201	depressive	_
19-5	3202-3210	symptoms	_
19-6	3211-3214	are	_
19-7	3215-3226	experienced	_
19-8	3227-3229	by	_
19-9	3230-3232	an	_
19-10	3233-3237	even	_
19-11	3238-3244	larger	_
19-12	3245-3255	percentage	_
19-13	3256-3258	of	_
19-14	3259-3267	patients	_
19-15	3268-3272	with	_
19-16	3273-3275	AD	_
19-17	3276-3277	(	_
19-18	3277-3280	80%	_
19-19	3280-3281	)	_
19-20	3281-3282	.	_

#Text=This comorbidity significantly increases the disease burden compared to each of the disorders alone.
20-1	3283-3287	This	_
20-2	3288-3299	comorbidity	_
20-3	3300-3313	significantly	_
20-4	3314-3323	increases	_
20-5	3324-3327	the	_
20-6	3328-3335	disease	_
20-7	3336-3342	burden	_
20-8	3343-3351	compared	_
20-9	3352-3354	to	_
20-10	3355-3359	each	_
20-11	3360-3362	of	_
20-12	3363-3366	the	_
20-13	3367-3376	disorders	_
20-14	3377-3382	alone	_
20-15	3382-3383	.	_

#Text=Moreover, it negatively affects treatment outcomes, which further increases economic losses; therefore, improving our understanding of the genetic underpinnings and neurobiological networks involved is important and may be a crucial step towards the development of novel prevention and treatment strategies.
21-1	3384-3392	Moreover	_
21-2	3392-3393	,	_
21-3	3394-3396	it	_
21-4	3397-3407	negatively	_
21-5	3408-3415	affects	_
21-6	3416-3425	treatment	_
21-7	3426-3434	outcomes	_
21-8	3434-3435	,	_
21-9	3436-3441	which	_
21-10	3442-3449	further	_
21-11	3450-3459	increases	_
21-12	3460-3468	economic	_
21-13	3469-3475	losses	_
21-14	3475-3476	;	_
21-15	3477-3486	therefore	_
21-16	3486-3487	,	_
21-17	3488-3497	improving	_
21-18	3498-3501	our	_
21-19	3502-3515	understanding	_
21-20	3516-3518	of	_
21-21	3519-3522	the	_
21-22	3523-3530	genetic	_
21-23	3531-3544	underpinnings	_
21-24	3545-3548	and	_
21-25	3549-3564	neurobiological	_
21-26	3565-3573	networks	_
21-27	3574-3582	involved	_
21-28	3583-3585	is	_
21-29	3586-3595	important	_
21-30	3596-3599	and	_
21-31	3600-3603	may	_
21-32	3604-3606	be	_
21-33	3607-3608	a	_
21-34	3609-3616	crucial	_
21-35	3617-3621	step	_
21-36	3622-3629	towards	_
21-37	3630-3633	the	_
21-38	3634-3645	development	_
21-39	3646-3648	of	_
21-40	3649-3654	novel	_
21-41	3655-3665	prevention	_
21-42	3666-3669	and	_
21-43	3670-3679	treatment	_
21-44	3680-3690	strategies	_
21-45	3690-3691	.	_

#Text=Both AD and MDD have substantial genetic contributions with heritability estimates of 50–60% for AD and 30–40% for MDD.
22-1	3692-3696	Both	_
22-2	3697-3699	AD	_
22-3	3700-3703	and	_
22-4	3704-3707	MDD	_
22-5	3708-3712	have	_
22-6	3713-3724	substantial	_
22-7	3725-3732	genetic	_
22-8	3733-3746	contributions	_
22-9	3747-3751	with	_
22-10	3752-3764	heritability	_
22-11	3765-3774	estimates	_
22-12	3775-3777	of	_
22-13	3778-3780	50	_
22-14	3780-3781	–	_
22-15	3781-3784	60%	_
22-16	3785-3788	for	_
22-17	3789-3791	AD	_
22-18	3792-3795	and	_
22-19	3796-3798	30	_
22-20	3798-3799	–	_
22-21	3799-3802	40%	_
22-22	3803-3806	for	_
22-23	3807-3810	MDD	_
22-24	3810-3811	.	_

#Text=A recent genome-wide association study (GWAS) found a genetic risk variant at the semaphorin 3A locus (SEMA3A) to be significantly associated with comorbid AD and MDD in African American but not European American individuals and concluded that further studies are needed to improve our understanding of the genetic underpinnings of this comorbidity.
23-1	3812-3813	A	_
23-2	3814-3820	recent	_
23-3	3821-3832	genome-wide	_
23-4	3833-3844	association	_
23-5	3845-3850	study	_
23-6	3851-3852	(	_
23-7	3852-3856	GWAS	_
23-8	3856-3857	)	_
23-9	3858-3863	found	_
23-10	3864-3865	a	_
23-11	3866-3873	genetic	_
23-12	3874-3878	risk	_
23-13	3879-3886	variant	_
23-14	3887-3889	at	_
23-15	3890-3893	the	_
23-16	3894-3904	semaphorin	_
23-17	3905-3907	3A	_
23-18	3908-3913	locus	_
23-19	3914-3915	(	_
23-20	3915-3921	SEMA3A	_
23-21	3921-3922	)	_
23-22	3923-3925	to	_
23-23	3926-3928	be	_
23-24	3929-3942	significantly	_
23-25	3943-3953	associated	_
23-26	3954-3958	with	_
23-27	3959-3967	comorbid	_
23-28	3968-3970	AD	_
23-29	3971-3974	and	_
23-30	3975-3978	MDD	_
23-31	3979-3981	in	_
23-32	3982-3989	African	_
23-33	3990-3998	American	_
23-34	3999-4002	but	_
23-35	4003-4006	not	_
23-36	4007-4015	European	_
23-37	4016-4024	American	_
23-38	4025-4036	individuals	_
23-39	4037-4040	and	_
23-40	4041-4050	concluded	_
23-41	4051-4055	that	_
23-42	4056-4063	further	_
23-43	4064-4071	studies	_
23-44	4072-4075	are	_
23-45	4076-4082	needed	_
23-46	4083-4085	to	_
23-47	4086-4093	improve	_
23-48	4094-4097	our	_
23-49	4098-4111	understanding	_
23-50	4112-4114	of	_
23-51	4115-4118	the	_
23-52	4119-4126	genetic	_
23-53	4127-4140	underpinnings	_
23-54	4141-4143	of	_
23-55	4144-4148	this	_
23-56	4149-4160	comorbidity	_
23-57	4160-4161	.	_

#Text=While genetic studies of AD have not been able to identify universal risk variants so far, a recent MDD GWAS using more than 300,000 individuals identified 15 genetic risk loci.
24-1	4162-4167	While	_
24-2	4168-4175	genetic	_
24-3	4176-4183	studies	_
24-4	4184-4186	of	_
24-5	4187-4189	AD	_
24-6	4190-4194	have	_
24-7	4195-4198	not	_
24-8	4199-4203	been	_
24-9	4204-4208	able	_
24-10	4209-4211	to	_
24-11	4212-4220	identify	_
24-12	4221-4230	universal	_
24-13	4231-4235	risk	_
24-14	4236-4244	variants	_
24-15	4245-4247	so	_
24-16	4248-4251	far	_
24-17	4251-4252	,	_
24-18	4253-4254	a	_
24-19	4255-4261	recent	_
24-20	4262-4265	MDD	_
24-21	4266-4270	GWAS	_
24-22	4271-4276	using	_
24-23	4277-4281	more	_
24-24	4282-4286	than	_
24-25	4287-4294	300,000	_
24-26	4295-4306	individuals	_
24-27	4307-4317	identified	_
24-28	4318-4320	15	_
24-29	4321-4328	genetic	_
24-30	4329-4333	risk	_
24-31	4334-4338	loci	_
24-32	4338-4339	.	_

#Text=The top locus in the joint meta-analysis and the independent replication sample was the single nucleotide polymorphism (SNP) rs10514299 within the TMEM161B-MEF2C gene cluster.
25-1	4340-4343	The	_
25-2	4344-4347	top	_
25-3	4348-4353	locus	_
25-4	4354-4356	in	_
25-5	4357-4360	the	_
25-6	4361-4366	joint	_
25-7	4367-4380	meta-analysis	_
25-8	4381-4384	and	_
25-9	4385-4388	the	_
25-10	4389-4400	independent	_
25-11	4401-4412	replication	_
25-12	4413-4419	sample	_
25-13	4420-4423	was	_
25-14	4424-4427	the	_
25-15	4428-4434	single	_
25-16	4435-4445	nucleotide	_
25-17	4446-4458	polymorphism	_
25-18	4459-4460	(	_
25-19	4460-4463	SNP	_
25-20	4463-4464	)	_
25-21	4465-4475	rs10514299	_
25-22	4476-4482	within	_
25-23	4483-4486	the	_
25-24	4487-4501	TMEM161B-MEF2C	_
25-25	4502-4506	gene	_
25-26	4507-4514	cluster	_
25-27	4514-4515	.	_

#Text=TMEM161B encodes the brain-expressed transmembrane protein 161B, and MEF2C encodes myocyte enhancer factor 2C, a transcription factor involved in brain development that has been associated with epilepsy, intellectual disability, and hyperkinesis; however, it remains unclear what the biological relevance of the rs10514299 variant is.
26-1	4516-4524	TMEM161B	_
26-2	4525-4532	encodes	_
26-3	4533-4536	the	_
26-4	4537-4552	brain-expressed	_
26-5	4553-4566	transmembrane	_
26-6	4567-4574	protein	_
26-7	4575-4579	161B	_
26-8	4579-4580	,	_
26-9	4581-4584	and	_
26-10	4585-4590	MEF2C	_
26-11	4591-4598	encodes	_
26-12	4599-4606	myocyte	_
26-13	4607-4615	enhancer	_
26-14	4616-4622	factor	_
26-15	4623-4625	2C	_
26-16	4625-4626	,	_
26-17	4627-4628	a	_
26-18	4629-4642	transcription	_
26-19	4643-4649	factor	_
26-20	4650-4658	involved	_
26-21	4659-4661	in	_
26-22	4662-4667	brain	_
26-23	4668-4679	development	_
26-24	4680-4684	that	_
26-25	4685-4688	has	_
26-26	4689-4693	been	_
26-27	4694-4704	associated	_
26-28	4705-4709	with	_
26-29	4710-4718	epilepsy	_
26-30	4718-4719	,	_
26-31	4720-4732	intellectual	_
26-32	4733-4743	disability	_
26-33	4743-4744	,	_
26-34	4745-4748	and	_
26-35	4749-4761	hyperkinesis	_
26-36	4761-4762	;	_
26-37	4763-4770	however	_
26-38	4770-4771	,	_
26-39	4772-4774	it	_
26-40	4775-4782	remains	_
26-41	4783-4790	unclear	_
26-42	4791-4795	what	_
26-43	4796-4799	the	_
26-44	4800-4810	biological	_
26-45	4811-4820	relevance	_
26-46	4821-4823	of	_
26-47	4824-4827	the	_
26-48	4828-4838	rs10514299	_
26-49	4839-4846	variant	_
26-50	4847-4849	is	_
26-51	4849-4850	.	_

#Text=One prominent clinical feature shared between both AD and MDD is anhedonia, a disruption in the ability to experience and regulate pleasure, which might be modulated by genetic variants.
27-1	4851-4854	One	_
27-2	4855-4864	prominent	_
27-3	4865-4873	clinical	_
27-4	4874-4881	feature	_
27-5	4882-4888	shared	_
27-6	4889-4896	between	_
27-7	4897-4901	both	_
27-8	4902-4904	AD	_
27-9	4905-4908	and	_
27-10	4909-4912	MDD	_
27-11	4913-4915	is	_
27-12	4916-4925	anhedonia	_
27-13	4925-4926	,	_
27-14	4927-4928	a	_
27-15	4929-4939	disruption	_
27-16	4940-4942	in	_
27-17	4943-4946	the	_
27-18	4947-4954	ability	_
27-19	4955-4957	to	_
27-20	4958-4968	experience	_
27-21	4969-4972	and	_
27-22	4973-4981	regulate	_
27-23	4982-4990	pleasure	_
27-24	4990-4991	,	_
27-25	4992-4997	which	_
27-26	4998-5003	might	_
27-27	5004-5006	be	_
27-28	5007-5016	modulated	_
27-29	5017-5019	by	_
27-30	5020-5027	genetic	_
27-31	5028-5036	variants	_
27-32	5036-5037	.	_

#Text=Clinical and preclinical research indicates that both disorders are associated with disruptions in the mesolimbic reward system, suggesting that its dysregulation might contribute to the comorbidity of AD and MDD.
28-1	5038-5046	Clinical	_
28-2	5047-5050	and	_
28-3	5051-5062	preclinical	_
28-4	5063-5071	research	_
28-5	5072-5081	indicates	_
28-6	5082-5086	that	_
28-7	5087-5091	both	_
28-8	5092-5101	disorders	_
28-9	5102-5105	are	_
28-10	5106-5116	associated	_
28-11	5117-5121	with	_
28-12	5122-5133	disruptions	_
28-13	5134-5136	in	_
28-14	5137-5140	the	_
28-15	5141-5151	mesolimbic	_
28-16	5152-5158	reward	_
28-17	5159-5165	system	_
28-18	5165-5166	,	_
28-19	5167-5177	suggesting	_
28-20	5178-5182	that	_
28-21	5183-5186	its	_
28-22	5187-5200	dysregulation	_
28-23	5201-5206	might	_
28-24	5207-5217	contribute	_
28-25	5218-5220	to	_
28-26	5221-5224	the	_
28-27	5225-5236	comorbidity	_
28-28	5237-5239	of	_
28-29	5240-5242	AD	_
28-30	5243-5246	and	_
28-31	5247-5250	MDD	_
28-32	5250-5251	.	_

#Text=Reward processes are an essential aspect of reward-based learning, specifically, the acquisition of stimulus-action-reward associations, which are crucial for advantageous decision-making and the selection of goal-directed behaviors.
29-1	5252-5258	Reward	_
29-2	5259-5268	processes	_
29-3	5269-5272	are	_
29-4	5273-5275	an	_
29-5	5276-5285	essential	_
29-6	5286-5292	aspect	_
29-7	5293-5295	of	_
29-8	5296-5308	reward-based	_
29-9	5309-5317	learning	_
29-10	5317-5318	,	_
29-11	5319-5331	specifically	_
29-12	5331-5332	,	_
29-13	5333-5336	the	_
29-14	5337-5348	acquisition	_
29-15	5349-5351	of	_
29-16	5352-5374	stimulus-action-reward	_
29-17	5375-5387	associations	_
29-18	5387-5388	,	_
29-19	5389-5394	which	_
29-20	5395-5398	are	_
29-21	5399-5406	crucial	_
29-22	5407-5410	for	_
29-23	5411-5423	advantageous	_
29-24	5424-5439	decision-making	_
29-25	5440-5443	and	_
29-26	5444-5447	the	_
29-27	5448-5457	selection	_
29-28	5458-5460	of	_
29-29	5461-5474	goal-directed	_
29-30	5475-5484	behaviors	_
29-31	5484-5485	.	_

#Text=The striatum is an important component of the underlying neurocircuitry.
30-1	5486-5489	The	_
30-2	5490-5498	striatum	_
30-3	5499-5501	is	_
30-4	5502-5504	an	_
30-5	5505-5514	important	_
30-6	5515-5524	component	_
30-7	5525-5527	of	_
30-8	5528-5531	the	_
30-9	5532-5542	underlying	_
30-10	5543-5557	neurocircuitry	_
30-11	5557-5558	.	_

#Text=Previous research demonstrates that the ventral striatum (i.e., nucleus accumbens) mediates the valuation of rewards and codes for reward prediction errors, while the dorsal striatum (caudate and putamen) appears to be crucial for stimulus-action-reward learning.
31-1	5559-5567	Previous	_
31-2	5568-5576	research	_
31-3	5577-5589	demonstrates	_
31-4	5590-5594	that	_
31-5	5595-5598	the	_
31-6	5599-5606	ventral	_
31-7	5607-5615	striatum	_
31-8	5616-5617	(	_
31-9	5617-5620	i.e	_
31-10	5620-5621	.	_
31-11	5621-5622	,	_
31-12	5623-5630	nucleus	_
31-13	5631-5640	accumbens	_
31-14	5640-5641	)	_
31-15	5642-5650	mediates	_
31-16	5651-5654	the	_
31-17	5655-5664	valuation	_
31-18	5665-5667	of	_
31-19	5668-5675	rewards	_
31-20	5676-5679	and	_
31-21	5680-5685	codes	_
31-22	5686-5689	for	_
31-23	5690-5696	reward	_
31-24	5697-5707	prediction	_
31-25	5708-5714	errors	_
31-26	5714-5715	,	_
31-27	5716-5721	while	_
31-28	5722-5725	the	_
31-29	5726-5732	dorsal	_
31-30	5733-5741	striatum	_
31-31	5742-5743	(	_
31-32	5743-5750	caudate	_
31-33	5751-5754	and	_
31-34	5755-5762	putamen	_
31-35	5762-5763	)	_
31-36	5764-5771	appears	_
31-37	5772-5774	to	_
31-38	5775-5777	be	_
31-39	5778-5785	crucial	_
31-40	5786-5789	for	_
31-41	5790-5812	stimulus-action-reward	_
31-42	5813-5821	learning	_
31-43	5821-5822	.	_

#Text=The ability to select appropriate behaviors based on available information about rewards and penalties influences an individual’s adaptability to new situations and whether or not desired outcomes can be achieved.
32-1	5823-5826	The	_
32-2	5827-5834	ability	_
32-3	5835-5837	to	_
32-4	5838-5844	select	_
32-5	5845-5856	appropriate	_
32-6	5857-5866	behaviors	_
32-7	5867-5872	based	_
32-8	5873-5875	on	_
32-9	5876-5885	available	_
32-10	5886-5897	information	_
32-11	5898-5903	about	_
32-12	5904-5911	rewards	_
32-13	5912-5915	and	_
32-14	5916-5925	penalties	_
32-15	5926-5936	influences	_
32-16	5937-5939	an	_
32-17	5940-5950	individual	_
32-18	5950-5951	’	_
32-19	5951-5952	s	_
32-20	5953-5965	adaptability	_
32-21	5966-5968	to	_
32-22	5969-5972	new	_
32-23	5973-5983	situations	_
32-24	5984-5987	and	_
32-25	5988-5995	whether	_
32-26	5996-5998	or	_
32-27	5999-6002	not	_
32-28	6003-6010	desired	_
32-29	6011-6019	outcomes	_
32-30	6020-6023	can	_
32-31	6024-6026	be	_
32-32	6027-6035	achieved	_
32-33	6035-6036	.	_

#Text=Therefore, there has been substantial interest in neural correlates of the anticipation of rewards/losses in substance use populations, including individuals with AD, where impaired decision-making (e.g., continued use despite adverse consequences) and alterations in sensitivity to rewards and punishments have been shown to contribute to alcohol use initiation, maintenance, and relapse.
33-1	6037-6046	Therefore	_
33-2	6046-6047	,	_
33-3	6048-6053	there	_
33-4	6054-6057	has	_
33-5	6058-6062	been	_
33-6	6063-6074	substantial	_
33-7	6075-6083	interest	_
33-8	6084-6086	in	_
33-9	6087-6093	neural	_
33-10	6094-6104	correlates	_
33-11	6105-6107	of	_
33-12	6108-6111	the	_
33-13	6112-6124	anticipation	_
33-14	6125-6127	of	_
33-15	6128-6135	rewards	_
33-16	6135-6136	/	_
33-17	6136-6142	losses	_
33-18	6143-6145	in	_
33-19	6146-6155	substance	_
33-20	6156-6159	use	_
33-21	6160-6171	populations	_
33-22	6171-6172	,	_
33-23	6173-6182	including	_
33-24	6183-6194	individuals	_
33-25	6195-6199	with	_
33-26	6200-6202	AD	_
33-27	6202-6203	,	_
33-28	6204-6209	where	_
33-29	6210-6218	impaired	_
33-30	6219-6234	decision-making	_
33-31	6235-6236	(	_
33-32	6236-6239	e.g	_
33-33	6239-6240	.	_
33-34	6240-6241	,	_
33-35	6242-6251	continued	_
33-36	6252-6255	use	_
33-37	6256-6263	despite	_
33-38	6264-6271	adverse	_
33-39	6272-6284	consequences	_
33-40	6284-6285	)	_
33-41	6286-6289	and	_
33-42	6290-6301	alterations	_
33-43	6302-6304	in	_
33-44	6305-6316	sensitivity	_
33-45	6317-6319	to	_
33-46	6320-6327	rewards	_
33-47	6328-6331	and	_
33-48	6332-6343	punishments	_
33-49	6344-6348	have	_
33-50	6349-6353	been	_
33-51	6354-6359	shown	_
33-52	6360-6362	to	_
33-53	6363-6373	contribute	_
33-54	6374-6376	to	_
33-55	6377-6384	alcohol	_
33-56	6385-6388	use	_
33-57	6389-6399	initiation	_
33-58	6399-6400	,	_
33-59	6401-6412	maintenance	_
33-60	6412-6413	,	_
33-61	6414-6417	and	_
33-62	6418-6425	relapse	_
33-63	6425-6426	.	_

#Text=The Monetary Incentive Delay (MID) task is a widely used and well-validated measure of reward processing in both healthy populations and those with substance use disorders, including AD.
34-1	6427-6430	The	_
34-2	6431-6439	Monetary	_
34-3	6440-6449	Incentive	_
34-4	6450-6455	Delay	_
34-5	6456-6457	(	_
34-6	6457-6460	MID	_
34-7	6460-6461	)	_
34-8	6462-6466	task	_
34-9	6467-6469	is	_
34-10	6470-6471	a	_
34-11	6472-6478	widely	_
34-12	6479-6483	used	_
34-13	6484-6487	and	_
34-14	6488-6502	well-validated	_
34-15	6503-6510	measure	_
34-16	6511-6513	of	_
34-17	6514-6520	reward	_
34-18	6521-6531	processing	_
34-19	6532-6534	in	_
34-20	6535-6539	both	_
34-21	6540-6547	healthy	_
34-22	6548-6559	populations	_
34-23	6560-6563	and	_
34-24	6564-6569	those	_
34-25	6570-6574	with	_
34-26	6575-6584	substance	_
34-27	6585-6588	use	_
34-28	6589-6598	disorders	_
34-29	6598-6599	,	_
34-30	6600-6609	including	_
34-31	6610-6612	AD	_
34-32	6612-6613	.	_

#Text=Functional neuroimaging studies using the MID task have demonstrated alterations in striatal responsiveness during reward/loss anticipation in individuals with AD, as well as MDD.
35-1	6614-6624	Functional	_
35-2	6625-6637	neuroimaging	_
35-3	6638-6645	studies	_
35-4	6646-6651	using	_
35-5	6652-6655	the	_
35-6	6656-6659	MID	_
35-7	6660-6664	task	_
35-8	6665-6669	have	_
35-9	6670-6682	demonstrated	_
35-10	6683-6694	alterations	_
35-11	6695-6697	in	_
35-12	6698-6706	striatal	_
35-13	6707-6721	responsiveness	_
35-14	6722-6728	during	_
35-15	6729-6735	reward	_
35-16	6735-6736	/	_
35-17	6736-6740	loss	_
35-18	6741-6753	anticipation	_
35-19	6754-6756	in	_
35-20	6757-6768	individuals	_
35-21	6769-6773	with	_
35-22	6774-6776	AD	_
35-23	6776-6777	,	_
35-24	6778-6780	as	_
35-25	6781-6785	well	_
35-26	6786-6788	as	_
35-27	6789-6792	MDD	_
35-28	6792-6793	.	_

#Text=The present study aimed to determine whether genetic variation in rs10514299 is associated with differences in blood-oxygen-level-dependent (BOLD) responses in the striatum (caudate, nucleus accumbens, putamen) during reward/loss anticipation, as assessed by the MID task in individuals with AD compared to healthy controls (HCs).
36-1	6794-6797	The	_
36-2	6798-6805	present	_
36-3	6806-6811	study	_
36-4	6812-6817	aimed	_
36-5	6818-6820	to	_
36-6	6821-6830	determine	_
36-7	6831-6838	whether	_
36-8	6839-6846	genetic	_
36-9	6847-6856	variation	_
36-10	6857-6859	in	_
36-11	6860-6870	rs10514299	_
36-12	6871-6873	is	_
36-13	6874-6884	associated	_
36-14	6885-6889	with	_
36-15	6890-6901	differences	_
36-16	6902-6904	in	_
36-17	6905-6933	blood-oxygen-level-dependent	_
36-18	6934-6935	(	_
36-19	6935-6939	BOLD	_
36-20	6939-6940	)	_
36-21	6941-6950	responses	_
36-22	6951-6953	in	_
36-23	6954-6957	the	_
36-24	6958-6966	striatum	_
36-25	6967-6968	(	_
36-26	6968-6975	caudate	_
36-27	6975-6976	,	_
36-28	6977-6984	nucleus	_
36-29	6985-6994	accumbens	_
36-30	6994-6995	,	_
36-31	6996-7003	putamen	_
36-32	7003-7004	)	_
36-33	7005-7011	during	_
36-34	7012-7018	reward	_
36-35	7018-7019	/	_
36-36	7019-7023	loss	_
36-37	7024-7036	anticipation	_
36-38	7036-7037	,	_
36-39	7038-7040	as	_
36-40	7041-7049	assessed	_
36-41	7050-7052	by	_
36-42	7053-7056	the	_
36-43	7057-7060	MID	_
36-44	7061-7065	task	_
36-45	7066-7068	in	_
36-46	7069-7080	individuals	_
36-47	7081-7085	with	_
36-48	7086-7088	AD	_
36-49	7089-7097	compared	_
36-50	7098-7100	to	_
36-51	7101-7108	healthy	_
36-52	7109-7117	controls	_
36-53	7118-7119	(	_
36-54	7119-7122	HCs	_
36-55	7122-7123	)	_
36-56	7123-7124	.	_

#Text=Secondary objectives were to test the hypotheses that genetic variation in rs10514299 would be associated (1) with a lifetime diagnosis of AD in a clinical sample (AD cases and controls) at the National Institute on Alcohol Abuse and Alcoholism (NIAAA Sample), as well as in a sample from the Study of Addiction: Genetics and Environment database (SAGE Sample); and (2) with scores on the Montgomery-Asberg Depression Rating (MADRS) scale in a subsample of the NIAAA Sample that reported a lifetime diagnosis of AD (Lifetime Alcohol Dependence Sample).
37-1	7125-7134	Secondary	_
37-2	7135-7145	objectives	_
37-3	7146-7150	were	_
37-4	7151-7153	to	_
37-5	7154-7158	test	_
37-6	7159-7162	the	_
37-7	7163-7173	hypotheses	_
37-8	7174-7178	that	_
37-9	7179-7186	genetic	_
37-10	7187-7196	variation	_
37-11	7197-7199	in	_
37-12	7200-7210	rs10514299	_
37-13	7211-7216	would	_
37-14	7217-7219	be	_
37-15	7220-7230	associated	_
37-16	7231-7232	(	_
37-17	7232-7233	1	_
37-18	7233-7234	)	_
37-19	7235-7239	with	_
37-20	7240-7241	a	_
37-21	7242-7250	lifetime	_
37-22	7251-7260	diagnosis	_
37-23	7261-7263	of	_
37-24	7264-7266	AD	_
37-25	7267-7269	in	_
37-26	7270-7271	a	_
37-27	7272-7280	clinical	_
37-28	7281-7287	sample	_
37-29	7288-7289	(	_
37-30	7289-7291	AD	_
37-31	7292-7297	cases	_
37-32	7298-7301	and	_
37-33	7302-7310	controls	_
37-34	7310-7311	)	_
37-35	7312-7314	at	_
37-36	7315-7318	the	_
37-37	7319-7327	National	_
37-38	7328-7337	Institute	_
37-39	7338-7340	on	_
37-40	7341-7348	Alcohol	_
37-41	7349-7354	Abuse	_
37-42	7355-7358	and	_
37-43	7359-7369	Alcoholism	_
37-44	7370-7371	(	_
37-45	7371-7376	NIAAA	_
37-46	7377-7383	Sample	_
37-47	7383-7384	)	_
37-48	7384-7385	,	_
37-49	7386-7388	as	_
37-50	7389-7393	well	_
37-51	7394-7396	as	_
37-52	7397-7399	in	_
37-53	7400-7401	a	_
37-54	7402-7408	sample	_
37-55	7409-7413	from	_
37-56	7414-7417	the	_
37-57	7418-7423	Study	_
37-58	7424-7426	of	_
37-59	7427-7436	Addiction	_
37-60	7436-7437	:	_
37-61	7438-7446	Genetics	_
37-62	7447-7450	and	_
37-63	7451-7462	Environment	_
37-64	7463-7471	database	_
37-65	7472-7473	(	_
37-66	7473-7477	SAGE	_
37-67	7478-7484	Sample	_
37-68	7484-7485	)	_
37-69	7485-7486	;	_
37-70	7487-7490	and	_
37-71	7491-7492	(	_
37-72	7492-7493	2	_
37-73	7493-7494	)	_
37-74	7495-7499	with	_
37-75	7500-7506	scores	_
37-76	7507-7509	on	_
37-77	7510-7513	the	_
37-78	7514-7531	Montgomery-Asberg	_
37-79	7532-7542	Depression	_
37-80	7543-7549	Rating	_
37-81	7550-7551	(	_
37-82	7551-7556	MADRS	_
37-83	7556-7557	)	_
37-84	7558-7563	scale	_
37-85	7564-7566	in	_
37-86	7567-7568	a	_
37-87	7569-7578	subsample	_
37-88	7579-7581	of	_
37-89	7582-7585	the	_
37-90	7586-7591	NIAAA	_
37-91	7592-7598	Sample	_
37-92	7599-7603	that	_
37-93	7604-7612	reported	_
37-94	7613-7614	a	_
37-95	7615-7623	lifetime	_
37-96	7624-7633	diagnosis	_
37-97	7634-7636	of	_
37-98	7637-7639	AD	_
37-99	7640-7641	(	_
37-100	7641-7649	Lifetime	_
37-101	7650-7657	Alcohol	_
37-102	7658-7668	Dependence	_
37-103	7669-7675	Sample	_
37-104	7675-7676	)	_
37-105	7676-7677	.	_

#Text=Materials and methods
#Text=Participants
#Text=Demographics and characteristics of the Neuroimaging Sample
#Text=\tAlcohol dependence N = 45\tHealthy controls N = 45\tp value\t \tGender\t\t\t0.004\t \t Male\t35 (77.8)\t22 (48.9)\t\t \t Female\t10 (22.2)\t23 (51.1)\t\t \tAge, mean years (SD)\t43.25 (10.73)\t36.30 (10.94)\t0.003\t \tEthnicity\t\t\t0.088\t \t Black/African American\t24 (53.3)\t18 (40.0)\t\t \t European American\t17 (37.8)\t16 (35.6)\t\t \t Asian\t0 (0.0)\t6 (13.3)\t\t \t Multiracial\t1 (2.2)\t3 (6.7)\t\t \t Unknown\t3 (6.7)\t2 (4.4)\t\t \tSmokers\t26 (57.8)\t0 (0.0)\t<0.0001\t \tRs10514299 Genotype\t \t CC\t35\t33\t0.624\t \t CT/TT\t10\t12\t\t \tAlcohol dependence severity score, mean (SD)\t19.68 (7.70) (N = 38)\t1.13 (2.25) (N = 31)\t<0.0001\t \tAverage number of drinking days in past 90 days, mean (SD)\t69.60 (25.19)\t18.76 (16.08)\t<0.0001\t \tNumber of heavy drinking days in past 90 days, mean (SD)\t59.49 (30.65)\t2.42 (7.19)\t<0.0001\t \tAverage number of drinks per drinking day, mean (SD)\t13.11 (8.84)\t1.80 (1.78)\t<0.0001\t \tMADRS Score, mean (SD)\t12.13 (10.21)\t0.87 (1.67)\t<0.0001\t \tAny anxiety disorder—current\t8 (9.0)\t1 (1.1)\t0.010\t \tAny anxiety disorder—lifetime\t11 (12.4)\t1 (1.1)\t0.002\t \tGeneralized anxiety disorder—current\t3 (3.4)\t1 (1.1)\t0.030\t \tGeneralized anxiety disorder—lifetime\t3 (3.4)\t1 (1.1)\t0.030\t \tPosttraumatic stress disorder—current\t2 (2.3)\t0 (0.0)\t0.150\t \tPosttraumatic stress disorder—lifetime\t2 (2.3)\t0 (0.0)\t0.150\t \tAny mood disorder—current\t5 (5.6)\t0 (0.0)\t0.020\t \tAny mood disorder—lifetime\t10 (11.2)\t8 (9.0)\t0.560\t \tMajor depressive disorder—current\t3 (3.4)\t0 (0.0)\t0.070\t \tMajor depressive disorder—lifetime\t9 (10.1)\t8 (9.0)\t0.750\t \t
#Text=Note.
38-1	7678-7687	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]
38-2	7688-7691	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]
38-3	7692-7699	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]
38-4	7700-7712	Participants	_
38-5	7713-7725	Demographics	_
38-6	7726-7729	and	_
38-7	7730-7745	characteristics	_
38-8	7746-7748	of	_
38-9	7749-7752	the	_
38-10	7753-7765	Neuroimaging	_
38-11	7766-7772	Sample	_
38-12	7774-7781	Alcohol	_
38-13	7782-7792	dependence	_
38-14	7793-7794	N	_
38-15	7795-7796	=	_
38-16	7797-7799	45	_
38-17	7800-7807	Healthy	_
38-18	7808-7816	controls	_
38-19	7817-7818	N	_
38-20	7819-7820	=	_
38-21	7821-7823	45	_
38-22	7824-7825	p	_
38-23	7826-7831	value	_
38-24	7834-7840	Gender	_
38-25	7843-7848	0.004	_
38-26	7852-7856	Male	_
38-27	7857-7859	35	_
38-28	7860-7861	(	_
38-29	7861-7865	77.8	_
38-30	7865-7866	)	_
38-31	7867-7869	22	_
38-32	7870-7871	(	_
38-33	7871-7875	48.9	_
38-34	7875-7876	)	_
38-35	7881-7887	Female	_
38-36	7888-7890	10	_
38-37	7891-7892	(	_
38-38	7892-7896	22.2	_
38-39	7896-7897	)	_
38-40	7898-7900	23	_
38-41	7901-7902	(	_
38-42	7902-7906	51.1	_
38-43	7906-7907	)	_
38-44	7911-7914	Age	_
38-45	7914-7915	,	_
38-46	7916-7920	mean	_
38-47	7921-7926	years	_
38-48	7927-7928	(	_
38-49	7928-7930	SD	_
38-50	7930-7931	)	_
38-51	7932-7937	43.25	_
38-52	7938-7939	(	_
38-53	7939-7944	10.73	_
38-54	7944-7945	)	_
38-55	7946-7951	36.30	_
38-56	7952-7953	(	_
38-57	7953-7958	10.94	_
38-58	7958-7959	)	_
38-59	7960-7965	0.003	_
38-60	7968-7977	Ethnicity	_
38-61	7980-7985	0.088	_
38-62	7989-7994	Black	_
38-63	7994-7995	/	_
38-64	7995-8002	African	_
38-65	8003-8011	American	_
38-66	8012-8014	24	_
38-67	8015-8016	(	_
38-68	8016-8020	53.3	_
38-69	8020-8021	)	_
38-70	8022-8024	18	_
38-71	8025-8026	(	_
38-72	8026-8030	40.0	_
38-73	8030-8031	)	_
38-74	8036-8044	European	_
38-75	8045-8053	American	_
38-76	8054-8056	17	_
38-77	8057-8058	(	_
38-78	8058-8062	37.8	_
38-79	8062-8063	)	_
38-80	8064-8066	16	_
38-81	8067-8068	(	_
38-82	8068-8072	35.6	_
38-83	8072-8073	)	_
38-84	8078-8083	Asian	_
38-85	8084-8085	0	_
38-86	8086-8087	(	_
38-87	8087-8090	0.0	_
38-88	8090-8091	)	_
38-89	8092-8093	6	_
38-90	8094-8095	(	_
38-91	8095-8099	13.3	_
38-92	8099-8100	)	_
38-93	8105-8116	Multiracial	_
38-94	8117-8118	1	_
38-95	8119-8120	(	_
38-96	8120-8123	2.2	_
38-97	8123-8124	)	_
38-98	8125-8126	3	_
38-99	8127-8128	(	_
38-100	8128-8131	6.7	_
38-101	8131-8132	)	_
38-102	8137-8144	Unknown	_
38-103	8145-8146	3	_
38-104	8147-8148	(	_
38-105	8148-8151	6.7	_
38-106	8151-8152	)	_
38-107	8153-8154	2	_
38-108	8155-8156	(	_
38-109	8156-8159	4.4	_
38-110	8159-8160	)	_
38-111	8164-8171	Smokers	_
38-112	8172-8174	26	_
38-113	8175-8176	(	_
38-114	8176-8180	57.8	_
38-115	8180-8181	)	_
38-116	8182-8183	0	_
38-117	8184-8185	(	_
38-118	8185-8188	0.0	_
38-119	8188-8189	)	_
38-120	8190-8191	<	_
38-121	8191-8197	0.0001	_
38-122	8200-8210	Rs10514299	_
38-123	8211-8219	Genotype	_
38-124	8223-8225	CC	_
38-125	8226-8228	35	_
38-126	8229-8231	33	_
38-127	8232-8237	0.624	_
38-128	8241-8243	CT	_
38-129	8243-8244	/	_
38-130	8244-8246	TT	_
38-131	8247-8249	10	_
38-132	8250-8252	12	_
38-133	8256-8263	Alcohol	_
38-134	8264-8274	dependence	_
38-135	8275-8283	severity	_
38-136	8284-8289	score	_
38-137	8289-8290	,	_
38-138	8291-8295	mean	_
38-139	8296-8297	(	_
38-140	8297-8299	SD	_
38-141	8299-8300	)	_
38-142	8301-8306	19.68	_
38-143	8307-8308	(	_
38-144	8308-8312	7.70	_
38-145	8312-8313	)	_
38-146	8314-8315	(	_
38-147	8315-8316	N	_
38-148	8317-8318	=	_
38-149	8319-8321	38	_
38-150	8321-8322	)	_
38-151	8323-8327	1.13	_
38-152	8328-8329	(	_
38-153	8329-8333	2.25	_
38-154	8333-8334	)	_
38-155	8335-8336	(	_
38-156	8336-8337	N	_
38-157	8338-8339	=	_
38-158	8340-8342	31	_
38-159	8342-8343	)	_
38-160	8344-8345	<	_
38-161	8345-8351	0.0001	_
38-162	8354-8361	Average	_
38-163	8362-8368	number	_
38-164	8369-8371	of	_
38-165	8372-8380	drinking	_
38-166	8381-8385	days	_
38-167	8386-8388	in	_
38-168	8389-8393	past	_
38-169	8394-8396	90	_
38-170	8397-8401	days	_
38-171	8401-8402	,	_
38-172	8403-8407	mean	_
38-173	8408-8409	(	_
38-174	8409-8411	SD	_
38-175	8411-8412	)	_
38-176	8413-8418	69.60	_
38-177	8419-8420	(	_
38-178	8420-8425	25.19	_
38-179	8425-8426	)	_
38-180	8427-8432	18.76	_
38-181	8433-8434	(	_
38-182	8434-8439	16.08	_
38-183	8439-8440	)	_
38-184	8441-8442	<	_
38-185	8442-8448	0.0001	_
38-186	8451-8457	Number	_
38-187	8458-8460	of	_
38-188	8461-8466	heavy	_
38-189	8467-8475	drinking	_
38-190	8476-8480	days	_
38-191	8481-8483	in	_
38-192	8484-8488	past	_
38-193	8489-8491	90	_
38-194	8492-8496	days	_
38-195	8496-8497	,	_
38-196	8498-8502	mean	_
38-197	8503-8504	(	_
38-198	8504-8506	SD	_
38-199	8506-8507	)	_
38-200	8508-8513	59.49	_
38-201	8514-8515	(	_
38-202	8515-8520	30.65	_
38-203	8520-8521	)	_
38-204	8522-8526	2.42	_
38-205	8527-8528	(	_
38-206	8528-8532	7.19	_
38-207	8532-8533	)	_
38-208	8534-8535	<	_
38-209	8535-8541	0.0001	_
38-210	8544-8551	Average	_
38-211	8552-8558	number	_
38-212	8559-8561	of	_
38-213	8562-8568	drinks	_
38-214	8569-8572	per	_
38-215	8573-8581	drinking	_
38-216	8582-8585	day	_
38-217	8585-8586	,	_
38-218	8587-8591	mean	_
38-219	8592-8593	(	_
38-220	8593-8595	SD	_
38-221	8595-8596	)	_
38-222	8597-8602	13.11	_
38-223	8603-8604	(	_
38-224	8604-8608	8.84	_
38-225	8608-8609	)	_
38-226	8610-8614	1.80	_
38-227	8615-8616	(	_
38-228	8616-8620	1.78	_
38-229	8620-8621	)	_
38-230	8622-8623	<	_
38-231	8623-8629	0.0001	_
38-232	8632-8637	MADRS	_
38-233	8638-8643	Score	_
38-234	8643-8644	,	_
38-235	8645-8649	mean	_
38-236	8650-8651	(	_
38-237	8651-8653	SD	_
38-238	8653-8654	)	_
38-239	8655-8660	12.13	_
38-240	8661-8662	(	_
38-241	8662-8667	10.21	_
38-242	8667-8668	)	_
38-243	8669-8673	0.87	_
38-244	8674-8675	(	_
38-245	8675-8679	1.67	_
38-246	8679-8680	)	_
38-247	8681-8682	<	_
38-248	8682-8688	0.0001	_
38-249	8691-8694	Any	_
38-250	8695-8702	anxiety	_
38-251	8703-8719	disorder—current	_
38-252	8720-8721	8	_
38-253	8722-8723	(	_
38-254	8723-8726	9.0	_
38-255	8726-8727	)	_
38-256	8728-8729	1	_
38-257	8730-8731	(	_
38-258	8731-8734	1.1	_
38-259	8734-8735	)	_
38-260	8736-8741	0.010	_
38-261	8744-8747	Any	_
38-262	8748-8755	anxiety	_
38-263	8756-8773	disorder—lifetime	_
38-264	8774-8776	11	_
38-265	8777-8778	(	_
38-266	8778-8782	12.4	_
38-267	8782-8783	)	_
38-268	8784-8785	1	_
38-269	8786-8787	(	_
38-270	8787-8790	1.1	_
38-271	8790-8791	)	_
38-272	8792-8797	0.002	_
38-273	8800-8811	Generalized	_
38-274	8812-8819	anxiety	_
38-275	8820-8836	disorder—current	_
38-276	8837-8838	3	_
38-277	8839-8840	(	_
38-278	8840-8843	3.4	_
38-279	8843-8844	)	_
38-280	8845-8846	1	_
38-281	8847-8848	(	_
38-282	8848-8851	1.1	_
38-283	8851-8852	)	_
38-284	8853-8858	0.030	_
38-285	8861-8872	Generalized	_
38-286	8873-8880	anxiety	_
38-287	8881-8898	disorder—lifetime	_
38-288	8899-8900	3	_
38-289	8901-8902	(	_
38-290	8902-8905	3.4	_
38-291	8905-8906	)	_
38-292	8907-8908	1	_
38-293	8909-8910	(	_
38-294	8910-8913	1.1	_
38-295	8913-8914	)	_
38-296	8915-8920	0.030	_
38-297	8923-8936	Posttraumatic	_
38-298	8937-8943	stress	_
38-299	8944-8960	disorder—current	_
38-300	8961-8962	2	_
38-301	8963-8964	(	_
38-302	8964-8967	2.3	_
38-303	8967-8968	)	_
38-304	8969-8970	0	_
38-305	8971-8972	(	_
38-306	8972-8975	0.0	_
38-307	8975-8976	)	_
38-308	8977-8982	0.150	_
38-309	8985-8998	Posttraumatic	_
38-310	8999-9005	stress	_
38-311	9006-9023	disorder—lifetime	_
38-312	9024-9025	2	_
38-313	9026-9027	(	_
38-314	9027-9030	2.3	_
38-315	9030-9031	)	_
38-316	9032-9033	0	_
38-317	9034-9035	(	_
38-318	9035-9038	0.0	_
38-319	9038-9039	)	_
38-320	9040-9045	0.150	_
38-321	9048-9051	Any	_
38-322	9052-9056	mood	_
38-323	9057-9073	disorder—current	_
38-324	9074-9075	5	_
38-325	9076-9077	(	_
38-326	9077-9080	5.6	_
38-327	9080-9081	)	_
38-328	9082-9083	0	_
38-329	9084-9085	(	_
38-330	9085-9088	0.0	_
38-331	9088-9089	)	_
38-332	9090-9095	0.020	_
38-333	9098-9101	Any	_
38-334	9102-9106	mood	_
38-335	9107-9124	disorder—lifetime	_
38-336	9125-9127	10	_
38-337	9128-9129	(	_
38-338	9129-9133	11.2	_
38-339	9133-9134	)	_
38-340	9135-9136	8	_
38-341	9137-9138	(	_
38-342	9138-9141	9.0	_
38-343	9141-9142	)	_
38-344	9143-9148	0.560	_
38-345	9151-9156	Major	_
38-346	9157-9167	depressive	_
38-347	9168-9184	disorder—current	_
38-348	9185-9186	3	_
38-349	9187-9188	(	_
38-350	9188-9191	3.4	_
38-351	9191-9192	)	_
38-352	9193-9194	0	_
38-353	9195-9196	(	_
38-354	9196-9199	0.0	_
38-355	9199-9200	)	_
38-356	9201-9206	0.070	_
38-357	9209-9214	Major	_
38-358	9215-9225	depressive	_
38-359	9226-9243	disorder—lifetime	_
38-360	9244-9245	9	_
38-361	9246-9247	(	_
38-362	9247-9251	10.1	_
38-363	9251-9252	)	_
38-364	9253-9254	8	_
38-365	9255-9256	(	_
38-366	9256-9259	9.0	_
38-367	9259-9260	)	_
38-368	9261-9266	0.750	_
38-369	9270-9274	Note	_
38-370	9274-9275	.	_

#Text=Boldface indicates a significant between-group difference.
39-1	9276-9284	Boldface	_
39-2	9285-9294	indicates	_
39-3	9295-9296	a	_
39-4	9297-9308	significant	_
39-5	9309-9322	between-group	_
39-6	9323-9333	difference	_
39-7	9333-9334	.	_

#Text=Numbers reported are N (%), unless stated otherwise.
40-1	9335-9342	Numbers	_
40-2	9343-9351	reported	_
40-3	9352-9355	are	_
40-4	9356-9357	N	_
40-5	9358-9359	(	_
40-6	9359-9360	%	_
40-7	9360-9361	)	_
40-8	9361-9362	,	_
40-9	9363-9369	unless	_
40-10	9370-9376	stated	_
40-11	9377-9386	otherwise	_
40-12	9386-9387	.	_

#Text=Ethnicity reported in this table was based on self-report.
41-1	9388-9397	Ethnicity	_
41-2	9398-9406	reported	_
41-3	9407-9409	in	_
41-4	9410-9414	this	_
41-5	9415-9420	table	_
41-6	9421-9424	was	_
41-7	9425-9430	based	_
41-8	9431-9433	on	_
41-9	9434-9445	self-report	_
41-10	9445-9446	.	_

#Text=Diagnoses are based on DSM-IV-TR and were assessed with the SCID-IV
#Text=MADRS Montgomery-Asberg Depression Rating Scale
#Text=The Neuroimaging Sample included 90 participants (45 AD and 45 HC) with a mean age of 39.78 (SD = 11.33; see Table 1).
42-1	9447-9456	Diagnoses	_
42-2	9457-9460	are	_
42-3	9461-9466	based	_
42-4	9467-9469	on	_
42-5	9470-9479	DSM-IV-TR	_
42-6	9480-9483	and	_
42-7	9484-9488	were	_
42-8	9489-9497	assessed	_
42-9	9498-9502	with	_
42-10	9503-9506	the	_
42-11	9507-9514	SCID-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder
42-12	9515-9520	MADRS	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale[6]
42-13	9521-9538	Montgomery-Asberg	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale[6]
42-14	9539-9549	Depression	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale[6]
42-15	9550-9556	Rating	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale[6]
42-16	9557-9562	Scale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale[6]
42-17	9563-9566	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-18	9567-9579	Neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-19	9580-9586	Sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-20	9587-9595	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-21	9596-9598	90	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-22	9599-9611	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-23	9612-9613	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-24	9613-9615	45	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-25	9616-9618	AD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[8]
42-26	9619-9622	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-27	9623-9625	45	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-28	9626-9628	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[9]
42-29	9628-9629	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-30	9630-9634	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-31	9635-9636	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-32	9637-9641	mean	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-33	9642-9645	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-34	9646-9648	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-35	9649-9654	39.78	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-36	9655-9656	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-37	9656-9658	SD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-38	9659-9660	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-39	9661-9666	11.33	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-40	9666-9667	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-41	9668-9671	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-42	9672-9677	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-43	9678-9679	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-44	9679-9680	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]
42-45	9680-9681	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[7]

#Text=Prior to study participation, participants in the Neuroimaging and NIAAA Sample provided informed written consent in accordance with the Declaration of Helsinki and as approved by the National Institute on Alcohol Abuse and Alcoholism Review Board.
43-1	9682-9687	Prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-2	9688-9690	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-3	9691-9696	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-4	9697-9710	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-5	9710-9711	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-6	9712-9724	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-7	9725-9727	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-8	9728-9731	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-9	9732-9744	Neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-10	9745-9748	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-11	9749-9754	NIAAA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-12	9755-9761	Sample	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-13	9762-9770	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-14	9771-9779	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-15	9780-9787	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-16	9788-9795	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-17	9796-9798	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-18	9799-9809	accordance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-19	9810-9814	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-20	9815-9818	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-21	9819-9830	Declaration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-22	9831-9833	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-23	9834-9842	Helsinki	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-24	9843-9846	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-25	9847-9849	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-26	9850-9858	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-27	9859-9861	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-28	9862-9865	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-29	9866-9874	National	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-30	9875-9884	Institute	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-31	9885-9887	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-32	9888-9895	Alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-33	9896-9901	Abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-34	9902-9905	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-35	9906-9916	Alcoholism	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-36	9917-9923	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-37	9924-9929	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
43-38	9929-9930	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]

#Text=All participants completed the Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID-IV).
44-1	9931-9934	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
44-2	9935-9947	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
44-3	9948-9957	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
44-4	9958-9961	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
44-5	9962-9972	Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[12]
44-6	9973-9981	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[12]
44-7	9982-9991	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[12]
44-8	9992-9995	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[12]
44-9	9996-10005	DSM-IV-TR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[12]
44-10	10006-10010	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[12]
44-11	10011-10012	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[12]
44-12	10013-10022	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[12]
44-13	10023-10024	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[12]
44-14	10024-10031	SCID-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[12]
44-15	10031-10032	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewfortheDiagnosticStatisticalManualofMentalDisorder[12]
44-16	10032-10033	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]

#Text=Given that DSM-5 criteria for alcohol use disorder are less stringent compared to DSM-IV criteria for AD, all individuals likely fall into the moderate/severe alcohol use disorder categories in DSM-5.
45-1	10034-10039	Given	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-2	10040-10044	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-3	10045-10048	DSM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-4	10048-10049	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-5	10049-10050	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-6	10051-10059	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-7	10060-10063	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-8	10064-10071	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-9	10072-10075	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-10	10076-10084	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-11	10085-10088	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-12	10089-10093	less	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-13	10094-10103	stringent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-14	10104-10112	compared	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-15	10113-10115	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-16	10116-10122	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-17	10123-10131	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-18	10132-10135	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-19	10136-10138	AD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[14]
45-20	10138-10139	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-21	10140-10143	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-22	10144-10155	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-23	10156-10162	likely	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-24	10163-10167	fall	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-25	10168-10172	into	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-26	10173-10176	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-27	10177-10185	moderate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-28	10185-10186	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-29	10186-10192	severe	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-30	10193-10200	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-31	10201-10204	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-32	10205-10213	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-33	10214-10224	categories	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-34	10225-10227	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-35	10228-10231	DSM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-36	10231-10232	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-37	10232-10233	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]
45-38	10233-10234	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]

#Text=Exclusion criteria included left-handedness, contraindications for MRI (e.g., claustrophobia or pregnancy), and the presence of any significant medical or neurological diagnoses as assessed by a history and physical exam.
46-1	10235-10244	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-2	10245-10253	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-3	10254-10262	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-4	10263-10278	left-handedness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-5	10278-10279	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-6	10280-10297	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-7	10298-10301	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-8	10302-10305	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-9	10306-10307	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-10	10307-10310	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-11	10310-10311	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-12	10311-10312	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-13	10313-10327	claustrophobia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-14	10328-10330	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-15	10331-10340	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-16	10340-10341	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-17	10341-10342	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-18	10343-10346	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-19	10347-10350	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-20	10351-10359	presence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-21	10360-10362	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-22	10363-10366	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-23	10367-10378	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-24	10379-10386	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-25	10387-10389	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-26	10390-10402	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-27	10403-10412	diagnoses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-28	10413-10415	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-29	10416-10424	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-30	10425-10427	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-31	10428-10429	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-32	10430-10437	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-33	10438-10441	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-34	10442-10450	physical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-35	10451-10455	exam	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
46-36	10455-10456	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]

#Text=Additional exclusion criteria for the HC group included DSM-IV-TR diagnoses of current/past AD, positive urine drug screens, and alcohol breathalyzer readings above zero.
47-1	10457-10467	Additional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-2	10468-10477	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-3	10478-10486	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-4	10487-10490	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-5	10491-10494	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-6	10495-10497	HC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[17]
47-7	10498-10503	group	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-8	10504-10512	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-9	10513-10522	DSM-IV-TR	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-10	10523-10532	diagnoses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-11	10533-10535	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-12	10536-10543	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-13	10543-10544	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-14	10544-10548	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-15	10549-10551	AD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[18]
47-16	10551-10552	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-17	10553-10561	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-18	10562-10567	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-19	10568-10572	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-20	10573-10580	screens	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-21	10580-10581	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-22	10582-10585	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-23	10586-10593	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-24	10594-10606	breathalyzer	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-25	10607-10615	readings	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-26	10616-10621	above	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-27	10622-10626	zero	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]
47-28	10626-10627	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]

#Text=FMRI scans were obtained while participants completed a modified version of the MID task where approximately 70% of trials were successful.
48-1	10628-10632	FMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
48-2	10633-10638	scans	_
48-3	10639-10643	were	_
48-4	10644-10652	obtained	_
48-5	10653-10658	while	_
48-6	10659-10671	participants	_
48-7	10672-10681	completed	_
48-8	10682-10683	a	_
48-9	10684-10692	modified	_
48-10	10693-10700	version	_
48-11	10701-10703	of	_
48-12	10704-10707	the	_
48-13	10708-10711	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]
48-14	10712-10716	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[19]
48-15	10717-10722	where	_
48-16	10723-10736	approximately	_
48-17	10737-10740	70%	_
48-18	10741-10743	of	_
48-19	10744-10750	trials	_
48-20	10751-10755	were	_
48-21	10756-10766	successful	_
48-22	10766-10767	.	_

#Text=Participants were not on any psychotropic medications on the day of the scan and there were no alcohol abstainers among the HC group.
49-1	10768-10780	Participants	_
49-2	10781-10785	were	_
49-3	10786-10789	not	_
49-4	10790-10792	on	_
49-5	10793-10796	any	_
49-6	10797-10809	psychotropic	_
49-7	10810-10821	medications	_
49-8	10822-10824	on	_
49-9	10825-10828	the	_
49-10	10829-10832	day	_
49-11	10833-10835	of	_
49-12	10836-10839	the	_
49-13	10840-10844	scan	_
49-14	10845-10848	and	_
49-15	10849-10854	there	_
49-16	10855-10859	were	_
49-17	10860-10862	no	_
49-18	10863-10870	alcohol	_
49-19	10871-10881	abstainers	_
49-20	10882-10887	among	_
49-21	10888-10891	the	_
49-22	10892-10894	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
49-23	10895-10900	group	_
49-24	10900-10901	.	_

#Text=DNA samples were obtained from all participants for genotyping.
50-1	10902-10905	DNA	_
50-2	10906-10913	samples	_
50-3	10914-10918	were	_
50-4	10919-10927	obtained	_
50-5	10928-10932	from	_
50-6	10933-10936	all	_
50-7	10937-10949	participants	_
50-8	10950-10953	for	_
50-9	10954-10964	genotyping	_
50-10	10964-10965	.	_

#Text=Demographics and characteristics of the NIAAA Sample and the Lifetime Alcohol Dependence Sample
#Text=\tNIAAA Sample N = 1858\tNIAAA subsample with lifetime AD\t \t\tCases N = 1123\tControls N = 735\tN = 955\t \tGender, N, (%)\t \t Male\t323 (28.8)\t325 (44.2)\t669 (70.0)\t \t Female\t800 (71.2)\t410 (55.8)\t286 (30.0)\t \tAge, mean years (SD)\t42.6 (10.9)\t32.8 (11.6)\t42.8 (10.8)\t \tEthnicity, N, (%)\t \t Black/African American\t507 (45.2)\t232 (31.6)\t439 (46.0)\t \t European American\t531 (47.3)\t411 (55.9)\t441 (46.1)\t \t Asian\t16 (1.4)\t47 (6.4)\t12 (1.3)\t \t Multiracial\t21 (1.9)\t20 (2.7)\t18 (1.9)\t \t Native American or Alaska Native\t5 (0.5)\t2 (0.3)\t5 (0.5)\t \t Native Hawaiian or other Pacific Islander\t1 (0.1)\t1 (0.1)\t1 (0.1)\t \t Unknown\t42 (3.7)\t22 (3.0)\t39 (4.1)\t \tSmokers, N, (%)\t662 (59.0)\t44 (6.1)\t595 (62.3)\t \tMADRS score, mean (SD)\t13.2 (9.8)\t1.3 (3.2)\t13.2 (9.8)\t \tMajor depressive disorder—current, N, (%)\t108 (5.8)\t8 (0.4)\t103 (10.8)\t \tMajor depressive disorder—lifetime, N, (%)\t216 (11.6)\t49 (2.6)\t196 (20.5)\t \t
#Text=Note.
51-1	10966-10978	Demographics	_
51-2	10979-10982	and	_
51-3	10983-10998	characteristics	_
51-4	10999-11001	of	_
51-5	11002-11005	the	_
51-6	11006-11011	NIAAA	_
51-7	11012-11018	Sample	_
51-8	11019-11022	and	_
51-9	11023-11026	the	_
51-10	11027-11035	Lifetime	_
51-11	11036-11043	Alcohol	_
51-12	11044-11054	Dependence	_
51-13	11055-11061	Sample	_
51-14	11063-11068	NIAAA	_
51-15	11069-11075	Sample	_
51-16	11076-11077	N	_
51-17	11078-11079	=	_
51-18	11080-11084	1858	_
51-19	11085-11090	NIAAA	_
51-20	11091-11100	subsample	_
51-21	11101-11105	with	_
51-22	11106-11114	lifetime	_
51-23	11115-11117	AD	_
51-24	11121-11126	Cases	_
51-25	11127-11128	N	_
51-26	11129-11130	=	_
51-27	11131-11135	1123	_
51-28	11136-11144	Controls	_
51-29	11145-11146	N	_
51-30	11147-11148	=	_
51-31	11149-11152	735	_
51-32	11153-11154	N	_
51-33	11155-11156	=	_
51-34	11157-11160	955	_
51-35	11163-11169	Gender	_
51-36	11169-11170	,	_
51-37	11171-11172	N	_
51-38	11172-11173	,	_
51-39	11174-11175	(	_
51-40	11175-11176	%	_
51-41	11176-11177	)	_
51-42	11181-11185	Male	_
51-43	11186-11189	323	_
51-44	11190-11191	(	_
51-45	11191-11195	28.8	_
51-46	11195-11196	)	_
51-47	11197-11200	325	_
51-48	11201-11202	(	_
51-49	11202-11206	44.2	_
51-50	11206-11207	)	_
51-51	11208-11211	669	_
51-52	11212-11213	(	_
51-53	11213-11217	70.0	_
51-54	11217-11218	)	_
51-55	11222-11228	Female	_
51-56	11229-11232	800	_
51-57	11233-11234	(	_
51-58	11234-11238	71.2	_
51-59	11238-11239	)	_
51-60	11240-11243	410	_
51-61	11244-11245	(	_
51-62	11245-11249	55.8	_
51-63	11249-11250	)	_
51-64	11251-11254	286	_
51-65	11255-11256	(	_
51-66	11256-11260	30.0	_
51-67	11260-11261	)	_
51-68	11264-11267	Age	_
51-69	11267-11268	,	_
51-70	11269-11273	mean	_
51-71	11274-11279	years	_
51-72	11280-11281	(	_
51-73	11281-11283	SD	_
51-74	11283-11284	)	_
51-75	11285-11289	42.6	_
51-76	11290-11291	(	_
51-77	11291-11295	10.9	_
51-78	11295-11296	)	_
51-79	11297-11301	32.8	_
51-80	11302-11303	(	_
51-81	11303-11307	11.6	_
51-82	11307-11308	)	_
51-83	11309-11313	42.8	_
51-84	11314-11315	(	_
51-85	11315-11319	10.8	_
51-86	11319-11320	)	_
51-87	11323-11332	Ethnicity	_
51-88	11332-11333	,	_
51-89	11334-11335	N	_
51-90	11335-11336	,	_
51-91	11337-11338	(	_
51-92	11338-11339	%	_
51-93	11339-11340	)	_
51-94	11344-11349	Black	_
51-95	11349-11350	/	_
51-96	11350-11357	African	_
51-97	11358-11366	American	_
51-98	11367-11370	507	_
51-99	11371-11372	(	_
51-100	11372-11376	45.2	_
51-101	11376-11377	)	_
51-102	11378-11381	232	_
51-103	11382-11383	(	_
51-104	11383-11387	31.6	_
51-105	11387-11388	)	_
51-106	11389-11392	439	_
51-107	11393-11394	(	_
51-108	11394-11398	46.0	_
51-109	11398-11399	)	_
51-110	11403-11411	European	_
51-111	11412-11420	American	_
51-112	11421-11424	531	_
51-113	11425-11426	(	_
51-114	11426-11430	47.3	_
51-115	11430-11431	)	_
51-116	11432-11435	411	_
51-117	11436-11437	(	_
51-118	11437-11441	55.9	_
51-119	11441-11442	)	_
51-120	11443-11446	441	_
51-121	11447-11448	(	_
51-122	11448-11452	46.1	_
51-123	11452-11453	)	_
51-124	11457-11462	Asian	_
51-125	11463-11465	16	_
51-126	11466-11467	(	_
51-127	11467-11470	1.4	_
51-128	11470-11471	)	_
51-129	11472-11474	47	_
51-130	11475-11476	(	_
51-131	11476-11479	6.4	_
51-132	11479-11480	)	_
51-133	11481-11483	12	_
51-134	11484-11485	(	_
51-135	11485-11488	1.3	_
51-136	11488-11489	)	_
51-137	11493-11504	Multiracial	_
51-138	11505-11507	21	_
51-139	11508-11509	(	_
51-140	11509-11512	1.9	_
51-141	11512-11513	)	_
51-142	11514-11516	20	_
51-143	11517-11518	(	_
51-144	11518-11521	2.7	_
51-145	11521-11522	)	_
51-146	11523-11525	18	_
51-147	11526-11527	(	_
51-148	11527-11530	1.9	_
51-149	11530-11531	)	_
51-150	11535-11541	Native	_
51-151	11542-11550	American	_
51-152	11551-11553	or	_
51-153	11554-11560	Alaska	_
51-154	11561-11567	Native	_
51-155	11568-11569	5	_
51-156	11570-11571	(	_
51-157	11571-11574	0.5	_
51-158	11574-11575	)	_
51-159	11576-11577	2	_
51-160	11578-11579	(	_
51-161	11579-11582	0.3	_
51-162	11582-11583	)	_
51-163	11584-11585	5	_
51-164	11586-11587	(	_
51-165	11587-11590	0.5	_
51-166	11590-11591	)	_
51-167	11595-11601	Native	_
51-168	11602-11610	Hawaiian	_
51-169	11611-11613	or	_
51-170	11614-11619	other	_
51-171	11620-11627	Pacific	_
51-172	11628-11636	Islander	_
51-173	11637-11638	1	_
51-174	11639-11640	(	_
51-175	11640-11643	0.1	_
51-176	11643-11644	)	_
51-177	11645-11646	1	_
51-178	11647-11648	(	_
51-179	11648-11651	0.1	_
51-180	11651-11652	)	_
51-181	11653-11654	1	_
51-182	11655-11656	(	_
51-183	11656-11659	0.1	_
51-184	11659-11660	)	_
51-185	11664-11671	Unknown	_
51-186	11672-11674	42	_
51-187	11675-11676	(	_
51-188	11676-11679	3.7	_
51-189	11679-11680	)	_
51-190	11681-11683	22	_
51-191	11684-11685	(	_
51-192	11685-11688	3.0	_
51-193	11688-11689	)	_
51-194	11690-11692	39	_
51-195	11693-11694	(	_
51-196	11694-11697	4.1	_
51-197	11697-11698	)	_
51-198	11701-11708	Smokers	_
51-199	11708-11709	,	_
51-200	11710-11711	N	_
51-201	11711-11712	,	_
51-202	11713-11714	(	_
51-203	11714-11715	%	_
51-204	11715-11716	)	_
51-205	11717-11720	662	_
51-206	11721-11722	(	_
51-207	11722-11726	59.0	_
51-208	11726-11727	)	_
51-209	11728-11730	44	_
51-210	11731-11732	(	_
51-211	11732-11735	6.1	_
51-212	11735-11736	)	_
51-213	11737-11740	595	_
51-214	11741-11742	(	_
51-215	11742-11746	62.3	_
51-216	11746-11747	)	_
51-217	11750-11755	MADRS	_
51-218	11756-11761	score	_
51-219	11761-11762	,	_
51-220	11763-11767	mean	_
51-221	11768-11769	(	_
51-222	11769-11771	SD	_
51-223	11771-11772	)	_
51-224	11773-11777	13.2	_
51-225	11778-11779	(	_
51-226	11779-11782	9.8	_
51-227	11782-11783	)	_
51-228	11784-11787	1.3	_
51-229	11788-11789	(	_
51-230	11789-11792	3.2	_
51-231	11792-11793	)	_
51-232	11794-11798	13.2	_
51-233	11799-11800	(	_
51-234	11800-11803	9.8	_
51-235	11803-11804	)	_
51-236	11807-11812	Major	_
51-237	11813-11823	depressive	_
51-238	11824-11840	disorder—current	_
51-239	11840-11841	,	_
51-240	11842-11843	N	_
51-241	11843-11844	,	_
51-242	11845-11846	(	_
51-243	11846-11847	%	_
51-244	11847-11848	)	_
51-245	11849-11852	108	_
51-246	11853-11854	(	_
51-247	11854-11857	5.8	_
51-248	11857-11858	)	_
51-249	11859-11860	8	_
51-250	11861-11862	(	_
51-251	11862-11865	0.4	_
51-252	11865-11866	)	_
51-253	11867-11870	103	_
51-254	11871-11872	(	_
51-255	11872-11876	10.8	_
51-256	11876-11877	)	_
51-257	11880-11885	Major	_
51-258	11886-11896	depressive	_
51-259	11897-11914	disorder—lifetime	_
51-260	11914-11915	,	_
51-261	11916-11917	N	_
51-262	11917-11918	,	_
51-263	11919-11920	(	_
51-264	11920-11921	%	_
51-265	11921-11922	)	_
51-266	11923-11926	216	_
51-267	11927-11928	(	_
51-268	11928-11932	11.6	_
51-269	11932-11933	)	_
51-270	11934-11936	49	_
51-271	11937-11938	(	_
51-272	11938-11941	2.6	_
51-273	11941-11942	)	_
51-274	11943-11946	196	_
51-275	11947-11948	(	_
51-276	11948-11952	20.5	_
51-277	11952-11953	)	_
51-278	11957-11961	Note	_
51-279	11961-11962	.	_

#Text=Ethnicity reported in this table was based on self-report
#Text=MADRS Montgomery-Asberg Depression Rating Scale
#Text=The NIAAA Sample consisted of 1123 individuals with a DSM-IV-TR diagnosis of AD and 735 HCs who enrolled in research studies at the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health Clinical Center in Bethesda, MD (see Table 2). 531 individuals with AD and 411 controls were of European American (EA) descent.
52-1	11963-11972	Ethnicity	_
52-2	11973-11981	reported	_
52-3	11982-11984	in	_
52-4	11985-11989	this	_
52-5	11990-11995	table	_
52-6	11996-11999	was	_
52-7	12000-12005	based	_
52-8	12006-12008	on	_
52-9	12009-12020	self-report	_
52-10	12021-12026	MADRS	_
52-11	12027-12044	Montgomery-Asberg	_
52-12	12045-12055	Depression	_
52-13	12056-12062	Rating	_
52-14	12063-12068	Scale	_
52-15	12069-12072	The	_
52-16	12073-12078	NIAAA	_
52-17	12079-12085	Sample	_
52-18	12086-12095	consisted	_
52-19	12096-12098	of	_
52-20	12099-12103	1123	_
52-21	12104-12115	individuals	_
52-22	12116-12120	with	_
52-23	12121-12122	a	_
52-24	12123-12132	DSM-IV-TR	_
52-25	12133-12142	diagnosis	_
52-26	12143-12145	of	_
52-27	12146-12148	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
52-28	12149-12152	and	_
52-29	12153-12156	735	_
52-30	12157-12160	HCs	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
52-31	12161-12164	who	_
52-32	12165-12173	enrolled	_
52-33	12174-12176	in	_
52-34	12177-12185	research	_
52-35	12186-12193	studies	_
52-36	12194-12196	at	_
52-37	12197-12200	the	_
52-38	12201-12209	National	_
52-39	12210-12219	Institute	_
52-40	12220-12222	on	_
52-41	12223-12230	Alcohol	_
52-42	12231-12236	Abuse	_
52-43	12237-12240	and	_
52-44	12241-12251	Alcoholism	_
52-45	12252-12254	at	_
52-46	12255-12258	the	_
52-47	12259-12267	National	_
52-48	12268-12278	Institutes	_
52-49	12279-12281	of	_
52-50	12282-12288	Health	_
52-51	12289-12297	Clinical	_
52-52	12298-12304	Center	_
52-53	12305-12307	in	_
52-54	12308-12316	Bethesda	_
52-55	12316-12317	,	_
52-56	12318-12320	MD	_
52-57	12321-12322	(	_
52-58	12322-12325	see	_
52-59	12326-12331	Table	_
52-60	12332-12333	2	_
52-61	12333-12334	)	_
52-62	12334-12335	.	_
52-63	12336-12339	531	_
52-64	12340-12351	individuals	_
52-65	12352-12356	with	_
52-66	12357-12359	AD	_
52-67	12360-12363	and	_
52-68	12364-12367	411	_
52-69	12368-12376	controls	_
52-70	12377-12381	were	_
52-71	12382-12384	of	_
52-72	12385-12393	European	_
52-73	12394-12402	American	_
52-74	12403-12404	(	_
52-75	12404-12406	EA	_
52-76	12406-12407	)	_
52-77	12408-12415	descent	_
52-78	12415-12416	.	_

#Text=A total of 507 individuals with AD and 232 controls were of African American (AA) descent.
53-1	12417-12418	A	_
53-2	12419-12424	total	_
53-3	12425-12427	of	_
53-4	12428-12431	507	_
53-5	12432-12443	individuals	_
53-6	12444-12448	with	_
53-7	12449-12451	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
53-8	12452-12455	and	_
53-9	12456-12459	232	_
53-10	12460-12468	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
53-11	12469-12473	were	_
53-12	12474-12476	of	_
53-13	12477-12484	African	_
53-14	12485-12493	American	_
53-15	12494-12495	(	_
53-16	12495-12497	AA	_
53-17	12497-12498	)	_
53-18	12499-12506	descent	_
53-19	12506-12507	.	_

#Text=All participants provided blood samples for genotyping.
54-1	12508-12511	All	_
54-2	12512-12524	participants	_
54-3	12525-12533	provided	_
54-4	12534-12539	blood	_
54-5	12540-12547	samples	_
54-6	12548-12551	for	_
54-7	12552-12562	genotyping	_
54-8	12562-12563	.	_

#Text=The SAGE was funded by the National Human Genome Research Institute as part of the Gene Environment Association Studies (GENEVA) that consisted of three major studies of addictive disorders: The Collaborative Study on the Genetics of Alcoholism (COGA), the Family Study of Cocaine Dependence (FSCD), and the Collaborative Genetic Study of Nicotine Dependence (COGEND).
55-1	12564-12567	The	_
55-2	12568-12572	SAGE	_
55-3	12573-12576	was	_
55-4	12577-12583	funded	_
55-5	12584-12586	by	_
55-6	12587-12590	the	_
55-7	12591-12599	National	_
55-8	12600-12605	Human	_
55-9	12606-12612	Genome	_
55-10	12613-12621	Research	_
55-11	12622-12631	Institute	_
55-12	12632-12634	as	_
55-13	12635-12639	part	_
55-14	12640-12642	of	_
55-15	12643-12646	the	_
55-16	12647-12651	Gene	_
55-17	12652-12663	Environment	_
55-18	12664-12675	Association	_
55-19	12676-12683	Studies	_
55-20	12684-12685	(	_
55-21	12685-12691	GENEVA	_
55-22	12691-12692	)	_
55-23	12693-12697	that	_
55-24	12698-12707	consisted	_
55-25	12708-12710	of	_
55-26	12711-12716	three	_
55-27	12717-12722	major	_
55-28	12723-12730	studies	_
55-29	12731-12733	of	_
55-30	12734-12743	addictive	_
55-31	12744-12753	disorders	_
55-32	12753-12754	:	_
55-33	12755-12758	The	_
55-34	12759-12772	Collaborative	_
55-35	12773-12778	Study	_
55-36	12779-12781	on	_
55-37	12782-12785	the	_
55-38	12786-12794	Genetics	_
55-39	12795-12797	of	_
55-40	12798-12808	Alcoholism	_
55-41	12809-12810	(	_
55-42	12810-12814	COGA	_
55-43	12814-12815	)	_
55-44	12815-12816	,	_
55-45	12817-12820	the	_
55-46	12821-12827	Family	_
55-47	12828-12833	Study	_
55-48	12834-12836	of	_
55-49	12837-12844	Cocaine	_
55-50	12845-12855	Dependence	_
55-51	12856-12857	(	_
55-52	12857-12861	FSCD	_
55-53	12861-12862	)	_
55-54	12862-12863	,	_
55-55	12864-12867	and	_
55-56	12868-12871	the	_
55-57	12872-12885	Collaborative	_
55-58	12886-12893	Genetic	_
55-59	12894-12899	Study	_
55-60	12900-12902	of	_
55-61	12903-12911	Nicotine	_
55-62	12912-12922	Dependence	_
55-63	12923-12924	(	_
55-64	12924-12930	COGEND	_
55-65	12930-12931	)	_
55-66	12931-12932	.	_

#Text=The accession number of dbGaP is phs000092.v1.p1.
56-1	12933-12936	The	_
56-2	12937-12946	accession	_
56-3	12947-12953	number	_
56-4	12954-12956	of	_
56-5	12957-12962	dbGaP	_
56-6	12963-12965	is	_
56-7	12966-12975	phs000092	_
56-8	12975-12976	.	_
56-9	12976-12978	v1	_
56-10	12978-12979	.	_
56-11	12979-12981	p1	_
56-12	12981-12982	.	_

#Text=The EA subgroup of the SAGE Sample consisted of 1162 cases (mean age = 38.2 (9.94); 62% male) and 1346 controls (mean age 38.6 (9.44); 30.3% male).
57-1	12983-12986	The	_
57-2	12987-12989	EA	_
57-3	12990-12998	subgroup	_
57-4	12999-13001	of	_
57-5	13002-13005	the	_
57-6	13006-13010	SAGE	_
57-7	13011-13017	Sample	_
57-8	13018-13027	consisted	_
57-9	13028-13030	of	_
57-10	13031-13035	1162	_
57-11	13036-13041	cases	_
57-12	13042-13043	(	_
57-13	13043-13047	mean	_
57-14	13048-13051	age	_
57-15	13052-13053	=	_
57-16	13054-13058	38.2	_
57-17	13059-13060	(	_
57-18	13060-13064	9.94	_
57-19	13064-13065	)	_
57-20	13065-13066	;	_
57-21	13067-13070	62%	_
57-22	13071-13075	male	_
57-23	13075-13076	)	_
57-24	13077-13080	and	_
57-25	13081-13085	1346	_
57-26	13086-13094	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
57-27	13095-13096	(	_
57-28	13096-13100	mean	_
57-29	13101-13104	age	_
57-30	13105-13109	38.6	_
57-31	13110-13111	(	_
57-32	13111-13115	9.44	_
57-33	13115-13116	)	_
57-34	13116-13117	;	_
57-35	13118-13123	30.3%	_
57-36	13124-13128	male	_
57-37	13128-13129	)	_
57-38	13129-13130	.	_

#Text=The AA subgroup consisted of 686 cases (mean age = 40.3 (7.7); 61% male) and 644 controls (mean age = 39.6 (7.2); 36% male).
58-1	13131-13134	The	_
58-2	13135-13137	AA	_
58-3	13138-13146	subgroup	_
58-4	13147-13156	consisted	_
58-5	13157-13159	of	_
58-6	13160-13163	686	_
58-7	13164-13169	cases	_
58-8	13170-13171	(	_
58-9	13171-13175	mean	_
58-10	13176-13179	age	_
58-11	13180-13181	=	_
58-12	13182-13186	40.3	_
58-13	13187-13188	(	_
58-14	13188-13191	7.7	_
58-15	13191-13192	)	_
58-16	13192-13193	;	_
58-17	13194-13197	61%	_
58-18	13198-13202	male	_
58-19	13202-13203	)	_
58-20	13204-13207	and	_
58-21	13208-13211	644	_
58-22	13212-13220	controls	_
58-23	13221-13222	(	_
58-24	13222-13226	mean	_
58-25	13227-13230	age	_
58-26	13231-13232	=	_
58-27	13233-13237	39.6	_
58-28	13238-13239	(	_
58-29	13239-13242	7.2	_
58-30	13242-13243	)	_
58-31	13243-13244	;	_
58-32	13245-13248	36%	_
58-33	13249-13253	male	_
58-34	13253-13254	)	_
58-35	13254-13255	.	_

#Text=All cases met lifetime DSM-IV criteria for AD, and were excluded if they had schizophrenia or any other psychotic illness.
59-1	13256-13259	All	_
59-2	13260-13265	cases	_
59-3	13266-13269	met	_
59-4	13270-13278	lifetime	_
59-5	13279-13285	DSM-IV	_
59-6	13286-13294	criteria	_
59-7	13295-13298	for	_
59-8	13299-13301	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
59-9	13301-13302	,	_
59-10	13303-13306	and	_
59-11	13307-13311	were	_
59-12	13312-13320	excluded	_
59-13	13321-13323	if	_
59-14	13324-13328	they	_
59-15	13329-13332	had	_
59-16	13333-13346	schizophrenia	_
59-17	13347-13349	or	_
59-18	13350-13353	any	_
59-19	13354-13359	other	_
59-20	13360-13369	psychotic	_
59-21	13370-13377	illness	_
59-22	13377-13378	.	_

#Text=Controls were defined as individuals who had been exposed to alcohol, but had not met lifetime criteria for AD or other illicit substances.
60-1	13379-13387	Controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
60-2	13388-13392	were	_
60-3	13393-13400	defined	_
60-4	13401-13403	as	_
60-5	13404-13415	individuals	_
60-6	13416-13419	who	_
60-7	13420-13423	had	_
60-8	13424-13428	been	_
60-9	13429-13436	exposed	_
60-10	13437-13439	to	_
60-11	13440-13447	alcohol	_
60-12	13447-13448	,	_
60-13	13449-13452	but	_
60-14	13453-13456	had	_
60-15	13457-13460	not	_
60-16	13461-13464	met	_
60-17	13465-13473	lifetime	_
60-18	13474-13482	criteria	_
60-19	13483-13486	for	_
60-20	13487-13489	AD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
60-21	13490-13492	or	_
60-22	13493-13498	other	_
60-23	13499-13506	illicit	_
60-24	13507-13517	substances	_
60-25	13517-13518	.	_

#Text=Experimental paradigm
#Text=Participants completed a modified version of the MID task, which required a fast button response to a target to win or avoid losing money.
61-1	13519-13531	Experimental	_
61-2	13532-13540	paradigm	_
61-3	13541-13553	Participants	_
61-4	13554-13563	completed	_
61-5	13564-13565	a	_
61-6	13566-13574	modified	_
61-7	13575-13582	version	_
61-8	13583-13585	of	_
61-9	13586-13589	the	_
61-10	13590-13593	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]
61-11	13594-13598	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[20]
61-12	13598-13599	,	_
61-13	13600-13605	which	_
61-14	13606-13614	required	_
61-15	13615-13616	a	_
61-16	13617-13621	fast	_
61-17	13622-13628	button	_
61-18	13629-13637	response	_
61-19	13638-13640	to	_
61-20	13641-13642	a	_
61-21	13643-13649	target	_
61-22	13650-13652	to	_
61-23	13653-13656	win	_
61-24	13657-13659	or	_
61-25	13660-13665	avoid	_
61-26	13666-13672	losing	_
61-27	13673-13678	money	_
61-28	13678-13679	.	_

#Text=A trial started with a crosshair for fixation, then a 2-second presentation of a cue (a shape indicating the type of trial: reward, loss, or neutral).
62-1	13680-13681	A	_
62-2	13682-13687	trial	_
62-3	13688-13695	started	_
62-4	13696-13700	with	_
62-5	13701-13702	a	_
62-6	13703-13712	crosshair	_
62-7	13713-13716	for	_
62-8	13717-13725	fixation	_
62-9	13725-13726	,	_
62-10	13727-13731	then	_
62-11	13732-13733	a	_
62-12	13734-13735	2	_
62-13	13735-13736	-	_
62-14	13736-13742	second	_
62-15	13743-13755	presentation	_
62-16	13756-13758	of	_
62-17	13759-13760	a	_
62-18	13761-13764	cue	_
62-19	13765-13766	(	_
62-20	13766-13767	a	_
62-21	13768-13773	shape	_
62-22	13774-13784	indicating	_
62-23	13785-13788	the	_
62-24	13789-13793	type	_
62-25	13794-13796	of	_
62-26	13797-13802	trial	_
62-27	13802-13803	:	_
62-28	13804-13810	reward	_
62-29	13810-13811	,	_
62-30	13812-13816	loss	_
62-31	13816-13817	,	_
62-32	13818-13820	or	_
62-33	13821-13828	neutral	_
62-34	13828-13829	)	_
62-35	13829-13830	.	_

#Text=After a delay screen of variable duration (between 0.75 and 1.75 s) the target was presented (a white-filled square to which the participants were trained to respond to).
63-1	13831-13836	After	_
63-2	13837-13838	a	_
63-3	13839-13844	delay	_
63-4	13845-13851	screen	_
63-5	13852-13854	of	_
63-6	13855-13863	variable	_
63-7	13864-13872	duration	_
63-8	13873-13874	(	_
63-9	13874-13881	between	_
63-10	13882-13886	0.75	_
63-11	13887-13890	and	_
63-12	13891-13895	1.75	_
63-13	13896-13897	s	_
63-14	13897-13898	)	_
63-15	13899-13902	the	_
63-16	13903-13909	target	_
63-17	13910-13913	was	_
63-18	13914-13923	presented	_
63-19	13924-13925	(	_
63-20	13925-13926	a	_
63-21	13927-13939	white-filled	_
63-22	13940-13946	square	_
63-23	13947-13949	to	_
63-24	13950-13955	which	_
63-25	13956-13959	the	_
63-26	13960-13972	participants	_
63-27	13973-13977	were	_
63-28	13978-13985	trained	_
63-29	13986-13988	to	_
63-30	13989-13996	respond	_
63-31	13997-13999	to	_
63-32	13999-14000	)	_
63-33	14000-14001	.	_

#Text=Next, another delay screen of variable duration (between 0.75 and 3 s) was presented before the feedback screen appeared.
64-1	14002-14006	Next	_
64-2	14006-14007	,	_
64-3	14008-14015	another	_
64-4	14016-14021	delay	_
64-5	14022-14028	screen	_
64-6	14029-14031	of	_
64-7	14032-14040	variable	_
64-8	14041-14049	duration	_
64-9	14050-14051	(	_
64-10	14051-14058	between	_
64-11	14059-14063	0.75	_
64-12	14064-14067	and	_
64-13	14068-14069	3	_
64-14	14070-14071	s	_
64-15	14071-14072	)	_
64-16	14073-14076	was	_
64-17	14077-14086	presented	_
64-18	14087-14093	before	_
64-19	14094-14097	the	_
64-20	14098-14106	feedback	_
64-21	14107-14113	screen	_
64-22	14114-14122	appeared	_
64-23	14122-14123	.	_

#Text=The feedback screen showed the amount that was won or lost in the previous trial, which represented if the participant had successfully pressed the button in time to win or avoid losing the target amount.
65-1	14124-14127	The	_
65-2	14128-14136	feedback	_
65-3	14137-14143	screen	_
65-4	14144-14150	showed	_
65-5	14151-14154	the	_
65-6	14155-14161	amount	_
65-7	14162-14166	that	_
65-8	14167-14170	was	_
65-9	14171-14174	won	_
65-10	14175-14177	or	_
65-11	14178-14182	lost	_
65-12	14183-14185	in	_
65-13	14186-14189	the	_
65-14	14190-14198	previous	_
65-15	14199-14204	trial	_
65-16	14204-14205	,	_
65-17	14206-14211	which	_
65-18	14212-14223	represented	_
65-19	14224-14226	if	_
65-20	14227-14230	the	_
65-21	14231-14242	participant	_
65-22	14243-14246	had	_
65-23	14247-14259	successfully	_
65-24	14260-14267	pressed	_
65-25	14268-14271	the	_
65-26	14272-14278	button	_
65-27	14279-14281	in	_
65-28	14282-14286	time	_
65-29	14287-14289	to	_
65-30	14290-14293	win	_
65-31	14294-14296	or	_
65-32	14297-14302	avoid	_
65-33	14303-14309	losing	_
65-34	14310-14313	the	_
65-35	14314-14320	target	_
65-36	14321-14327	amount	_
65-37	14327-14328	.	_

#Text=The total amount of money accumulated up to that point was also presented on the feedback screen.
66-1	14329-14332	The	_
66-2	14333-14338	total	_
66-3	14339-14345	amount	_
66-4	14346-14348	of	_
66-5	14349-14354	money	_
66-6	14355-14366	accumulated	_
66-7	14367-14369	up	_
66-8	14370-14372	to	_
66-9	14373-14377	that	_
66-10	14378-14383	point	_
66-11	14384-14387	was	_
66-12	14388-14392	also	_
66-13	14393-14402	presented	_
66-14	14403-14405	on	_
66-15	14406-14409	the	_
66-16	14410-14418	feedback	_
66-17	14419-14425	screen	_
66-18	14425-14426	.	_

#Text=After practicing outside of the scanner and being informed that gains/losses during the task would be reflected in their final payment, each subject completed a 12-minute fMRI session of the MID task.
67-1	14427-14432	After	_
67-2	14433-14443	practicing	_
67-3	14444-14451	outside	_
67-4	14452-14454	of	_
67-5	14455-14458	the	_
67-6	14459-14466	scanner	_
67-7	14467-14470	and	_
67-8	14471-14476	being	_
67-9	14477-14485	informed	_
67-10	14486-14490	that	_
67-11	14491-14496	gains	_
67-12	14496-14497	/	_
67-13	14497-14503	losses	_
67-14	14504-14510	during	_
67-15	14511-14514	the	_
67-16	14515-14519	task	_
67-17	14520-14525	would	_
67-18	14526-14528	be	_
67-19	14529-14538	reflected	_
67-20	14539-14541	in	_
67-21	14542-14547	their	_
67-22	14548-14553	final	_
67-23	14554-14561	payment	_
67-24	14561-14562	,	_
67-25	14563-14567	each	_
67-26	14568-14575	subject	_
67-27	14576-14585	completed	_
67-28	14586-14587	a	_
67-29	14588-14590	12	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]
67-30	14590-14591	-	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]
67-31	14591-14597	minute	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]
67-32	14598-14602	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]
67-33	14603-14610	session	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]
67-34	14611-14613	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]
67-35	14614-14617	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]
67-36	14618-14621	MID	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]
67-37	14622-14626	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]
67-38	14626-14627	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[21]

#Text=Five different cues were presented thirty times, each representing a different trial condition; neutral (no reward/no loss), low loss, high loss, low reward, and high reward.
68-1	14628-14632	Five	_
68-2	14633-14642	different	_
68-3	14643-14647	cues	_
68-4	14648-14652	were	_
68-5	14653-14662	presented	_
68-6	14663-14669	thirty	_
68-7	14670-14675	times	_
68-8	14675-14676	,	_
68-9	14677-14681	each	_
68-10	14682-14694	representing	_
68-11	14695-14696	a	_
68-12	14697-14706	different	_
68-13	14707-14712	trial	_
68-14	14713-14722	condition	_
68-15	14722-14723	;	_
68-16	14724-14731	neutral	_
68-17	14732-14733	(	_
68-18	14733-14735	no	_
68-19	14736-14742	reward	_
68-20	14742-14743	/	_
68-21	14743-14745	no	_
68-22	14746-14750	loss	_
68-23	14750-14751	)	_
68-24	14751-14752	,	_
68-25	14753-14756	low	_
68-26	14757-14761	loss	_
68-27	14761-14762	,	_
68-28	14763-14767	high	_
68-29	14768-14772	loss	_
68-30	14772-14773	,	_
68-31	14774-14777	low	_
68-32	14778-14784	reward	_
68-33	14784-14785	,	_
68-34	14786-14789	and	_
68-35	14790-14794	high	_
68-36	14795-14801	reward	_
68-37	14801-14802	.	_

#Text=MRI data acquisition and preprocessing
#Text=A Siemens 3 T Skyra scanner was used to collect whole-brain echo-planar imaging functional (36 axial slices, 4 mm slice thickness, 64 × 64 matrix and repetition time of 2000 ms) and MPRGE structural data.
69-1	14803-14806	MRI	_
69-2	14807-14811	data	_
69-3	14812-14823	acquisition	_
69-4	14824-14827	and	_
69-5	14828-14841	preprocessing	_
69-6	14842-14843	A	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
69-7	14844-14851	Siemens	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
69-8	14852-14853	3	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
69-9	14854-14855	T	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
69-10	14856-14861	Skyra	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
69-11	14862-14869	scanner	http://www.case.edu/ProvCaRe/provcare#MagneticResonanceImagingInstrument[22]
69-12	14870-14873	was	_
69-13	14874-14878	used	_
69-14	14879-14881	to	_
69-15	14882-14889	collect	_
69-16	14890-14901	whole-brain	_
69-17	14902-14913	echo-planar	_
69-18	14914-14921	imaging	_
69-19	14922-14932	functional	_
69-20	14933-14934	(	_
69-21	14934-14936	36	_
69-22	14937-14942	axial	_
69-23	14943-14949	slices	_
69-24	14949-14950	,	_
69-25	14951-14952	4	_
69-26	14953-14955	mm	_
69-27	14956-14961	slice	_
69-28	14962-14971	thickness	_
69-29	14971-14972	,	_
69-30	14973-14975	64	_
69-31	14976-14977	×	_
69-32	14978-14980	64	_
69-33	14981-14987	matrix	_
69-34	14988-14991	and	_
69-35	14992-15002	repetition	_
69-36	15003-15007	time	_
69-37	15008-15010	of	_
69-38	15011-15015	2000	_
69-39	15016-15018	ms	_
69-40	15018-15019	)	_
69-41	15020-15023	and	_
69-42	15024-15029	MPRGE	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[23]
69-43	15030-15040	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[23]
69-44	15041-15045	data	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[23]
69-45	15045-15046	.	_

#Text=Preprocessing and analysis was performed using AFNI software package.
70-1	15047-15060	Preprocessing	_
70-2	15061-15064	and	_
70-3	15065-15073	analysis	_
70-4	15074-15077	was	_
70-5	15078-15087	performed	_
70-6	15088-15093	using	_
70-7	15094-15098	AFNI	_
70-8	15099-15107	software	_
70-9	15108-15115	package	_
70-10	15115-15116	.	_

#Text=Large transients removal was performed before slice-time correction, then nuisance variables were de-trended, including the six parameter estimates for head motion.
71-1	15117-15122	Large	_
71-2	15123-15133	transients	_
71-3	15134-15141	removal	_
71-4	15142-15145	was	_
71-5	15146-15155	performed	_
71-6	15156-15162	before	_
71-7	15163-15173	slice-time	_
71-8	15174-15184	correction	_
71-9	15184-15185	,	_
71-10	15186-15190	then	_
71-11	15191-15199	nuisance	_
71-12	15200-15209	variables	_
71-13	15210-15214	were	_
71-14	15215-15225	de-trended	_
71-15	15225-15226	,	_
71-16	15227-15236	including	_
71-17	15237-15240	the	_
71-18	15241-15244	six	_
71-19	15245-15254	parameter	_
71-20	15255-15264	estimates	_
71-21	15265-15268	for	_
71-22	15269-15273	head	_
71-23	15274-15280	motion	_
71-24	15280-15281	.	_

#Text=No participants had any condition censored more than 20% (motion higher than 0.3 mm was censored out), a criterion to be excluded from the analysis.
72-1	15282-15284	No	_
72-2	15285-15297	participants	_
72-3	15298-15301	had	_
72-4	15302-15305	any	_
72-5	15306-15315	condition	_
72-6	15316-15324	censored	_
72-7	15325-15329	more	_
72-8	15330-15334	than	_
72-9	15335-15338	20%	_
72-10	15339-15340	(	_
72-11	15340-15346	motion	_
72-12	15347-15353	higher	_
72-13	15354-15358	than	_
72-14	15359-15362	0.3	_
72-15	15363-15365	mm	_
72-16	15366-15369	was	_
72-17	15370-15378	censored	_
72-18	15379-15382	out	_
72-19	15382-15383	)	_
72-20	15383-15384	,	_
72-21	15385-15386	a	_
72-22	15387-15396	criterion	_
72-23	15397-15399	to	_
72-24	15400-15402	be	_
72-25	15403-15411	excluded	_
72-26	15412-15416	from	_
72-27	15417-15420	the	_
72-28	15421-15429	analysis	_
72-29	15429-15430	.	_

#Text=Images were then coregistered to the individual structural image, resampled (2-mm isotropic), smoothed (4-mm full-width-half-maximum Gaussian kernel), normalized by the mean signal intensity in each voxel to reflect percent signal change, and finally transformed into the standardized.
73-1	15431-15437	Images	_
73-2	15438-15442	were	_
73-3	15443-15447	then	_
73-4	15448-15460	coregistered	_
73-5	15461-15463	to	_
73-6	15464-15467	the	_
73-7	15468-15478	individual	_
73-8	15479-15489	structural	_
73-9	15490-15495	image	_
73-10	15495-15496	,	_
73-11	15497-15506	resampled	_
73-12	15507-15508	(	_
73-13	15508-15509	2	_
73-14	15509-15510	-	_
73-15	15510-15512	mm	_
73-16	15513-15522	isotropic	_
73-17	15522-15523	)	_
73-18	15523-15524	,	_
73-19	15525-15533	smoothed	_
73-20	15534-15535	(	_
73-21	15535-15536	4	_
73-22	15536-15537	-	_
73-23	15537-15539	mm	_
73-24	15540-15563	full-width-half-maximum	_
73-25	15564-15572	Gaussian	_
73-26	15573-15579	kernel	_
73-27	15579-15580	)	_
73-28	15580-15581	,	_
73-29	15582-15592	normalized	_
73-30	15593-15595	by	_
73-31	15596-15599	the	_
73-32	15600-15604	mean	_
73-33	15605-15611	signal	_
73-34	15612-15621	intensity	_
73-35	15622-15624	in	_
73-36	15625-15629	each	_
73-37	15630-15635	voxel	_
73-38	15636-15638	to	_
73-39	15639-15646	reflect	_
73-40	15647-15654	percent	_
73-41	15655-15661	signal	_
73-42	15662-15668	change	_
73-43	15668-15669	,	_
73-44	15670-15673	and	_
73-45	15674-15681	finally	_
73-46	15682-15693	transformed	_
73-47	15694-15698	into	_
73-48	15699-15702	the	_
73-49	15703-15715	standardized	_
73-50	15715-15716	.	_

#Text=BOLD fMRI data and ROI analysis
#Text=Single-subject level analysis was performed using AFNI.
74-1	15717-15721	BOLD	_
74-2	15722-15726	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
74-3	15727-15731	data	_
74-4	15732-15735	and	_
74-5	15736-15739	ROI	_
74-6	15740-15748	analysis	_
74-7	15749-15763	Single-subject	_
74-8	15764-15769	level	_
74-9	15770-15778	analysis	_
74-10	15779-15782	was	_
74-11	15783-15792	performed	_
74-12	15793-15798	using	_
74-13	15799-15803	AFNI	_
74-14	15803-15804	.	_

#Text=Then, using ROI masks of the bilateral caudate, putamen, and nucleus accumbens, generated with AFNI DrawDataset plugins and following previously published literature and subtracting all nuances effects (such as pre-motor activations), except reward/loss response, we computed average percent signal change (beta weights) of the following comparisons: high reward > neutral, low reward > neutral, high loss > neutral, low loss > neutral.
75-1	15805-15809	Then	_
75-2	15809-15810	,	_
75-3	15811-15816	using	_
75-4	15817-15820	ROI	_
75-5	15821-15826	masks	_
75-6	15827-15829	of	_
75-7	15830-15833	the	_
75-8	15834-15843	bilateral	_
75-9	15844-15851	caudate	_
75-10	15851-15852	,	_
75-11	15853-15860	putamen	_
75-12	15860-15861	,	_
75-13	15862-15865	and	_
75-14	15866-15873	nucleus	_
75-15	15874-15883	accumbens	_
75-16	15883-15884	,	_
75-17	15885-15894	generated	_
75-18	15895-15899	with	_
75-19	15900-15904	AFNI	_
75-20	15905-15916	DrawDataset	_
75-21	15917-15924	plugins	_
75-22	15925-15928	and	_
75-23	15929-15938	following	_
75-24	15939-15949	previously	_
75-25	15950-15959	published	_
75-26	15960-15970	literature	_
75-27	15971-15974	and	_
75-28	15975-15986	subtracting	_
75-29	15987-15990	all	_
75-30	15991-15998	nuances	_
75-31	15999-16006	effects	_
75-32	16007-16008	(	_
75-33	16008-16012	such	_
75-34	16013-16015	as	_
75-35	16016-16025	pre-motor	_
75-36	16026-16037	activations	_
75-37	16037-16038	)	_
75-38	16038-16039	,	_
75-39	16040-16046	except	_
75-40	16047-16053	reward	_
75-41	16053-16054	/	_
75-42	16054-16058	loss	_
75-43	16059-16067	response	_
75-44	16067-16068	,	_
75-45	16069-16071	we	_
75-46	16072-16080	computed	_
75-47	16081-16088	average	_
75-48	16089-16096	percent	_
75-49	16097-16103	signal	_
75-50	16104-16110	change	_
75-51	16111-16112	(	_
75-52	16112-16116	beta	_
75-53	16117-16124	weights	_
75-54	16124-16125	)	_
75-55	16126-16128	of	_
75-56	16129-16132	the	_
75-57	16133-16142	following	_
75-58	16143-16154	comparisons	_
75-59	16154-16155	:	_
75-60	16156-16160	high	_
75-61	16161-16167	reward	_
75-62	16168-16169	>	_
75-63	16170-16177	neutral	_
75-64	16177-16178	,	_
75-65	16179-16182	low	_
75-66	16183-16189	reward	_
75-67	16190-16191	>	_
75-68	16192-16199	neutral	_
75-69	16199-16200	,	_
75-70	16201-16205	high	_
75-71	16206-16210	loss	_
75-72	16211-16212	>	_
75-73	16213-16220	neutral	_
75-74	16220-16221	,	_
75-75	16222-16225	low	_
75-76	16226-16230	loss	_
75-77	16231-16232	>	_
75-78	16233-16240	neutral	_
75-79	16240-16241	.	_

#Text=For simplification purposes, we refer to these as high reward, low reward, high loss, and low loss, respectively.
76-1	16242-16245	For	_
76-2	16246-16260	simplification	_
76-3	16261-16269	purposes	_
76-4	16269-16270	,	_
76-5	16271-16273	we	_
76-6	16274-16279	refer	_
76-7	16280-16282	to	_
76-8	16283-16288	these	_
76-9	16289-16291	as	_
76-10	16292-16296	high	_
76-11	16297-16303	reward	_
76-12	16303-16304	,	_
76-13	16305-16308	low	_
76-14	16309-16315	reward	_
76-15	16315-16316	,	_
76-16	16317-16321	high	_
76-17	16322-16326	loss	_
76-18	16326-16327	,	_
76-19	16328-16331	and	_
76-20	16332-16335	low	_
76-21	16336-16340	loss	_
76-22	16340-16341	,	_
76-23	16342-16354	respectively	_
76-24	16354-16355	.	_

#Text=Genotyping
#Text=NIAAA Sample
#Text=Large-scale genotyping was performed at the NIAAA Laboratory of Neurogenetics using the Illumina OmniExpress BeadChip (Illumina, San Diego, CA).
77-1	16356-16366	Genotyping	_
77-2	16367-16372	NIAAA	_
77-3	16373-16379	Sample	_
77-4	16380-16391	Large-scale	_
77-5	16392-16402	genotyping	_
77-6	16403-16406	was	_
77-7	16407-16416	performed	_
77-8	16417-16419	at	_
77-9	16420-16423	the	_
77-10	16424-16429	NIAAA	_
77-11	16430-16440	Laboratory	_
77-12	16441-16443	of	_
77-13	16444-16457	Neurogenetics	_
77-14	16458-16463	using	_
77-15	16464-16467	the	_
77-16	16468-16476	Illumina	_
77-17	16477-16488	OmniExpress	_
77-18	16489-16497	BeadChip	_
77-19	16498-16499	(	_
77-20	16499-16507	Illumina	_
77-21	16507-16508	,	_
77-22	16509-16512	San	_
77-23	16513-16518	Diego	_
77-24	16518-16519	,	_
77-25	16520-16522	CA	_
77-26	16522-16523	)	_
77-27	16523-16524	.	_

#Text=Data for the SNP rs10514299 located within the TMEM161B-AS1 gene cluster was extracted from the larger array.
78-1	16525-16529	Data	_
78-2	16530-16533	for	_
78-3	16534-16537	the	_
78-4	16538-16541	SNP	_
78-5	16542-16552	rs10514299	_
78-6	16553-16560	located	_
78-7	16561-16567	within	_
78-8	16568-16571	the	_
78-9	16572-16584	TMEM161B-AS1	_
78-10	16585-16589	gene	_
78-11	16590-16597	cluster	_
78-12	16598-16601	was	_
78-13	16602-16611	extracted	_
78-14	16612-16616	from	_
78-15	16617-16620	the	_
78-16	16621-16627	larger	_
78-17	16628-16633	array	_
78-18	16633-16634	.	_

#Text=Ancestry informative markers (AIMs; n = 2500) were extracted from the Illumina array to calculate ancestral proportions for all study participants.
79-1	16635-16643	Ancestry	_
79-2	16644-16655	informative	_
79-3	16656-16663	markers	_
79-4	16664-16665	(	_
79-5	16665-16669	AIMs	_
79-6	16669-16670	;	_
79-7	16671-16672	n	_
79-8	16673-16674	=	_
79-9	16675-16679	2500	_
79-10	16679-16680	)	_
79-11	16681-16685	were	_
79-12	16686-16695	extracted	_
79-13	16696-16700	from	_
79-14	16701-16704	the	_
79-15	16705-16713	Illumina	_
79-16	16714-16719	array	_
79-17	16720-16722	to	_
79-18	16723-16732	calculate	_
79-19	16733-16742	ancestral	_
79-20	16743-16754	proportions	_
79-21	16755-16758	for	_
79-22	16759-16762	all	_
79-23	16763-16768	study	_
79-24	16769-16781	participants	_
79-25	16781-16782	.	_

#Text=Using methods described previously for an AIM panel including 186 markers, which were not available for the current data set, the ancestry assessment identified 6 ethnic factors (Africa, Europe, Asia, Far East Asia, Oceania, and Americas).
80-1	16783-16788	Using	_
80-2	16789-16796	methods	_
80-3	16797-16806	described	_
80-4	16807-16817	previously	_
80-5	16818-16821	for	_
80-6	16822-16824	an	_
80-7	16825-16828	AIM	_
80-8	16829-16834	panel	_
80-9	16835-16844	including	_
80-10	16845-16848	186	_
80-11	16849-16856	markers	_
80-12	16856-16857	,	_
80-13	16858-16863	which	_
80-14	16864-16868	were	_
80-15	16869-16872	not	_
80-16	16873-16882	available	_
80-17	16883-16886	for	_
80-18	16887-16890	the	_
80-19	16891-16898	current	_
80-20	16899-16903	data	_
80-21	16904-16907	set	_
80-22	16907-16908	,	_
80-23	16909-16912	the	_
80-24	16913-16921	ancestry	_
80-25	16922-16932	assessment	_
80-26	16933-16943	identified	_
80-27	16944-16945	6	_
80-28	16946-16952	ethnic	_
80-29	16953-16960	factors	_
80-30	16961-16962	(	_
80-31	16962-16968	Africa	_
80-32	16968-16969	,	_
80-33	16970-16976	Europe	_
80-34	16976-16977	,	_
80-35	16978-16982	Asia	_
80-36	16982-16983	,	_
80-37	16984-16987	Far	_
80-38	16988-16992	East	_
80-39	16993-16997	Asia	_
80-40	16997-16998	,	_
80-41	16999-17006	Oceania	_
80-42	17006-17007	,	_
80-43	17008-17011	and	_
80-44	17012-17020	Americas	_
80-45	17020-17021	)	_
80-46	17021-17022	.	_

#Text=SAGE Sample
#Text=Whole-genome genotyping was completed using the Illumina Human-1M platform (Illumina Inc., San Diego, CA).
81-1	17023-17027	SAGE	_
81-2	17028-17034	Sample	_
81-3	17035-17047	Whole-genome	_
81-4	17048-17058	genotyping	_
81-5	17059-17062	was	_
81-6	17063-17072	completed	_
81-7	17073-17078	using	_
81-8	17079-17082	the	_
81-9	17083-17091	Illumina	_
81-10	17092-17097	Human	_
81-11	17097-17098	-	_
81-12	17098-17100	1M	_
81-13	17101-17109	platform	_
81-14	17110-17111	(	_
81-15	17111-17119	Illumina	_
81-16	17120-17123	Inc	_
81-17	17123-17124	.	_
81-18	17124-17125	,	_
81-19	17126-17129	San	_
81-20	17130-17135	Diego	_
81-21	17135-17136	,	_
81-22	17137-17139	CA	_
81-23	17139-17140	)	_
81-24	17140-17141	.	_

#Text=The 190 HapMap samples (48 HapMap control samples, 55 CEU, 55 YUR, 13 CHB, and 17 JPT)  were genotyped in the same platform and population stratification analyses were performed using principal component analysis.
82-1	17142-17145	The	_
82-2	17146-17149	190	_
82-3	17150-17156	HapMap	_
82-4	17157-17164	samples	_
82-5	17165-17166	(	_
82-6	17166-17168	48	_
82-7	17169-17175	HapMap	_
82-8	17176-17183	control	_
82-9	17184-17191	samples	_
82-10	17191-17192	,	_
82-11	17193-17195	55	_
82-12	17196-17199	CEU	_
82-13	17199-17200	,	_
82-14	17201-17203	55	_
82-15	17204-17207	YUR	_
82-16	17207-17208	,	_
82-17	17209-17211	13	_
82-18	17212-17215	CHB	_
82-19	17215-17216	,	_
82-20	17217-17220	and	_
82-21	17221-17223	17	_
82-22	17224-17227	JPT	_
82-23	17227-17228	)	_
82-24	17230-17234	were	_
82-25	17235-17244	genotyped	_
82-26	17245-17247	in	_
82-27	17248-17251	the	_
82-28	17252-17256	same	_
82-29	17257-17265	platform	_
82-30	17266-17269	and	_
82-31	17270-17280	population	_
82-32	17281-17295	stratification	_
82-33	17296-17304	analyses	_
82-34	17305-17309	were	_
82-35	17310-17319	performed	_
82-36	17320-17325	using	_
82-37	17326-17335	principal	_
82-38	17336-17345	component	_
82-39	17346-17354	analysis	_
82-40	17354-17355	.	_

#Text=After a series of quality control procedures (p value of Hardy-Weinberg equilibrium (HWE) < 10e-5, missing rate by SNP > 2%, missing rate by individual > 2%, minor allele frequency < 1%, sex inconsistency), there were 1162 case and 1346 control samples in the EA subgroup and 686 case and 644 control samples in AA subgroup.
83-1	17356-17361	After	_
83-2	17362-17363	a	_
83-3	17364-17370	series	_
83-4	17371-17373	of	_
83-5	17374-17381	quality	_
83-6	17382-17389	control	_
83-7	17390-17400	procedures	_
83-8	17401-17402	(	_
83-9	17402-17403	p	_
83-10	17404-17409	value	_
83-11	17410-17412	of	_
83-12	17413-17427	Hardy-Weinberg	_
83-13	17428-17439	equilibrium	_
83-14	17440-17441	(	_
83-15	17441-17444	HWE	_
83-16	17444-17445	)	_
83-17	17446-17447	<	_
83-18	17448-17451	10e	_
83-19	17451-17452	-	_
83-20	17452-17453	5	_
83-21	17453-17454	,	_
83-22	17455-17462	missing	_
83-23	17463-17467	rate	_
83-24	17468-17470	by	_
83-25	17471-17474	SNP	_
83-26	17475-17476	>	_
83-27	17477-17479	2%	_
83-28	17479-17480	,	_
83-29	17481-17488	missing	_
83-30	17489-17493	rate	_
83-31	17494-17496	by	_
83-32	17497-17507	individual	_
83-33	17508-17509	>	_
83-34	17510-17512	2%	_
83-35	17512-17513	,	_
83-36	17514-17519	minor	_
83-37	17520-17526	allele	_
83-38	17527-17536	frequency	_
83-39	17537-17538	<	_
83-40	17539-17541	1%	_
83-41	17541-17542	,	_
83-42	17543-17546	sex	_
83-43	17547-17560	inconsistency	_
83-44	17560-17561	)	_
83-45	17561-17562	,	_
83-46	17563-17568	there	_
83-47	17569-17573	were	_
83-48	17574-17578	1162	_
83-49	17579-17583	case	_
83-50	17584-17587	and	_
83-51	17588-17592	1346	_
83-52	17593-17600	control	_
83-53	17601-17608	samples	_
83-54	17609-17611	in	_
83-55	17612-17615	the	_
83-56	17616-17618	EA	_
83-57	17619-17627	subgroup	_
83-58	17628-17631	and	_
83-59	17632-17635	686	_
83-60	17636-17640	case	_
83-61	17641-17644	and	_
83-62	17645-17648	644	_
83-63	17649-17656	control	_
83-64	17657-17664	samples	_
83-65	17665-17667	in	_
83-66	17668-17670	AA	_
83-67	17671-17679	subgroup	_
83-68	17679-17680	.	_

#Text=Two population stratification scores (PSS) calculated based on principal component analysis were used for statistical analyses.
84-1	17681-17684	Two	_
84-2	17685-17695	population	_
84-3	17696-17710	stratification	_
84-4	17711-17717	scores	_
84-5	17718-17719	(	_
84-6	17719-17722	PSS	_
84-7	17722-17723	)	_
84-8	17724-17734	calculated	_
84-9	17735-17740	based	_
84-10	17741-17743	on	_
84-11	17744-17753	principal	_
84-12	17754-17763	component	_
84-13	17764-17772	analysis	_
84-14	17773-17777	were	_
84-15	17778-17782	used	_
84-16	17783-17786	for	_
84-17	17787-17798	statistical	_
84-18	17799-17807	analyses	_
84-19	17807-17808	.	_

#Text=Statistical analysis
#Text=Main analyses of the Neuroimaging Sample were run using SPSS statistical software package (IBM SPSS Statistics ® 20, IBM Corp. ©, Armonk, NY).
85-1	17809-17820	Statistical	_
85-2	17821-17829	analysis	_
85-3	17830-17834	Main	_
85-4	17835-17843	analyses	_
85-5	17844-17846	of	_
85-6	17847-17850	the	_
85-7	17851-17863	Neuroimaging	_
85-8	17864-17870	Sample	_
85-9	17871-17875	were	_
85-10	17876-17879	run	_
85-11	17880-17885	using	_
85-12	17886-17890	SPSS	_
85-13	17891-17902	statistical	_
85-14	17903-17911	software	_
85-15	17912-17919	package	_
85-16	17920-17921	(	_
85-17	17921-17924	IBM	_
85-18	17925-17929	SPSS	_
85-19	17930-17940	Statistics	_
85-20	17941-17942	®	_
85-21	17943-17945	20	_
85-22	17945-17946	,	_
85-23	17947-17950	IBM	_
85-24	17951-17955	Corp	_
85-25	17955-17956	.	_
85-26	17957-17958	©	_
85-27	17958-17959	,	_
85-28	17960-17966	Armonk	_
85-29	17966-17967	,	_
85-30	17968-17970	NY	_
85-31	17970-17971	)	_
85-32	17971-17972	.	_

#Text=Baseline differences in demographic variables between cases and controls were determined using t-tests for continuous and chi-square tests for categorical variables.
86-1	17973-17981	Baseline	_
86-2	17982-17993	differences	_
86-3	17994-17996	in	_
86-4	17997-18008	demographic	_
86-5	18009-18018	variables	_
86-6	18019-18026	between	_
86-7	18027-18032	cases	_
86-8	18033-18036	and	_
86-9	18037-18045	controls	_
86-10	18046-18050	were	_
86-11	18051-18061	determined	_
86-12	18062-18067	using	_
86-13	18068-18075	t-tests	_
86-14	18076-18079	for	_
86-15	18080-18090	continuous	_
86-16	18091-18094	and	_
86-17	18095-18105	chi-square	_
86-18	18106-18111	tests	_
86-19	18112-18115	for	_
86-20	18116-18127	categorical	_
86-21	18128-18137	variables	_
86-22	18137-18138	.	_

#Text=Chi-square tests were performed to test the genotypic distribution of the SNP in both cases and controls.
87-1	18139-18149	Chi-square	_
87-2	18150-18155	tests	_
87-3	18156-18160	were	_
87-4	18161-18170	performed	_
87-5	18171-18173	to	_
87-6	18174-18178	test	_
87-7	18179-18182	the	_
87-8	18183-18192	genotypic	_
87-9	18193-18205	distribution	_
87-10	18206-18208	of	_
87-11	18209-18212	the	_
87-12	18213-18216	SNP	_
87-13	18217-18219	in	_
87-14	18220-18224	both	_
87-15	18225-18230	cases	_
87-16	18231-18234	and	_
87-17	18235-18243	controls	_
87-18	18243-18244	.	_

#Text=The primary outcome measure was activation in the caudate, putamen, and nucleus accumbens during reward/loss anticipation as measured by BOLD fMRI.
88-1	18245-18248	The	_
88-2	18249-18256	primary	_
88-3	18257-18264	outcome	_
88-4	18265-18272	measure	_
88-5	18273-18276	was	_
88-6	18277-18287	activation	_
88-7	18288-18290	in	_
88-8	18291-18294	the	_
88-9	18295-18302	caudate	_
88-10	18302-18303	,	_
88-11	18304-18311	putamen	_
88-12	18311-18312	,	_
88-13	18313-18316	and	_
88-14	18317-18324	nucleus	_
88-15	18325-18334	accumbens	_
88-16	18335-18341	during	_
88-17	18342-18348	reward	_
88-18	18348-18349	/	_
88-19	18349-18353	loss	_
88-20	18354-18366	anticipation	_
88-21	18367-18369	as	_
88-22	18370-18378	measured	_
88-23	18379-18381	by	_
88-24	18382-18386	BOLD	_
88-25	18387-18391	fMRI	_
88-26	18391-18392	.	_

#Text=Shapiro-Wilk tests confirmed that all four imaging outcomes (high reward, low reward, high loss, low loss) were normally distributed (all p ≥ 0.407).
89-1	18393-18405	Shapiro-Wilk	_
89-2	18406-18411	tests	_
89-3	18412-18421	confirmed	_
89-4	18422-18426	that	_
89-5	18427-18430	all	_
89-6	18431-18435	four	_
89-7	18436-18443	imaging	_
89-8	18444-18452	outcomes	_
89-9	18453-18454	(	_
89-10	18454-18458	high	_
89-11	18459-18465	reward	_
89-12	18465-18466	,	_
89-13	18467-18470	low	_
89-14	18471-18477	reward	_
89-15	18477-18478	,	_
89-16	18479-18483	high	_
89-17	18484-18488	loss	_
89-18	18488-18489	,	_
89-19	18490-18493	low	_
89-20	18494-18498	loss	_
89-21	18498-18499	)	_
89-22	18500-18504	were	_
89-23	18505-18513	normally	_
89-24	18514-18525	distributed	_
89-25	18526-18527	(	_
89-26	18527-18530	all	_
89-27	18531-18532	p	_
89-28	18533-18534	≥	_
89-29	18535-18540	0.407	_
89-30	18540-18541	)	_
89-31	18541-18542	.	_

#Text=For the main analysis of effects of diagnosis, genotype, and their interaction on BOLD responses in the caudate, putamen, and nucleus accumbens, we conducted 2 × 2 analyses of covariance (ANCOVAs) with group (AD vs.
90-1	18543-18546	For	_
90-2	18547-18550	the	_
90-3	18551-18555	main	_
90-4	18556-18564	analysis	_
90-5	18565-18567	of	_
90-6	18568-18575	effects	_
90-7	18576-18578	of	_
90-8	18579-18588	diagnosis	_
90-9	18588-18589	,	_
90-10	18590-18598	genotype	_
90-11	18598-18599	,	_
90-12	18600-18603	and	_
90-13	18604-18609	their	_
90-14	18610-18621	interaction	_
90-15	18622-18624	on	_
90-16	18625-18629	BOLD	_
90-17	18630-18639	responses	_
90-18	18640-18642	in	_
90-19	18643-18646	the	_
90-20	18647-18654	caudate	_
90-21	18654-18655	,	_
90-22	18656-18663	putamen	_
90-23	18663-18664	,	_
90-24	18665-18668	and	_
90-25	18669-18676	nucleus	_
90-26	18677-18686	accumbens	_
90-27	18686-18687	,	_
90-28	18688-18690	we	_
90-29	18691-18700	conducted	_
90-30	18701-18702	2	_
90-31	18703-18704	×	_
90-32	18705-18706	2	_
90-33	18707-18715	analyses	_
90-34	18716-18718	of	_
90-35	18719-18729	covariance	_
90-36	18730-18731	(	_
90-37	18731-18738	ANCOVAs	_
90-38	18738-18739	)	_
90-39	18740-18744	with	_
90-40	18745-18750	group	_
90-41	18751-18752	(	_
90-42	18752-18754	AD	_
90-43	18755-18757	vs	_
90-44	18757-18758	.	_

#Text=HC) T allele carrier status (CC vs.
91-1	18759-18761	HC	_
91-2	18761-18762	)	_
91-3	18763-18764	T	_
91-4	18765-18771	allele	_
91-5	18772-18779	carrier	_
91-6	18780-18786	status	_
91-7	18787-18788	(	_
91-8	18788-18790	CC	_
91-9	18791-18793	vs	_
91-10	18793-18794	.	_

#Text=TT/CT–assuming a dominant model) as factors and age, gender, AIM score Europe, and AIM score Africa as covariates.
92-1	18795-18797	TT	_
92-2	18797-18798	/	_
92-3	18798-18809	CT–assuming	_
92-4	18810-18811	a	_
92-5	18812-18820	dominant	_
92-6	18821-18826	model	_
92-7	18826-18827	)	_
92-8	18828-18830	as	_
92-9	18831-18838	factors	_
92-10	18839-18842	and	_
92-11	18843-18846	age	_
92-12	18846-18847	,	_
92-13	18848-18854	gender	_
92-14	18854-18855	,	_
92-15	18856-18859	AIM	_
92-16	18860-18865	score	_
92-17	18866-18872	Europe	_
92-18	18872-18873	,	_
92-19	18874-18877	and	_
92-20	18878-18881	AIM	_
92-21	18882-18887	score	_
92-22	18888-18894	Africa	_
92-23	18895-18897	as	_
92-24	18898-18908	covariates	_
92-25	18908-18909	.	_

#Text=All tests were two-tailed and considered to be statistically significant at p < 0.05.
93-1	18910-18913	All	_
93-2	18914-18919	tests	_
93-3	18920-18924	were	_
93-4	18925-18935	two-tailed	_
93-5	18936-18939	and	_
93-6	18940-18950	considered	_
93-7	18951-18953	to	_
93-8	18954-18956	be	_
93-9	18957-18970	statistically	_
93-10	18971-18982	significant	_
93-11	18983-18985	at	_
93-12	18986-18987	p	_
93-13	18988-18989	<	_
93-14	18990-18994	0.05	_
93-15	18994-18995	.	_

#Text=For the NIAAA Sample, minor allele frequency, HWE, and association analyses were conducted using PLINK version 1.07.
94-1	18996-18999	For	_
94-2	19000-19003	the	_
94-3	19004-19009	NIAAA	_
94-4	19010-19016	Sample	_
94-5	19016-19017	,	_
94-6	19018-19023	minor	_
94-7	19024-19030	allele	_
94-8	19031-19040	frequency	_
94-9	19040-19041	,	_
94-10	19042-19045	HWE	_
94-11	19045-19046	,	_
94-12	19047-19050	and	_
94-13	19051-19062	association	_
94-14	19063-19071	analyses	_
94-15	19072-19076	were	_
94-16	19077-19086	conducted	_
94-17	19087-19092	using	_
94-18	19093-19098	PLINK	_
94-19	19099-19106	version	_
94-20	19107-19111	1.07	_
94-21	19111-19112	.	_

#Text=Analyses were conducted first in the entire sample, and then separately for EA and AA subgroups, based on self-report.
95-1	19113-19121	Analyses	_
95-2	19122-19126	were	_
95-3	19127-19136	conducted	_
95-4	19137-19142	first	_
95-5	19143-19145	in	_
95-6	19146-19149	the	_
95-7	19150-19156	entire	_
95-8	19157-19163	sample	_
95-9	19163-19164	,	_
95-10	19165-19168	and	_
95-11	19169-19173	then	_
95-12	19174-19184	separately	_
95-13	19185-19188	for	_
95-14	19189-19191	EA	_
95-15	19192-19195	and	_
95-16	19196-19198	AA	_
95-17	19199-19208	subgroups	_
95-18	19208-19209	,	_
95-19	19210-19215	based	_
95-20	19216-19218	on	_
95-21	19219-19230	self-report	_
95-22	19230-19231	.	_

#Text=Case-control association with lifetime AD was determined using logistic regression, while association with the MADRS scale was determined using linear regression.
96-1	19232-19244	Case-control	_
96-2	19245-19256	association	_
96-3	19257-19261	with	_
96-4	19262-19270	lifetime	_
96-5	19271-19273	AD	_
96-6	19274-19277	was	_
96-7	19278-19288	determined	_
96-8	19289-19294	using	_
96-9	19295-19303	logistic	_
96-10	19304-19314	regression	_
96-11	19314-19315	,	_
96-12	19316-19321	while	_
96-13	19322-19333	association	_
96-14	19334-19338	with	_
96-15	19339-19342	the	_
96-16	19343-19348	MADRS	_
96-17	19349-19354	scale	_
96-18	19355-19358	was	_
96-19	19359-19369	determined	_
96-20	19370-19375	using	_
96-21	19376-19382	linear	_
96-22	19383-19393	regression	_
96-23	19393-19394	.	_

#Text=Both analyses used an additive model and adjusted for age, gender, and AIM scores for European and African ancestry.
97-1	19395-19399	Both	_
97-2	19400-19408	analyses	_
97-3	19409-19413	used	_
97-4	19414-19416	an	_
97-5	19417-19425	additive	_
97-6	19426-19431	model	_
97-7	19432-19435	and	_
97-8	19436-19444	adjusted	_
97-9	19445-19448	for	_
97-10	19449-19452	age	_
97-11	19452-19453	,	_
97-12	19454-19460	gender	_
97-13	19460-19461	,	_
97-14	19462-19465	and	_
97-15	19466-19469	AIM	_
97-16	19470-19476	scores	_
97-17	19477-19480	for	_
97-18	19481-19489	European	_
97-19	19490-19493	and	_
97-20	19494-19501	African	_
97-21	19502-19510	ancestry	_
97-22	19510-19511	.	_

#Text=Similarly, for the SAGE Sample, a logistic regression model controlling for age, gender, and 2 PSS for African and European ancestry was performed with the assumption of an additive model.
98-1	19512-19521	Similarly	_
98-2	19521-19522	,	_
98-3	19523-19526	for	_
98-4	19527-19530	the	_
98-5	19531-19535	SAGE	_
98-6	19536-19542	Sample	_
98-7	19542-19543	,	_
98-8	19544-19545	a	_
98-9	19546-19554	logistic	_
98-10	19555-19565	regression	_
98-11	19566-19571	model	_
98-12	19572-19583	controlling	_
98-13	19584-19587	for	_
98-14	19588-19591	age	_
98-15	19591-19592	,	_
98-16	19593-19599	gender	_
98-17	19599-19600	,	_
98-18	19601-19604	and	_
98-19	19605-19606	2	_
98-20	19607-19610	PSS	_
98-21	19611-19614	for	_
98-22	19615-19622	African	_
98-23	19623-19626	and	_
98-24	19627-19635	European	_
98-25	19636-19644	ancestry	_
98-26	19645-19648	was	_
98-27	19649-19658	performed	_
98-28	19659-19663	with	_
98-29	19664-19667	the	_
98-30	19668-19678	assumption	_
98-31	19679-19681	of	_
98-32	19682-19684	an	_
98-33	19685-19693	additive	_
98-34	19694-19699	model	_
98-35	19699-19700	.	_

#Text=Analyses were performed separately in individuals of European and African ancestry.
99-1	19701-19709	Analyses	_
99-2	19710-19714	were	_
99-3	19715-19724	performed	_
99-4	19725-19735	separately	_
99-5	19736-19738	in	_
99-6	19739-19750	individuals	_
99-7	19751-19753	of	_
99-8	19754-19762	European	_
99-9	19763-19766	and	_
99-10	19767-19774	African	_
99-11	19775-19783	ancestry	_
99-12	19783-19784	.	_

#Text=Results
#Text=Neuroimaging Sample
#Text=Chi-square goodness-of-fit tests demonstrated that none of the genotype counts deviated significantly from the HWE both in the whole sample (p = 0.657), as well as in the subgroups (AD: p = 0.649; HC: p = 0.302).
100-1	19785-19792	Results	_
100-2	19793-19805	Neuroimaging	_
100-3	19806-19812	Sample	_
100-4	19813-19823	Chi-square	_
100-5	19824-19839	goodness-of-fit	_
100-6	19840-19845	tests	_
100-7	19846-19858	demonstrated	_
100-8	19859-19863	that	_
100-9	19864-19868	none	_
100-10	19869-19871	of	_
100-11	19872-19875	the	_
100-12	19876-19884	genotype	_
100-13	19885-19891	counts	_
100-14	19892-19900	deviated	_
100-15	19901-19914	significantly	_
100-16	19915-19919	from	_
100-17	19920-19923	the	_
100-18	19924-19927	HWE	_
100-19	19928-19932	both	_
100-20	19933-19935	in	_
100-21	19936-19939	the	_
100-22	19940-19945	whole	_
100-23	19946-19952	sample	_
100-24	19953-19954	(	_
100-25	19954-19955	p	_
100-26	19956-19957	=	_
100-27	19958-19963	0.657	_
100-28	19963-19964	)	_
100-29	19964-19965	,	_
100-30	19966-19968	as	_
100-31	19969-19973	well	_
100-32	19974-19976	as	_
100-33	19977-19979	in	_
100-34	19980-19983	the	_
100-35	19984-19993	subgroups	_
100-36	19994-19995	(	_
100-37	19995-19997	AD	_
100-38	19997-19998	:	_
100-39	19999-20000	p	_
100-40	20001-20002	=	_
100-41	20003-20008	0.649	_
100-42	20008-20009	;	_
100-43	20010-20012	HC	_
100-44	20012-20013	:	_
100-45	20014-20015	p	_
100-46	20016-20017	=	_
100-47	20018-20023	0.302	_
100-48	20023-20024	)	_
100-49	20024-20025	.	_

#Text=Parameter estimates of main analysis ANCOVAs examining effects of group, rs10514299 genotype, and their interaction on putamen MID task percent signal change controlling for age, gender, and ancestry informative markers
#Text=Putamen activation\tB\tStandard error\tt\tp value\tPartial eta squared\t \tHigh reward\t \t Group\t0.21\t0.06\t−3.34\t0.001\t0.12\t \t MA (T) carrier\t0.15\t0.05\t−2.92\t0.005\t0.09\t \t Interaction\t0.18\t0.07\t2.52\t0.014\t0.07\t \tLow reward\t \t Group\t0.14\t0.07\t−1.94\t0.055\t0.04\t \t MA (T) carrier\t0.08\t0.06\t−1.38\t0.173\t0.02\t \t Interaction\t0.14\t0.08\t1.77\t0.081\t0.04\t \tHigh loss\t \t Group\t0.24\t0.08\t−3.15\t0.002\t0.11\t \t MA (T) carrier\t0.1\t0.06\t−1.59\t0.115\t0.03\t \t Interaction\t0.2\t0.09\t2.29\t0.024\t0.06\t \tLow loss\t \t Group\t0.17\t0.07\t−2.49\t0.015\t0.07\t \t MA (T) carrier\t0.08\t0.06\t−1.46\t0.148\t0.03\t \t Interaction\t0.16\t0.08\t2.03\t0.046\t0.05\t \t
#Text=Note.
101-1	20026-20035	Parameter	_
101-2	20036-20045	estimates	_
101-3	20046-20048	of	_
101-4	20049-20053	main	_
101-5	20054-20062	analysis	_
101-6	20063-20070	ANCOVAs	_
101-7	20071-20080	examining	_
101-8	20081-20088	effects	_
101-9	20089-20091	of	_
101-10	20092-20097	group	_
101-11	20097-20098	,	_
101-12	20099-20109	rs10514299	_
101-13	20110-20118	genotype	_
101-14	20118-20119	,	_
101-15	20120-20123	and	_
101-16	20124-20129	their	_
101-17	20130-20141	interaction	_
101-18	20142-20144	on	_
101-19	20145-20152	putamen	_
101-20	20153-20156	MID	_
101-21	20157-20161	task	_
101-22	20162-20169	percent	_
101-23	20170-20176	signal	_
101-24	20177-20183	change	_
101-25	20184-20195	controlling	_
101-26	20196-20199	for	_
101-27	20200-20203	age	_
101-28	20203-20204	,	_
101-29	20205-20211	gender	_
101-30	20211-20212	,	_
101-31	20213-20216	and	_
101-32	20217-20225	ancestry	_
101-33	20226-20237	informative	_
101-34	20238-20245	markers	_
101-35	20246-20253	Putamen	_
101-36	20254-20264	activation	_
101-37	20265-20266	B	_
101-38	20267-20275	Standard	_
101-39	20276-20281	error	_
101-40	20282-20283	t	_
101-41	20284-20285	p	_
101-42	20286-20291	value	_
101-43	20292-20299	Partial	_
101-44	20300-20303	eta	_
101-45	20304-20311	squared	_
101-46	20314-20318	High	_
101-47	20319-20325	reward	_
101-48	20329-20334	Group	_
101-49	20335-20339	0.21	_
101-50	20340-20344	0.06	_
101-51	20345-20346	−	_
101-52	20346-20350	3.34	_
101-53	20351-20356	0.001	_
101-54	20357-20361	0.12	_
101-55	20365-20367	MA	_
101-56	20368-20369	(	_
101-57	20369-20370	T	_
101-58	20370-20371	)	_
101-59	20372-20379	carrier	_
101-60	20380-20384	0.15	_
101-61	20385-20389	0.05	_
101-62	20390-20391	−	_
101-63	20391-20395	2.92	_
101-64	20396-20401	0.005	_
101-65	20402-20406	0.09	_
101-66	20410-20421	Interaction	_
101-67	20422-20426	0.18	_
101-68	20427-20431	0.07	_
101-69	20432-20436	2.52	_
101-70	20437-20442	0.014	_
101-71	20443-20447	0.07	_
101-72	20450-20453	Low	_
101-73	20454-20460	reward	_
101-74	20464-20469	Group	_
101-75	20470-20474	0.14	_
101-76	20475-20479	0.07	_
101-77	20480-20481	−	_
101-78	20481-20485	1.94	_
101-79	20486-20491	0.055	_
101-80	20492-20496	0.04	_
101-81	20500-20502	MA	_
101-82	20503-20504	(	_
101-83	20504-20505	T	_
101-84	20505-20506	)	_
101-85	20507-20514	carrier	_
101-86	20515-20519	0.08	_
101-87	20520-20524	0.06	_
101-88	20525-20526	−	_
101-89	20526-20530	1.38	_
101-90	20531-20536	0.173	_
101-91	20537-20541	0.02	_
101-92	20545-20556	Interaction	_
101-93	20557-20561	0.14	_
101-94	20562-20566	0.08	_
101-95	20567-20571	1.77	_
101-96	20572-20577	0.081	_
101-97	20578-20582	0.04	_
101-98	20585-20589	High	_
101-99	20590-20594	loss	_
101-100	20598-20603	Group	_
101-101	20604-20608	0.24	_
101-102	20609-20613	0.08	_
101-103	20614-20615	−	_
101-104	20615-20619	3.15	_
101-105	20620-20625	0.002	_
101-106	20626-20630	0.11	_
101-107	20634-20636	MA	_
101-108	20637-20638	(	_
101-109	20638-20639	T	_
101-110	20639-20640	)	_
101-111	20641-20648	carrier	_
101-112	20649-20652	0.1	_
101-113	20653-20657	0.06	_
101-114	20658-20659	−	_
101-115	20659-20663	1.59	_
101-116	20664-20669	0.115	_
101-117	20670-20674	0.03	_
101-118	20678-20689	Interaction	_
101-119	20690-20693	0.2	_
101-120	20694-20698	0.09	_
101-121	20699-20703	2.29	_
101-122	20704-20709	0.024	_
101-123	20710-20714	0.06	_
101-124	20717-20720	Low	_
101-125	20721-20725	loss	_
101-126	20729-20734	Group	_
101-127	20735-20739	0.17	_
101-128	20740-20744	0.07	_
101-129	20745-20746	−	_
101-130	20746-20750	2.49	_
101-131	20751-20756	0.015	_
101-132	20757-20761	0.07	_
101-133	20765-20767	MA	_
101-134	20768-20769	(	_
101-135	20769-20770	T	_
101-136	20770-20771	)	_
101-137	20772-20779	carrier	_
101-138	20780-20784	0.08	_
101-139	20785-20789	0.06	_
101-140	20790-20791	−	_
101-141	20791-20795	1.46	_
101-142	20796-20801	0.148	_
101-143	20802-20806	0.03	_
101-144	20810-20821	Interaction	_
101-145	20822-20826	0.16	_
101-146	20827-20831	0.08	_
101-147	20832-20836	2.03	_
101-148	20837-20842	0.046	_
101-149	20843-20847	0.05	_
101-150	20851-20855	Note	_
101-151	20855-20856	.	_

#Text=MA (T) minor allele T
#Text=Boldface indicates significance
#Text=Interaction effects of rs10514299 and alcohol dependence on putamen activation.
102-1	20857-20859	MA	_
102-2	20860-20861	(	_
102-3	20861-20862	T	_
102-4	20862-20863	)	_
102-5	20864-20869	minor	_
102-6	20870-20876	allele	_
102-7	20877-20878	T	_
102-8	20879-20887	Boldface	_
102-9	20888-20897	indicates	_
102-10	20898-20910	significance	_
102-11	20911-20922	Interaction	_
102-12	20923-20930	effects	_
102-13	20931-20933	of	_
102-14	20934-20944	rs10514299	_
102-15	20945-20948	and	_
102-16	20949-20956	alcohol	_
102-17	20957-20967	dependence	_
102-18	20968-20970	on	_
102-19	20971-20978	putamen	_
102-20	20979-20989	activation	_
102-21	20989-20990	.	_

#Text=Bar graphs of the interaction between rs10514299 genotype and alcohol dependence diagnosis on putamen activation during (a) high reward anticipation; (b) low reward anticipation; (c) high loss anticipation; and (d) low loss anticipation.
103-1	20991-20994	Bar	_
103-2	20995-21001	graphs	_
103-3	21002-21004	of	_
103-4	21005-21008	the	_
103-5	21009-21020	interaction	_
103-6	21021-21028	between	_
103-7	21029-21039	rs10514299	_
103-8	21040-21048	genotype	_
103-9	21049-21052	and	_
103-10	21053-21060	alcohol	_
103-11	21061-21071	dependence	_
103-12	21072-21081	diagnosis	_
103-13	21082-21084	on	_
103-14	21085-21092	putamen	_
103-15	21093-21103	activation	_
103-16	21104-21110	during	_
103-17	21111-21112	(	_
103-18	21112-21113	a	_
103-19	21113-21114	)	_
103-20	21115-21119	high	_
103-21	21120-21126	reward	_
103-22	21127-21139	anticipation	_
103-23	21139-21140	;	_
103-24	21141-21142	(	_
103-25	21142-21143	b	_
103-26	21143-21144	)	_
103-27	21145-21148	low	_
103-28	21149-21155	reward	_
103-29	21156-21168	anticipation	_
103-30	21168-21169	;	_
103-31	21170-21171	(	_
103-32	21171-21172	c	_
103-33	21172-21173	)	_
103-34	21174-21178	high	_
103-35	21179-21183	loss	_
103-36	21184-21196	anticipation	_
103-37	21196-21197	;	_
103-38	21198-21201	and	_
103-39	21202-21203	(	_
103-40	21203-21204	d	_
103-41	21204-21205	)	_
103-42	21206-21209	low	_
103-43	21210-21214	loss	_
103-44	21215-21227	anticipation	_
103-45	21227-21228	.	_

#Text=Error bars represent standard error of the mean.
104-1	21229-21234	Error	_
104-2	21235-21239	bars	_
104-3	21240-21249	represent	_
104-4	21250-21258	standard	_
104-5	21259-21264	error	_
104-6	21265-21267	of	_
104-7	21268-21271	the	_
104-8	21272-21276	mean	_
104-9	21276-21277	.	_

#Text=(e) Putamen mask (displayed at z = 5) obtained from Talairach Daemon Atlas in AFNI used to extract individual subjects’ beta coefficients for reward/loss anticipation.
105-1	21278-21279	(	_
105-2	21279-21280	e	_
105-3	21280-21281	)	_
105-4	21282-21289	Putamen	_
105-5	21290-21294	mask	_
105-6	21295-21296	(	_
105-7	21296-21305	displayed	_
105-8	21306-21308	at	_
105-9	21309-21310	z	_
105-10	21311-21312	=	_
105-11	21313-21314	5	_
105-12	21314-21315	)	_
105-13	21316-21324	obtained	_
105-14	21325-21329	from	_
105-15	21330-21339	Talairach	_
105-16	21340-21346	Daemon	_
105-17	21347-21352	Atlas	_
105-18	21353-21355	in	_
105-19	21356-21360	AFNI	_
105-20	21361-21365	used	_
105-21	21366-21368	to	_
105-22	21369-21376	extract	_
105-23	21377-21387	individual	_
105-24	21388-21396	subjects	_
105-25	21396-21397	’	_
105-26	21398-21402	beta	_
105-27	21403-21415	coefficients	_
105-28	21416-21419	for	_
105-29	21420-21426	reward	_
105-30	21426-21427	/	_
105-31	21427-21431	loss	_
105-32	21432-21444	anticipation	_
105-33	21444-21445	.	_

#Text=AD alcohol-dependent group, HC healthy control group
#Text=For the main analyses, effects of diagnosis (AD vs.
106-1	21446-21448	AD	_
106-2	21449-21466	alcohol-dependent	_
106-3	21467-21472	group	_
106-4	21472-21473	,	_
106-5	21474-21476	HC	_
106-6	21477-21484	healthy	_
106-7	21485-21492	control	_
106-8	21493-21498	group	_
106-9	21499-21502	For	_
106-10	21503-21506	the	_
106-11	21507-21511	main	_
106-12	21512-21520	analyses	_
106-13	21520-21521	,	_
106-14	21522-21529	effects	_
106-15	21530-21532	of	_
106-16	21533-21542	diagnosis	_
106-17	21543-21544	(	_
106-18	21544-21546	AD	_
106-19	21547-21549	vs	_
106-20	21549-21550	.	_

#Text=HC), rs10514299 genotype (CC vs.
107-1	21551-21553	HC	_
107-2	21553-21554	)	_
107-3	21554-21555	,	_
107-4	21556-21566	rs10514299	_
107-5	21567-21575	genotype	_
107-6	21576-21577	(	_
107-7	21577-21579	CC	_
107-8	21580-21582	vs	_
107-9	21582-21583	.	_

#Text=TT/CT), and their interaction on striatal activation were examined using 2 × 2 ANCOVAs controlling for age, gender, AIM Africa, and AIM Europe.
108-1	21584-21586	TT	_
108-2	21586-21587	/	_
108-3	21587-21589	CT	_
108-4	21589-21590	)	_
108-5	21590-21591	,	_
108-6	21592-21595	and	_
108-7	21596-21601	their	_
108-8	21602-21613	interaction	_
108-9	21614-21616	on	_
108-10	21617-21625	striatal	_
108-11	21626-21636	activation	_
108-12	21637-21641	were	_
108-13	21642-21650	examined	_
108-14	21651-21656	using	_
108-15	21657-21658	2	_
108-16	21659-21660	×	_
108-17	21661-21662	2	_
108-18	21663-21670	ANCOVAs	_
108-19	21671-21682	controlling	_
108-20	21683-21686	for	_
108-21	21687-21690	age	_
108-22	21690-21691	,	_
108-23	21692-21698	gender	_
108-24	21698-21699	,	_
108-25	21700-21703	AIM	_
108-26	21704-21710	Africa	_
108-27	21710-21711	,	_
108-28	21712-21715	and	_
108-29	21716-21719	AIM	_
108-30	21720-21726	Europe	_
108-31	21726-21727	.	_

#Text=Parameter estimates can be found in Table 3.
109-1	21728-21737	Parameter	_
109-2	21738-21747	estimates	_
109-3	21748-21751	can	_
109-4	21752-21754	be	_
109-5	21755-21760	found	_
109-6	21761-21763	in	_
109-7	21764-21769	Table	_
109-8	21770-21771	3	_
109-9	21771-21772	.	_

#Text=Levene’s test and normality checks were carried out and assumptions were met.
110-1	21773-21779	Levene	_
110-2	21779-21780	’	_
110-3	21780-21781	s	_
110-4	21782-21786	test	_
110-5	21787-21790	and	_
110-6	21791-21800	normality	_
110-7	21801-21807	checks	_
110-8	21808-21812	were	_
110-9	21813-21820	carried	_
110-10	21821-21824	out	_
110-11	21825-21828	and	_
110-12	21829-21840	assumptions	_
110-13	21841-21845	were	_
110-14	21846-21849	met	_
110-15	21849-21850	.	_

#Text=There were no significant group-by-genotype findings for the caudate and nucleus accumbens (see Supplementary Table 1).
111-1	21851-21856	There	_
111-2	21857-21861	were	_
111-3	21862-21864	no	_
111-4	21865-21876	significant	_
111-5	21877-21894	group-by-genotype	_
111-6	21895-21903	findings	_
111-7	21904-21907	for	_
111-8	21908-21911	the	_
111-9	21912-21919	caudate	_
111-10	21920-21923	and	_
111-11	21924-21931	nucleus	_
111-12	21932-21941	accumbens	_
111-13	21942-21943	(	_
111-14	21943-21946	see	_
111-15	21947-21960	Supplementary	_
111-16	21961-21966	Table	_
111-17	21967-21968	1	_
111-18	21968-21969	)	_
111-19	21969-21970	.	_

#Text=However, results showed a significant diagnosis-genotype interaction effect (F(1,82) = 6.37, p = 0.014, ηp2 = 0.07) on putamen activation during high reward anticipation.
112-1	21971-21978	However	_
112-2	21978-21979	,	_
112-3	21980-21987	results	_
112-4	21988-21994	showed	_
112-5	21995-21996	a	_
112-6	21997-22008	significant	_
112-7	22009-22027	diagnosis-genotype	_
112-8	22028-22039	interaction	_
112-9	22040-22046	effect	_
112-10	22047-22048	(	_
112-11	22048-22049	F	_
112-12	22049-22050	(	_
112-13	22050-22054	1,82	_
112-14	22054-22055	)	_
112-15	22056-22057	=	_
112-16	22058-22062	6.37	_
112-17	22062-22063	,	_
112-18	22064-22065	p	_
112-19	22066-22067	=	_
112-20	22068-22073	0.014	_
112-21	22073-22074	,	_
112-22	22075-22078	ηp2	_
112-23	22079-22080	=	_
112-24	22081-22085	0.07	_
112-25	22085-22086	)	_
112-26	22087-22089	on	_
112-27	22090-22097	putamen	_
112-28	22098-22108	activation	_
112-29	22109-22115	during	_
112-30	22116-22120	high	_
112-31	22121-22127	reward	_
112-32	22128-22140	anticipation	_
112-33	22140-22141	.	_

#Text=In the control group, both genotype groups showed similar putamen activation during high reward anticipation; however, in the AD group, individuals who carry the minor allele T (TT/CT) showed significantly greater putamen activation during high reward anticipation compared to CC carriers (see Fig. 1a).
113-1	22142-22144	In	_
113-2	22145-22148	the	_
113-3	22149-22156	control	_
113-4	22157-22162	group	_
113-5	22162-22163	,	_
113-6	22164-22168	both	_
113-7	22169-22177	genotype	_
113-8	22178-22184	groups	_
113-9	22185-22191	showed	_
113-10	22192-22199	similar	_
113-11	22200-22207	putamen	_
113-12	22208-22218	activation	_
113-13	22219-22225	during	_
113-14	22226-22230	high	_
113-15	22231-22237	reward	_
113-16	22238-22250	anticipation	_
113-17	22250-22251	;	_
113-18	22252-22259	however	_
113-19	22259-22260	,	_
113-20	22261-22263	in	_
113-21	22264-22267	the	_
113-22	22268-22270	AD	_
113-23	22271-22276	group	_
113-24	22276-22277	,	_
113-25	22278-22289	individuals	_
113-26	22290-22293	who	_
113-27	22294-22299	carry	_
113-28	22300-22303	the	_
113-29	22304-22309	minor	_
113-30	22310-22316	allele	_
113-31	22317-22318	T	_
113-32	22319-22320	(	_
113-33	22320-22322	TT	_
113-34	22322-22323	/	_
113-35	22323-22325	CT	_
113-36	22325-22326	)	_
113-37	22327-22333	showed	_
113-38	22334-22347	significantly	_
113-39	22348-22355	greater	_
113-40	22356-22363	putamen	_
113-41	22364-22374	activation	_
113-42	22375-22381	during	_
113-43	22382-22386	high	_
113-44	22387-22393	reward	_
113-45	22394-22406	anticipation	_
113-46	22407-22415	compared	_
113-47	22416-22418	to	_
113-48	22419-22421	CC	_
113-49	22422-22430	carriers	_
113-50	22431-22432	(	_
113-51	22432-22435	see	_
113-52	22436-22439	Fig	_
113-53	22439-22440	.	_
113-54	22441-22443	1a	_
113-55	22443-22444	)	_
113-56	22444-22445	.	_

#Text=Furthermore, there was a trend-level diagnosis-genotype interaction effect (F(1,82) = 3.12, p = 0.081, ηp2 = 0.04) on BOLD activation in the putamen during the anticipation of low reward.
114-1	22446-22457	Furthermore	_
114-2	22457-22458	,	_
114-3	22459-22464	there	_
114-4	22465-22468	was	_
114-5	22469-22470	a	_
114-6	22471-22482	trend-level	_
114-7	22483-22501	diagnosis-genotype	_
114-8	22502-22513	interaction	_
114-9	22514-22520	effect	_
114-10	22521-22522	(	_
114-11	22522-22523	F	_
114-12	22523-22524	(	_
114-13	22524-22528	1,82	_
114-14	22528-22529	)	_
114-15	22530-22531	=	_
114-16	22532-22536	3.12	_
114-17	22536-22537	,	_
114-18	22538-22539	p	_
114-19	22540-22541	=	_
114-20	22542-22547	0.081	_
114-21	22547-22548	,	_
114-22	22549-22552	ηp2	_
114-23	22553-22554	=	_
114-24	22555-22559	0.04	_
114-25	22559-22560	)	_
114-26	22561-22563	on	_
114-27	22564-22568	BOLD	_
114-28	22569-22579	activation	_
114-29	22580-22582	in	_
114-30	22583-22586	the	_
114-31	22587-22594	putamen	_
114-32	22595-22601	during	_
114-33	22602-22605	the	_
114-34	22606-22618	anticipation	_
114-35	22619-22621	of	_
114-36	22622-22625	low	_
114-37	22626-22632	reward	_
114-38	22632-22633	.	_

#Text=Carrying the T allele was associated with decreased putamen activation during low reward anticipation in the HCs, while it was associated with increased putamen activation during low reward anticipation in individuals with AD (see Fig. 1b).
115-1	22634-22642	Carrying	_
115-2	22643-22646	the	_
115-3	22647-22648	T	_
115-4	22649-22655	allele	_
115-5	22656-22659	was	_
115-6	22660-22670	associated	_
115-7	22671-22675	with	_
115-8	22676-22685	decreased	_
115-9	22686-22693	putamen	_
115-10	22694-22704	activation	_
115-11	22705-22711	during	_
115-12	22712-22715	low	_
115-13	22716-22722	reward	_
115-14	22723-22735	anticipation	_
115-15	22736-22738	in	_
115-16	22739-22742	the	_
115-17	22743-22746	HCs	_
115-18	22746-22747	,	_
115-19	22748-22753	while	_
115-20	22754-22756	it	_
115-21	22757-22760	was	_
115-22	22761-22771	associated	_
115-23	22772-22776	with	_
115-24	22777-22786	increased	_
115-25	22787-22794	putamen	_
115-26	22795-22805	activation	_
115-27	22806-22812	during	_
115-28	22813-22816	low	_
115-29	22817-22823	reward	_
115-30	22824-22836	anticipation	_
115-31	22837-22839	in	_
115-32	22840-22851	individuals	_
115-33	22852-22856	with	_
115-34	22857-22859	AD	_
115-35	22860-22861	(	_
115-36	22861-22864	see	_
115-37	22865-22868	Fig	_
115-38	22868-22869	.	_
115-39	22870-22872	1b	_
115-40	22872-22873	)	_
115-41	22873-22874	.	_

#Text=Additionally, there was a significant diagnosis-genotype interaction effect (F(1,82) = 5.25, p = 0.024, ηp2 = 0.06) on BOLD activation in the putamen during the anticipation of high loss.
116-1	22875-22887	Additionally	_
116-2	22887-22888	,	_
116-3	22889-22894	there	_
116-4	22895-22898	was	_
116-5	22899-22900	a	_
116-6	22901-22912	significant	_
116-7	22913-22931	diagnosis-genotype	_
116-8	22932-22943	interaction	_
116-9	22944-22950	effect	_
116-10	22951-22952	(	_
116-11	22952-22953	F	_
116-12	22953-22954	(	_
116-13	22954-22958	1,82	_
116-14	22958-22959	)	_
116-15	22960-22961	=	_
116-16	22962-22966	5.25	_
116-17	22966-22967	,	_
116-18	22968-22969	p	_
116-19	22970-22971	=	_
116-20	22972-22977	0.024	_
116-21	22977-22978	,	_
116-22	22979-22982	ηp2	_
116-23	22983-22984	=	_
116-24	22985-22989	0.06	_
116-25	22989-22990	)	_
116-26	22991-22993	on	_
116-27	22994-22998	BOLD	_
116-28	22999-23009	activation	_
116-29	23010-23012	in	_
116-30	23013-23016	the	_
116-31	23017-23024	putamen	_
116-32	23025-23031	during	_
116-33	23032-23035	the	_
116-34	23036-23048	anticipation	_
116-35	23049-23051	of	_
116-36	23052-23056	high	_
116-37	23057-23061	loss	_
116-38	23061-23062	.	_

#Text=Carrying the T allele was associated with significantly decreased putamen activation during high loss anticipation in the HCs, while it was associated with significantly increased putamen activation in individuals with AD (see Fig. 1c).
117-1	23063-23071	Carrying	_
117-2	23072-23075	the	_
117-3	23076-23077	T	_
117-4	23078-23084	allele	_
117-5	23085-23088	was	_
117-6	23089-23099	associated	_
117-7	23100-23104	with	_
117-8	23105-23118	significantly	_
117-9	23119-23128	decreased	_
117-10	23129-23136	putamen	_
117-11	23137-23147	activation	_
117-12	23148-23154	during	_
117-13	23155-23159	high	_
117-14	23160-23164	loss	_
117-15	23165-23177	anticipation	_
117-16	23178-23180	in	_
117-17	23181-23184	the	_
117-18	23185-23188	HCs	_
117-19	23188-23189	,	_
117-20	23190-23195	while	_
117-21	23196-23198	it	_
117-22	23199-23202	was	_
117-23	23203-23213	associated	_
117-24	23214-23218	with	_
117-25	23219-23232	significantly	_
117-26	23233-23242	increased	_
117-27	23243-23250	putamen	_
117-28	23251-23261	activation	_
117-29	23262-23264	in	_
117-30	23265-23276	individuals	_
117-31	23277-23281	with	_
117-32	23282-23284	AD	_
117-33	23285-23286	(	_
117-34	23286-23289	see	_
117-35	23290-23293	Fig	_
117-36	23293-23294	.	_
117-37	23295-23297	1c	_
117-38	23297-23298	)	_
117-39	23298-23299	.	_

#Text=Similarly, there was a significant diagnosis-genotype interaction effect (F(1,82) = 4.10, p = 0.046, ηp2 = 0.05) on putamen activation during low loss anticipation.
118-1	23300-23309	Similarly	_
118-2	23309-23310	,	_
118-3	23311-23316	there	_
118-4	23317-23320	was	_
118-5	23321-23322	a	_
118-6	23323-23334	significant	_
118-7	23335-23353	diagnosis-genotype	_
118-8	23354-23365	interaction	_
118-9	23366-23372	effect	_
118-10	23373-23374	(	_
118-11	23374-23375	F	_
118-12	23375-23376	(	_
118-13	23376-23380	1,82	_
118-14	23380-23381	)	_
118-15	23382-23383	=	_
118-16	23384-23388	4.10	_
118-17	23388-23389	,	_
118-18	23390-23391	p	_
118-19	23392-23393	=	_
118-20	23394-23399	0.046	_
118-21	23399-23400	,	_
118-22	23401-23404	ηp2	_
118-23	23405-23406	=	_
118-24	23407-23411	0.05	_
118-25	23411-23412	)	_
118-26	23413-23415	on	_
118-27	23416-23423	putamen	_
118-28	23424-23434	activation	_
118-29	23435-23441	during	_
118-30	23442-23445	low	_
118-31	23446-23450	loss	_
118-32	23451-23463	anticipation	_
118-33	23463-23464	.	_

#Text=In the HC group, T allele carriers showed significantly lower putamen activation, whereas individuals with AD showed significantly greater putamen activation during low loss anticipation (see Fig. 1d).
119-1	23465-23467	In	_
119-2	23468-23471	the	_
119-3	23472-23474	HC	_
119-4	23475-23480	group	_
119-5	23480-23481	,	_
119-6	23482-23483	T	_
119-7	23484-23490	allele	_
119-8	23491-23499	carriers	_
119-9	23500-23506	showed	_
119-10	23507-23520	significantly	_
119-11	23521-23526	lower	_
119-12	23527-23534	putamen	_
119-13	23535-23545	activation	_
119-14	23545-23546	,	_
119-15	23547-23554	whereas	_
119-16	23555-23566	individuals	_
119-17	23567-23571	with	_
119-18	23572-23574	AD	_
119-19	23575-23581	showed	_
119-20	23582-23595	significantly	_
119-21	23596-23603	greater	_
119-22	23604-23611	putamen	_
119-23	23612-23622	activation	_
119-24	23623-23629	during	_
119-25	23630-23633	low	_
119-26	23634-23638	loss	_
119-27	23639-23651	anticipation	_
119-28	23652-23653	(	_
119-29	23653-23656	see	_
119-30	23657-23660	Fig	_
119-31	23660-23661	.	_
119-32	23662-23664	1d	_
119-33	23664-23665	)	_
119-34	23665-23666	.	_

#Text=NIAAA Sample
#Text=The minor allele T frequency of rs10514299 was 0.21 in the full sample (n = 1858), 0.25 in subjects of European ancestry (n = 942), and 0.18 in subjects of African ancestry (n = 739).
120-1	23667-23672	NIAAA	_
120-2	23673-23679	Sample	_
120-3	23680-23683	The	_
120-4	23684-23689	minor	_
120-5	23690-23696	allele	_
120-6	23697-23698	T	_
120-7	23699-23708	frequency	_
120-8	23709-23711	of	_
120-9	23712-23722	rs10514299	_
120-10	23723-23726	was	_
120-11	23727-23731	0.21	_
120-12	23732-23734	in	_
120-13	23735-23738	the	_
120-14	23739-23743	full	_
120-15	23744-23750	sample	_
120-16	23751-23752	(	_
120-17	23752-23753	n	_
120-18	23754-23755	=	_
120-19	23756-23760	1858	_
120-20	23760-23761	)	_
120-21	23761-23762	,	_
120-22	23763-23767	0.25	_
120-23	23768-23770	in	_
120-24	23771-23779	subjects	_
120-25	23780-23782	of	_
120-26	23783-23791	European	_
120-27	23792-23800	ancestry	_
120-28	23801-23802	(	_
120-29	23802-23803	n	_
120-30	23804-23805	=	_
120-31	23806-23809	942	_
120-32	23809-23810	)	_
120-33	23810-23811	,	_
120-34	23812-23815	and	_
120-35	23816-23820	0.18	_
120-36	23821-23823	in	_
120-37	23824-23832	subjects	_
120-38	23833-23835	of	_
120-39	23836-23843	African	_
120-40	23844-23852	ancestry	_
120-41	23853-23854	(	_
120-42	23854-23855	n	_
120-43	23856-23857	=	_
120-44	23858-23861	739	_
120-45	23861-23862	)	_
120-46	23862-23863	.	_

#Text=HWE was not violated in the full sample (p = 0.33), nor in the EA (p = 0.10) or AA (p = 0.53) subgroups.
121-1	23864-23867	HWE	_
121-2	23868-23871	was	_
121-3	23872-23875	not	_
121-4	23876-23884	violated	_
121-5	23885-23887	in	_
121-6	23888-23891	the	_
121-7	23892-23896	full	_
121-8	23897-23903	sample	_
121-9	23904-23905	(	_
121-10	23905-23906	p	_
121-11	23907-23908	=	_
121-12	23909-23913	0.33	_
121-13	23913-23914	)	_
121-14	23914-23915	,	_
121-15	23916-23919	nor	_
121-16	23920-23922	in	_
121-17	23923-23926	the	_
121-18	23927-23929	EA	_
121-19	23930-23931	(	_
121-20	23931-23932	p	_
121-21	23933-23934	=	_
121-22	23935-23939	0.10	_
121-23	23939-23940	)	_
121-24	23941-23943	or	_
121-25	23944-23946	AA	_
121-26	23947-23948	(	_
121-27	23948-23949	p	_
121-28	23950-23951	=	_
121-29	23952-23956	0.53	_
121-30	23956-23957	)	_
121-31	23958-23967	subgroups	_
121-32	23967-23968	.	_

#Text=Results of association analyses in the NIAAA Clinical Sample
#Text=\tLifetime alcohol dependence\tMADRS scorea\t \tSample\tCases (n)\tControls (n)\tCases MAF\tControls MAF\tOdds ratio\tp value\tSample (n)\tBeta\tp value\t \tAll subjects\t1123\t735\t0.21\t0.22\t0.95\t0.45\t955\t1.25\t0.02\t \tEuropean/Caucasianb\t531\t411\t0.23\t0.28\t0.82\t0.09\t442\t0.85\t0.27\t \tAfrican Americanb\t507\t232\t0.18\t0.17\t1.07\t0.67\t439\t2.10\t0.008\t \t
#Text=Note.
122-1	23969-23976	Results	_
122-2	23977-23979	of	_
122-3	23980-23991	association	_
122-4	23992-24000	analyses	_
122-5	24001-24003	in	_
122-6	24004-24007	the	_
122-7	24008-24013	NIAAA	_
122-8	24014-24022	Clinical	_
122-9	24023-24029	Sample	_
122-10	24031-24039	Lifetime	_
122-11	24040-24047	alcohol	_
122-12	24048-24058	dependence	_
122-13	24059-24064	MADRS	_
122-14	24065-24071	scorea	_
122-15	24074-24080	Sample	_
122-16	24081-24086	Cases	_
122-17	24087-24088	(	_
122-18	24088-24089	n	_
122-19	24089-24090	)	_
122-20	24091-24099	Controls	_
122-21	24100-24101	(	_
122-22	24101-24102	n	_
122-23	24102-24103	)	_
122-24	24104-24109	Cases	_
122-25	24110-24113	MAF	_
122-26	24114-24122	Controls	_
122-27	24123-24126	MAF	_
122-28	24127-24131	Odds	_
122-29	24132-24137	ratio	_
122-30	24138-24139	p	_
122-31	24140-24145	value	_
122-32	24146-24152	Sample	_
122-33	24153-24154	(	_
122-34	24154-24155	n	_
122-35	24155-24156	)	_
122-36	24157-24161	Beta	_
122-37	24162-24163	p	_
122-38	24164-24169	value	_
122-39	24172-24175	All	_
122-40	24176-24184	subjects	_
122-41	24185-24189	1123	_
122-42	24190-24193	735	_
122-43	24194-24198	0.21	_
122-44	24199-24203	0.22	_
122-45	24204-24208	0.95	_
122-46	24209-24213	0.45	_
122-47	24214-24217	955	_
122-48	24218-24222	1.25	_
122-49	24223-24227	0.02	_
122-50	24230-24238	European	_
122-51	24238-24239	/	_
122-52	24239-24249	Caucasianb	_
122-53	24250-24253	531	_
122-54	24254-24257	411	_
122-55	24258-24262	0.23	_
122-56	24263-24267	0.28	_
122-57	24268-24272	0.82	_
122-58	24273-24277	0.09	_
122-59	24278-24281	442	_
122-60	24282-24286	0.85	_
122-61	24287-24291	0.27	_
122-62	24294-24301	African	_
122-63	24302-24311	Americanb	_
122-64	24312-24315	507	_
122-65	24316-24319	232	_
122-66	24320-24324	0.18	_
122-67	24325-24329	0.17	_
122-68	24330-24334	1.07	_
122-69	24335-24339	0.67	_
122-70	24340-24343	439	_
122-71	24344-24348	2.10	_
122-72	24349-24354	0.008	_
122-73	24358-24362	Note	_
122-74	24362-24363	.	_

#Text=MAF minor allele T frequency, MADRS Montgomery-Asberg Depression Rating scale
#Text=aOnly in subjects with lifetime alcohol dependence.
123-1	24364-24367	MAF	_
123-2	24368-24373	minor	_
123-3	24374-24380	allele	_
123-4	24381-24382	T	_
123-5	24383-24392	frequency	_
123-6	24392-24393	,	_
123-7	24394-24399	MADRS	_
123-8	24400-24417	Montgomery-Asberg	_
123-9	24418-24428	Depression	_
123-10	24429-24435	Rating	_
123-11	24436-24441	scale	_
123-12	24442-24447	aOnly	_
123-13	24448-24450	in	_
123-14	24451-24459	subjects	_
123-15	24460-24464	with	_
123-16	24465-24473	lifetime	_
123-17	24474-24481	alcohol	_
123-18	24482-24492	dependence	_
123-19	24492-24493	.	_

#Text=Boldface indicates significance.
#Text=bBased on self-report
#Text=Case-control analysis revealed a trend association between rs10514299 and lifetime diagnosis of AD but only in the EA subgroup (Table 4).
124-1	24494-24502	Boldface	_
124-2	24503-24512	indicates	_
124-3	24513-24525	significance	_
124-4	24525-24526	.	_
124-5	24527-24533	bBased	_
124-6	24534-24536	on	_
124-7	24537-24548	self-report	_
124-8	24549-24561	Case-control	_
124-9	24562-24570	analysis	_
124-10	24571-24579	revealed	_
124-11	24580-24581	a	_
124-12	24582-24587	trend	_
124-13	24588-24599	association	_
124-14	24600-24607	between	_
124-15	24608-24618	rs10514299	_
124-16	24619-24622	and	_
124-17	24623-24631	lifetime	_
124-18	24632-24641	diagnosis	_
124-19	24642-24644	of	_
124-20	24645-24647	AD	_
124-21	24648-24651	but	_
124-22	24652-24656	only	_
124-23	24657-24659	in	_
124-24	24660-24663	the	_
124-25	24664-24666	EA	_
124-26	24667-24675	subgroup	_
124-27	24676-24677	(	_
124-28	24677-24682	Table	_
124-29	24683-24684	4	_
124-30	24684-24685	)	_
124-31	24685-24686	.	_

#Text=In this sample, the minor allele T was associated with a protective effect against lifetime AD (odds ratio = 0.82, p = 0.09).
125-1	24687-24689	In	_
125-2	24690-24694	this	_
125-3	24695-24701	sample	_
125-4	24701-24702	,	_
125-5	24703-24706	the	_
125-6	24707-24712	minor	_
125-7	24713-24719	allele	_
125-8	24720-24721	T	_
125-9	24722-24725	was	_
125-10	24726-24736	associated	_
125-11	24737-24741	with	_
125-12	24742-24743	a	_
125-13	24744-24754	protective	_
125-14	24755-24761	effect	_
125-15	24762-24769	against	_
125-16	24770-24778	lifetime	_
125-17	24779-24781	AD	_
125-18	24782-24783	(	_
125-19	24783-24787	odds	_
125-20	24788-24793	ratio	_
125-21	24794-24795	=	_
125-22	24796-24800	0.82	_
125-23	24800-24801	,	_
125-24	24802-24803	p	_
125-25	24804-24805	=	_
125-26	24806-24810	0.09	_
125-27	24810-24811	)	_
125-28	24811-24812	.	_

#Text=Among subjects reporting a lifetime AD diagnosis, there was a significant association between rs10514299 and the MADRS score in the full sample, as well as in the AA subgroup (Table 4).
126-1	24813-24818	Among	_
126-2	24819-24827	subjects	_
126-3	24828-24837	reporting	_
126-4	24838-24839	a	_
126-5	24840-24848	lifetime	_
126-6	24849-24851	AD	_
126-7	24852-24861	diagnosis	_
126-8	24861-24862	,	_
126-9	24863-24868	there	_
126-10	24869-24872	was	_
126-11	24873-24874	a	_
126-12	24875-24886	significant	_
126-13	24887-24898	association	_
126-14	24899-24906	between	_
126-15	24907-24917	rs10514299	_
126-16	24918-24921	and	_
126-17	24922-24925	the	_
126-18	24926-24931	MADRS	_
126-19	24932-24937	score	_
126-20	24938-24940	in	_
126-21	24941-24944	the	_
126-22	24945-24949	full	_
126-23	24950-24956	sample	_
126-24	24956-24957	,	_
126-25	24958-24960	as	_
126-26	24961-24965	well	_
126-27	24966-24968	as	_
126-28	24969-24971	in	_
126-29	24972-24975	the	_
126-30	24976-24978	AA	_
126-31	24979-24987	subgroup	_
126-32	24988-24989	(	_
126-33	24989-24994	Table	_
126-34	24995-24996	4	_
126-35	24996-24997	)	_
126-36	24997-24998	.	_

#Text=Specifically, the minor allele T was associated with an increased MADRS score (full sample: β = 1.25, p = 0.019; AA subgroup: β = 2.10, p = 0.008).
127-1	24999-25011	Specifically	_
127-2	25011-25012	,	_
127-3	25013-25016	the	_
127-4	25017-25022	minor	_
127-5	25023-25029	allele	_
127-6	25030-25031	T	_
127-7	25032-25035	was	_
127-8	25036-25046	associated	_
127-9	25047-25051	with	_
127-10	25052-25054	an	_
127-11	25055-25064	increased	_
127-12	25065-25070	MADRS	_
127-13	25071-25076	score	_
127-14	25077-25078	(	_
127-15	25078-25082	full	_
127-16	25083-25089	sample	_
127-17	25089-25090	:	_
127-18	25091-25092	β	_
127-19	25093-25094	=	_
127-20	25095-25099	1.25	_
127-21	25099-25100	,	_
127-22	25101-25102	p	_
127-23	25103-25104	=	_
127-24	25105-25110	0.019	_
127-25	25110-25111	;	_
127-26	25112-25114	AA	_
127-27	25115-25123	subgroup	_
127-28	25123-25124	:	_
127-29	25125-25126	β	_
127-30	25127-25128	=	_
127-31	25129-25133	2.10	_
127-32	25133-25134	,	_
127-33	25135-25136	p	_
127-34	25137-25138	=	_
127-35	25139-25144	0.008	_
127-36	25144-25145	)	_
127-37	25145-25146	.	_

#Text=SAGE Sample
#Text=The minor allele T frequency of rs10514299 was 0.23 in the full sample (n = 3838), 0.24 in subjects of European ancestry (n = 2508), and 0.18 in subjects of African ancestry (n = 1330).
128-1	25147-25151	SAGE	_
128-2	25152-25158	Sample	_
128-3	25159-25162	The	_
128-4	25163-25168	minor	_
128-5	25169-25175	allele	_
128-6	25176-25177	T	_
128-7	25178-25187	frequency	_
128-8	25188-25190	of	_
128-9	25191-25201	rs10514299	_
128-10	25202-25205	was	_
128-11	25206-25210	0.23	_
128-12	25211-25213	in	_
128-13	25214-25217	the	_
128-14	25218-25222	full	_
128-15	25223-25229	sample	_
128-16	25230-25231	(	_
128-17	25231-25232	n	_
128-18	25233-25234	=	_
128-19	25235-25239	3838	_
128-20	25239-25240	)	_
128-21	25240-25241	,	_
128-22	25242-25246	0.24	_
128-23	25247-25249	in	_
128-24	25250-25258	subjects	_
128-25	25259-25261	of	_
128-26	25262-25270	European	_
128-27	25271-25279	ancestry	_
128-28	25280-25281	(	_
128-29	25281-25282	n	_
128-30	25283-25284	=	_
128-31	25285-25289	2508	_
128-32	25289-25290	)	_
128-33	25290-25291	,	_
128-34	25292-25295	and	_
128-35	25296-25300	0.18	_
128-36	25301-25303	in	_
128-37	25304-25312	subjects	_
128-38	25313-25315	of	_
128-39	25316-25323	African	_
128-40	25324-25332	ancestry	_
128-41	25333-25334	(	_
128-42	25334-25335	n	_
128-43	25336-25337	=	_
128-44	25338-25342	1330	_
128-45	25342-25343	)	_
128-46	25343-25344	.	_

#Text=Genotypes did not deviate from HWE.
129-1	25345-25354	Genotypes	_
129-2	25355-25358	did	_
129-3	25359-25362	not	_
129-4	25363-25370	deviate	_
129-5	25371-25375	from	_
129-6	25376-25379	HWE	_
129-7	25379-25380	.	_

#Text=There was no significant association of the T allele with AD in either the EA sample (1162 cases, 1346 controls; odds ratio = 0.97, p = 0.700) or the AA sample (686 cases, 644 controls; odds ratio = 1.06, p = 0.560).
130-1	25381-25386	There	_
130-2	25387-25390	was	_
130-3	25391-25393	no	_
130-4	25394-25405	significant	_
130-5	25406-25417	association	_
130-6	25418-25420	of	_
130-7	25421-25424	the	_
130-8	25425-25426	T	_
130-9	25427-25433	allele	_
130-10	25434-25438	with	_
130-11	25439-25441	AD	_
130-12	25442-25444	in	_
130-13	25445-25451	either	_
130-14	25452-25455	the	_
130-15	25456-25458	EA	_
130-16	25459-25465	sample	_
130-17	25466-25467	(	_
130-18	25467-25471	1162	_
130-19	25472-25477	cases	_
130-20	25477-25478	,	_
130-21	25479-25483	1346	_
130-22	25484-25492	controls	_
130-23	25492-25493	;	_
130-24	25494-25498	odds	_
130-25	25499-25504	ratio	_
130-26	25505-25506	=	_
130-27	25507-25511	0.97	_
130-28	25511-25512	,	_
130-29	25513-25514	p	_
130-30	25515-25516	=	_
130-31	25517-25522	0.700	_
130-32	25522-25523	)	_
130-33	25524-25526	or	_
130-34	25527-25530	the	_
130-35	25531-25533	AA	_
130-36	25534-25540	sample	_
130-37	25541-25542	(	_
130-38	25542-25545	686	_
130-39	25546-25551	cases	_
130-40	25551-25552	,	_
130-41	25553-25556	644	_
130-42	25557-25565	controls	_
130-43	25565-25566	;	_
130-44	25567-25571	odds	_
130-45	25572-25577	ratio	_
130-46	25578-25579	=	_
130-47	25580-25584	1.06	_
130-48	25584-25585	,	_
130-49	25586-25587	p	_
130-50	25588-25589	=	_
130-51	25590-25595	0.560	_
130-52	25595-25596	)	_
130-53	25596-25597	.	_

#Text=Discussion
#Text=The present study investigated the influence of a recent GWAS-identified risk variant in the TMEM161B-MEF2C gene cluster for MDD on striatal activation during the anticipation of high/low rewards/losses in individuals with AD and HCs.
131-1	25598-25608	Discussion	_
131-2	25609-25612	The	_
131-3	25613-25620	present	_
131-4	25621-25626	study	_
131-5	25627-25639	investigated	_
131-6	25640-25643	the	_
131-7	25644-25653	influence	_
131-8	25654-25656	of	_
131-9	25657-25658	a	_
131-10	25659-25665	recent	_
131-11	25666-25681	GWAS-identified	_
131-12	25682-25686	risk	_
131-13	25687-25694	variant	_
131-14	25695-25697	in	_
131-15	25698-25701	the	_
131-16	25702-25716	TMEM161B-MEF2C	_
131-17	25717-25721	gene	_
131-18	25722-25729	cluster	_
131-19	25730-25733	for	_
131-20	25734-25737	MDD	_
131-21	25738-25740	on	_
131-22	25741-25749	striatal	_
131-23	25750-25760	activation	_
131-24	25761-25767	during	_
131-25	25768-25771	the	_
131-26	25772-25784	anticipation	_
131-27	25785-25787	of	_
131-28	25788-25792	high	_
131-29	25792-25793	/	_
131-30	25793-25796	low	_
131-31	25797-25804	rewards	_
131-32	25804-25805	/	_
131-33	25805-25811	losses	_
131-34	25812-25814	in	_
131-35	25815-25826	individuals	_
131-36	25827-25831	with	_
131-37	25832-25834	AD	_
131-38	25835-25838	and	_
131-39	25839-25842	HCs	_
131-40	25842-25843	.	_

#Text=Furthermore, we examined associations between genetic variation in rs10514299 and a lifetime AD diagnosis in two clinical samples, and its association with depressive symptom severity as measured by the MADRS in a subsample of individuals with a lifetime AD diagnosis.
132-1	25844-25855	Furthermore	_
132-2	25855-25856	,	_
132-3	25857-25859	we	_
132-4	25860-25868	examined	_
132-5	25869-25881	associations	_
132-6	25882-25889	between	_
132-7	25890-25897	genetic	_
132-8	25898-25907	variation	_
132-9	25908-25910	in	_
132-10	25911-25921	rs10514299	_
132-11	25922-25925	and	_
132-12	25926-25927	a	_
132-13	25928-25936	lifetime	_
132-14	25937-25939	AD	_
132-15	25940-25949	diagnosis	_
132-16	25950-25952	in	_
132-17	25953-25956	two	_
132-18	25957-25965	clinical	_
132-19	25966-25973	samples	_
132-20	25973-25974	,	_
132-21	25975-25978	and	_
132-22	25979-25982	its	_
132-23	25983-25994	association	_
132-24	25995-25999	with	_
132-25	26000-26010	depressive	_
132-26	26011-26018	symptom	_
132-27	26019-26027	severity	_
132-28	26028-26030	as	_
132-29	26031-26039	measured	_
132-30	26040-26042	by	_
132-31	26043-26046	the	_
132-32	26047-26052	MADRS	_
132-33	26053-26055	in	_
132-34	26056-26057	a	_
132-35	26058-26067	subsample	_
132-36	26068-26070	of	_
132-37	26071-26082	individuals	_
132-38	26083-26087	with	_
132-39	26088-26089	a	_
132-40	26090-26098	lifetime	_
132-41	26099-26101	AD	_
132-42	26102-26111	diagnosis	_
132-43	26111-26112	.	_

#Text=Our data show for the first time an association of rs10514299 with a neuronal phenotype, namely putamen activation during a reward task.
133-1	26113-26116	Our	_
133-2	26117-26121	data	_
133-3	26122-26126	show	_
133-4	26127-26130	for	_
133-5	26131-26134	the	_
133-6	26135-26140	first	_
133-7	26141-26145	time	_
133-8	26146-26148	an	_
133-9	26149-26160	association	_
133-10	26161-26163	of	_
133-11	26164-26174	rs10514299	_
133-12	26175-26179	with	_
133-13	26180-26181	a	_
133-14	26182-26190	neuronal	_
133-15	26191-26200	phenotype	_
133-16	26200-26201	,	_
133-17	26202-26208	namely	_
133-18	26209-26216	putamen	_
133-19	26217-26227	activation	_
133-20	26228-26234	during	_
133-21	26235-26236	a	_
133-22	26237-26243	reward	_
133-23	26244-26248	task	_
133-24	26248-26249	.	_

#Text=We found that patients with AD who carry the minor allele T showed significantly greater putamen activation during the anticipation of high reward compared to controls (Table 3; Fig. 1a).
134-1	26250-26252	We	_
134-2	26253-26258	found	_
134-3	26259-26263	that	_
134-4	26264-26272	patients	_
134-5	26273-26277	with	_
134-6	26278-26280	AD	_
134-7	26281-26284	who	_
134-8	26285-26290	carry	_
134-9	26291-26294	the	_
134-10	26295-26300	minor	_
134-11	26301-26307	allele	_
134-12	26308-26309	T	_
134-13	26310-26316	showed	_
134-14	26317-26330	significantly	_
134-15	26331-26338	greater	_
134-16	26339-26346	putamen	_
134-17	26347-26357	activation	_
134-18	26358-26364	during	_
134-19	26365-26368	the	_
134-20	26369-26381	anticipation	_
134-21	26382-26384	of	_
134-22	26385-26389	high	_
134-23	26390-26396	reward	_
134-24	26397-26405	compared	_
134-25	26406-26408	to	_
134-26	26409-26417	controls	_
134-27	26418-26419	(	_
134-28	26419-26424	Table	_
134-29	26425-26426	3	_
134-30	26426-26427	;	_
134-31	26428-26431	Fig	_
134-32	26431-26432	.	_
134-33	26433-26435	1a	_
134-34	26435-26436	)	_
134-35	26436-26437	.	_

#Text=Furthermore, carrying the T allele was associated with a significant increase in putamen activation during high and low loss anticipation in patients with AD, but with a significant decrease in the controls, indicating that the minor allele T differentially affects this neural phenotype in AD (Table 3; Fig. 1c, d).
135-1	26438-26449	Furthermore	_
135-2	26449-26450	,	_
135-3	26451-26459	carrying	_
135-4	26460-26463	the	_
135-5	26464-26465	T	_
135-6	26466-26472	allele	_
135-7	26473-26476	was	_
135-8	26477-26487	associated	_
135-9	26488-26492	with	_
135-10	26493-26494	a	_
135-11	26495-26506	significant	_
135-12	26507-26515	increase	_
135-13	26516-26518	in	_
135-14	26519-26526	putamen	_
135-15	26527-26537	activation	_
135-16	26538-26544	during	_
135-17	26545-26549	high	_
135-18	26550-26553	and	_
135-19	26554-26557	low	_
135-20	26558-26562	loss	_
135-21	26563-26575	anticipation	_
135-22	26576-26578	in	_
135-23	26579-26587	patients	_
135-24	26588-26592	with	_
135-25	26593-26595	AD	_
135-26	26595-26596	,	_
135-27	26597-26600	but	_
135-28	26601-26605	with	_
135-29	26606-26607	a	_
135-30	26608-26619	significant	_
135-31	26620-26628	decrease	_
135-32	26629-26631	in	_
135-33	26632-26635	the	_
135-34	26636-26644	controls	_
135-35	26644-26645	,	_
135-36	26646-26656	indicating	_
135-37	26657-26661	that	_
135-38	26662-26665	the	_
135-39	26666-26671	minor	_
135-40	26672-26678	allele	_
135-41	26679-26680	T	_
135-42	26681-26695	differentially	_
135-43	26696-26703	affects	_
135-44	26704-26708	this	_
135-45	26709-26715	neural	_
135-46	26716-26725	phenotype	_
135-47	26726-26728	in	_
135-48	26729-26731	AD	_
135-49	26732-26733	(	_
135-50	26733-26738	Table	_
135-51	26739-26740	3	_
135-52	26740-26741	;	_
135-53	26742-26745	Fig	_
135-54	26745-26746	.	_
135-55	26747-26749	1c	_
135-56	26749-26750	,	_
135-57	26751-26752	d	_
135-58	26752-26753	)	_
135-59	26753-26754	.	_

#Text=These data are in line with prior studies that have shown disruptions in the dorsal striatum in individuals with AD during reward anticipation. e.g.,.
136-1	26755-26760	These	_
136-2	26761-26765	data	_
136-3	26766-26769	are	_
136-4	26770-26772	in	_
136-5	26773-26777	line	_
136-6	26778-26782	with	_
136-7	26783-26788	prior	_
136-8	26789-26796	studies	_
136-9	26797-26801	that	_
136-10	26802-26806	have	_
136-11	26807-26812	shown	_
136-12	26813-26824	disruptions	_
136-13	26825-26827	in	_
136-14	26828-26831	the	_
136-15	26832-26838	dorsal	_
136-16	26839-26847	striatum	_
136-17	26848-26850	in	_
136-18	26851-26862	individuals	_
136-19	26863-26867	with	_
136-20	26868-26870	AD	_
136-21	26871-26877	during	_
136-22	26878-26884	reward	_
136-23	26885-26897	anticipation	_
136-24	26897-26898	.	_
136-25	26899-26902	e.g	_
136-26	26902-26903	.	_
136-27	26903-26904	,	_
136-28	26904-26905	.	_

#Text=Neuroimaging studies in humans and neural recording studies in monkeys indicate that the putamen and caudate are involved in different aspects of reward-based learning e.g.,.
137-1	26906-26918	Neuroimaging	_
137-2	26919-26926	studies	_
137-3	26927-26929	in	_
137-4	26930-26936	humans	_
137-5	26937-26940	and	_
137-6	26941-26947	neural	_
137-7	26948-26957	recording	_
137-8	26958-26965	studies	_
137-9	26966-26968	in	_
137-10	26969-26976	monkeys	_
137-11	26977-26985	indicate	_
137-12	26986-26990	that	_
137-13	26991-26994	the	_
137-14	26995-27002	putamen	_
137-15	27003-27006	and	_
137-16	27007-27014	caudate	_
137-17	27015-27018	are	_
137-18	27019-27027	involved	_
137-19	27028-27030	in	_
137-20	27031-27040	different	_
137-21	27041-27048	aspects	_
137-22	27049-27051	of	_
137-23	27052-27064	reward-based	_
137-24	27065-27073	learning	_
137-25	27074-27077	e.g	_
137-26	27077-27078	.	_
137-27	27078-27079	,	_
137-28	27079-27080	.	_

#Text=While the caudate is involved in the coding of prediction errors, the putamen has been shown to mediate stimulus-action-reward associations.
138-1	27081-27086	While	_
138-2	27087-27090	the	_
138-3	27091-27098	caudate	_
138-4	27099-27101	is	_
138-5	27102-27110	involved	_
138-6	27111-27113	in	_
138-7	27114-27117	the	_
138-8	27118-27124	coding	_
138-9	27125-27127	of	_
138-10	27128-27138	prediction	_
138-11	27139-27145	errors	_
138-12	27145-27146	,	_
138-13	27147-27150	the	_
138-14	27151-27158	putamen	_
138-15	27159-27162	has	_
138-16	27163-27167	been	_
138-17	27168-27173	shown	_
138-18	27174-27176	to	_
138-19	27177-27184	mediate	_
138-20	27185-27207	stimulus-action-reward	_
138-21	27208-27220	associations	_
138-22	27220-27221	.	_

#Text=Our present study suggests that genetic variation in rs10514299 within the TMEM161B-MEF2C gene cluster may serve as a biomarker for disrupted reward processing in the putamen in alcohol-dependent individuals.
139-1	27222-27225	Our	_
139-2	27226-27233	present	_
139-3	27234-27239	study	_
139-4	27240-27248	suggests	_
139-5	27249-27253	that	_
139-6	27254-27261	genetic	_
139-7	27262-27271	variation	_
139-8	27272-27274	in	_
139-9	27275-27285	rs10514299	_
139-10	27286-27292	within	_
139-11	27293-27296	the	_
139-12	27297-27311	TMEM161B-MEF2C	_
139-13	27312-27316	gene	_
139-14	27317-27324	cluster	_
139-15	27325-27328	may	_
139-16	27329-27334	serve	_
139-17	27335-27337	as	_
139-18	27338-27339	a	_
139-19	27340-27349	biomarker	_
139-20	27350-27353	for	_
139-21	27354-27363	disrupted	_
139-22	27364-27370	reward	_
139-23	27371-27381	processing	_
139-24	27382-27384	in	_
139-25	27385-27388	the	_
139-26	27389-27396	putamen	_
139-27	27397-27399	in	_
139-28	27400-27417	alcohol-dependent	_
139-29	27418-27429	individuals	_
139-30	27429-27430	.	_

#Text=Future studies are needed to further investigate the functional relevance of this SNP in individuals with AD and to examine its association with the behavioral impairments in decision-making and reward-based learning that are often observed in AD populations.
140-1	27431-27437	Future	_
140-2	27438-27445	studies	_
140-3	27446-27449	are	_
140-4	27450-27456	needed	_
140-5	27457-27459	to	_
140-6	27460-27467	further	_
140-7	27468-27479	investigate	_
140-8	27480-27483	the	_
140-9	27484-27494	functional	_
140-10	27495-27504	relevance	_
140-11	27505-27507	of	_
140-12	27508-27512	this	_
140-13	27513-27516	SNP	_
140-14	27517-27519	in	_
140-15	27520-27531	individuals	_
140-16	27532-27536	with	_
140-17	27537-27539	AD	_
140-18	27540-27543	and	_
140-19	27544-27546	to	_
140-20	27547-27554	examine	_
140-21	27555-27558	its	_
140-22	27559-27570	association	_
140-23	27571-27575	with	_
140-24	27576-27579	the	_
140-25	27580-27590	behavioral	_
140-26	27591-27602	impairments	_
140-27	27603-27605	in	_
140-28	27606-27621	decision-making	_
140-29	27622-27625	and	_
140-30	27626-27638	reward-based	_
140-31	27639-27647	learning	_
140-32	27648-27652	that	_
140-33	27653-27656	are	_
140-34	27657-27662	often	_
140-35	27663-27671	observed	_
140-36	27672-27674	in	_
140-37	27675-27677	AD	_
140-38	27678-27689	populations	_
140-39	27689-27690	.	_

#Text=Furthermore, future studies should include seed-based correlation analyses to investigate the functional connectivity between reward-associated structures of the striatum (caudate, putamen, nucleus accumbens) and associated brain regions.
141-1	27691-27702	Furthermore	_
141-2	27702-27703	,	_
141-3	27704-27710	future	_
141-4	27711-27718	studies	_
141-5	27719-27725	should	_
141-6	27726-27733	include	_
141-7	27734-27744	seed-based	_
141-8	27745-27756	correlation	_
141-9	27757-27765	analyses	_
141-10	27766-27768	to	_
141-11	27769-27780	investigate	_
141-12	27781-27784	the	_
141-13	27785-27795	functional	_
141-14	27796-27808	connectivity	_
141-15	27809-27816	between	_
141-16	27817-27834	reward-associated	_
141-17	27835-27845	structures	_
141-18	27846-27848	of	_
141-19	27849-27852	the	_
141-20	27853-27861	striatum	_
141-21	27862-27863	(	_
141-22	27863-27870	caudate	_
141-23	27870-27871	,	_
141-24	27872-27879	putamen	_
141-25	27879-27880	,	_
141-26	27881-27888	nucleus	_
141-27	27889-27898	accumbens	_
141-28	27898-27899	)	_
141-29	27900-27903	and	_
141-30	27904-27914	associated	_
141-31	27915-27920	brain	_
141-32	27921-27928	regions	_
141-33	27928-27929	.	_

#Text=Our finding is intriguing given the often observed deficit of reward processing in MDD that is described clinically as anhedonia.
142-1	27930-27933	Our	_
142-2	27934-27941	finding	_
142-3	27942-27944	is	_
142-4	27945-27955	intriguing	_
142-5	27956-27961	given	_
142-6	27962-27965	the	_
142-7	27966-27971	often	_
142-8	27972-27980	observed	_
142-9	27981-27988	deficit	_
142-10	27989-27991	of	_
142-11	27992-27998	reward	_
142-12	27999-28009	processing	_
142-13	28010-28012	in	_
142-14	28013-28016	MDD	_
142-15	28017-28021	that	_
142-16	28022-28024	is	_
142-17	28025-28034	described	_
142-18	28035-28045	clinically	_
142-19	28046-28048	as	_
142-20	28049-28058	anhedonia	_
142-21	28058-28059	.	_

#Text=Similar to other psychiatric disorders, current DSM-5 nosology for mood disorders and substance use disorders is only descriptive and does not capture the underlying neurobiological pathophysiology.
143-1	28060-28067	Similar	_
143-2	28068-28070	to	_
143-3	28071-28076	other	_
143-4	28077-28088	psychiatric	_
143-5	28089-28098	disorders	_
143-6	28098-28099	,	_
143-7	28100-28107	current	_
143-8	28108-28111	DSM	_
143-9	28111-28112	-	_
143-10	28112-28113	5	_
143-11	28114-28122	nosology	_
143-12	28123-28126	for	_
143-13	28127-28131	mood	_
143-14	28132-28141	disorders	_
143-15	28142-28145	and	_
143-16	28146-28155	substance	_
143-17	28156-28159	use	_
143-18	28160-28169	disorders	_
143-19	28170-28172	is	_
143-20	28173-28177	only	_
143-21	28178-28189	descriptive	_
143-22	28190-28193	and	_
143-23	28194-28198	does	_
143-24	28199-28202	not	_
143-25	28203-28210	capture	_
143-26	28211-28214	the	_
143-27	28215-28225	underlying	_
143-28	28226-28241	neurobiological	_
143-29	28242-28257	pathophysiology	_
143-30	28257-28258	.	_

#Text=The fact that a MDD risk variant was also shown to have an effect in an AD neuroimaging sample supports a potential role of this genetic variant in an endophenotype related to reward processing that might cross DSM-IV/DSM-5 categories.
144-1	28259-28262	The	_
144-2	28263-28267	fact	_
144-3	28268-28272	that	_
144-4	28273-28274	a	_
144-5	28275-28278	MDD	_
144-6	28279-28283	risk	_
144-7	28284-28291	variant	_
144-8	28292-28295	was	_
144-9	28296-28300	also	_
144-10	28301-28306	shown	_
144-11	28307-28309	to	_
144-12	28310-28314	have	_
144-13	28315-28317	an	_
144-14	28318-28324	effect	_
144-15	28325-28327	in	_
144-16	28328-28330	an	_
144-17	28331-28333	AD	_
144-18	28334-28346	neuroimaging	_
144-19	28347-28353	sample	_
144-20	28354-28362	supports	_
144-21	28363-28364	a	_
144-22	28365-28374	potential	_
144-23	28375-28379	role	_
144-24	28380-28382	of	_
144-25	28383-28387	this	_
144-26	28388-28395	genetic	_
144-27	28396-28403	variant	_
144-28	28404-28406	in	_
144-29	28407-28409	an	_
144-30	28410-28423	endophenotype	_
144-31	28424-28431	related	_
144-32	28432-28434	to	_
144-33	28435-28441	reward	_
144-34	28442-28452	processing	_
144-35	28453-28457	that	_
144-36	28458-28463	might	_
144-37	28464-28469	cross	_
144-38	28470-28476	DSM-IV	_
144-39	28476-28477	/	_
144-40	28477-28480	DSM	_
144-41	28480-28481	-	_
144-42	28481-28482	5	_
144-43	28483-28493	categories	_
144-44	28493-28494	.	_

#Text=Myocyte enhancer factor 2C is a transcription factor that has been shown to be involved in neurodevelopment, hippocampus-dependent learning, and memory.
145-1	28495-28502	Myocyte	_
145-2	28503-28511	enhancer	_
145-3	28512-28518	factor	_
145-4	28519-28521	2C	_
145-5	28522-28524	is	_
145-6	28525-28526	a	_
145-7	28527-28540	transcription	_
145-8	28541-28547	factor	_
145-9	28548-28552	that	_
145-10	28553-28556	has	_
145-11	28557-28561	been	_
145-12	28562-28567	shown	_
145-13	28568-28570	to	_
145-14	28571-28573	be	_
145-15	28574-28582	involved	_
145-16	28583-28585	in	_
145-17	28586-28602	neurodevelopment	_
145-18	28602-28603	,	_
145-19	28604-28625	hippocampus-dependent	_
145-20	28626-28634	learning	_
145-21	28634-28635	,	_
145-22	28636-28639	and	_
145-23	28640-28646	memory	_
145-24	28646-28647	.	_

#Text=Prior studies have shown MEF2C haploinsufficiency, deletions, and point mutations to be associated with seizures, cortical malformations, intellectual disability, and hyperkinesis.
146-1	28648-28653	Prior	_
146-2	28654-28661	studies	_
146-3	28662-28666	have	_
146-4	28667-28672	shown	_
146-5	28673-28678	MEF2C	_
146-6	28679-28697	haploinsufficiency	_
146-7	28697-28698	,	_
146-8	28699-28708	deletions	_
146-9	28708-28709	,	_
146-10	28710-28713	and	_
146-11	28714-28719	point	_
146-12	28720-28729	mutations	_
146-13	28730-28732	to	_
146-14	28733-28735	be	_
146-15	28736-28746	associated	_
146-16	28747-28751	with	_
146-17	28752-28760	seizures	_
146-18	28760-28761	,	_
146-19	28762-28770	cortical	_
146-20	28771-28784	malformations	_
146-21	28784-28785	,	_
146-22	28786-28798	intellectual	_
146-23	28799-28809	disability	_
146-24	28809-28810	,	_
146-25	28811-28814	and	_
146-26	28815-28827	hyperkinesis	_
146-27	28827-28828	.	_

#Text=TMEM161B is largely uncharacterized and the present study is one of the first to identify its potential functional relevance for a neuronal phenotype in a clinical population.
147-1	28829-28837	TMEM161B	_
147-2	28838-28840	is	_
147-3	28841-28848	largely	_
147-4	28849-28864	uncharacterized	_
147-5	28865-28868	and	_
147-6	28869-28872	the	_
147-7	28873-28880	present	_
147-8	28881-28886	study	_
147-9	28887-28889	is	_
147-10	28890-28893	one	_
147-11	28894-28896	of	_
147-12	28897-28900	the	_
147-13	28901-28906	first	_
147-14	28907-28909	to	_
147-15	28910-28918	identify	_
147-16	28919-28922	its	_
147-17	28923-28932	potential	_
147-18	28933-28943	functional	_
147-19	28944-28953	relevance	_
147-20	28954-28957	for	_
147-21	28958-28959	a	_
147-22	28960-28968	neuronal	_
147-23	28969-28978	phenotype	_
147-24	28979-28981	in	_
147-25	28982-28983	a	_
147-26	28984-28992	clinical	_
147-27	28993-29003	population	_
147-28	29003-29004	.	_

#Text=Future clinical and preclinical studies should further investigate the relevance of this gene for anhedonia-related symptomatology in psychiatric disorders, such as substance use disorders, schizophrenia, MDD, and their co-occurrence to dissect potential genetic effects on reward circuitry.
148-1	29005-29011	Future	_
148-2	29012-29020	clinical	_
148-3	29021-29024	and	_
148-4	29025-29036	preclinical	_
148-5	29037-29044	studies	_
148-6	29045-29051	should	_
148-7	29052-29059	further	_
148-8	29060-29071	investigate	_
148-9	29072-29075	the	_
148-10	29076-29085	relevance	_
148-11	29086-29088	of	_
148-12	29089-29093	this	_
148-13	29094-29098	gene	_
148-14	29099-29102	for	_
148-15	29103-29120	anhedonia-related	_
148-16	29121-29135	symptomatology	_
148-17	29136-29138	in	_
148-18	29139-29150	psychiatric	_
148-19	29151-29160	disorders	_
148-20	29160-29161	,	_
148-21	29162-29166	such	_
148-22	29167-29169	as	_
148-23	29170-29179	substance	_
148-24	29180-29183	use	_
148-25	29184-29193	disorders	_
148-26	29193-29194	,	_
148-27	29195-29208	schizophrenia	_
148-28	29208-29209	,	_
148-29	29210-29213	MDD	_
148-30	29213-29214	,	_
148-31	29215-29218	and	_
148-32	29219-29224	their	_
148-33	29225-29238	co-occurrence	_
148-34	29239-29241	to	_
148-35	29242-29249	dissect	_
148-36	29250-29259	potential	_
148-37	29260-29267	genetic	_
148-38	29268-29275	effects	_
148-39	29276-29278	on	_
148-40	29279-29285	reward	_
148-41	29286-29295	circuitry	_
148-42	29295-29296	.	_

#Text=To further investigate the role of this MDD risk variant in AD, we conducted association analyses in two independent clinical samples.
149-1	29297-29299	To	_
149-2	29300-29307	further	_
149-3	29308-29319	investigate	_
149-4	29320-29323	the	_
149-5	29324-29328	role	_
149-6	29329-29331	of	_
149-7	29332-29336	this	_
149-8	29337-29340	MDD	_
149-9	29341-29345	risk	_
149-10	29346-29353	variant	_
149-11	29354-29356	in	_
149-12	29357-29359	AD	_
149-13	29359-29360	,	_
149-14	29361-29363	we	_
149-15	29364-29373	conducted	_
149-16	29374-29385	association	_
149-17	29386-29394	analyses	_
149-18	29395-29397	in	_
149-19	29398-29401	two	_
149-20	29402-29413	independent	_
149-21	29414-29422	clinical	_
149-22	29423-29430	samples	_
149-23	29430-29431	.	_

#Text=In the NIAAA Sample, we found a trend-level association between rs10514299 and a lifetime diagnosis of AD in the EA subgroup only, where the minor allele T appeared to have a protective effect.
150-1	29432-29434	In	_
150-2	29435-29438	the	_
150-3	29439-29444	NIAAA	_
150-4	29445-29451	Sample	_
150-5	29451-29452	,	_
150-6	29453-29455	we	_
150-7	29456-29461	found	_
150-8	29462-29463	a	_
150-9	29464-29475	trend-level	_
150-10	29476-29487	association	_
150-11	29488-29495	between	_
150-12	29496-29506	rs10514299	_
150-13	29507-29510	and	_
150-14	29511-29512	a	_
150-15	29513-29521	lifetime	_
150-16	29522-29531	diagnosis	_
150-17	29532-29534	of	_
150-18	29535-29537	AD	_
150-19	29538-29540	in	_
150-20	29541-29544	the	_
150-21	29545-29547	EA	_
150-22	29548-29556	subgroup	_
150-23	29557-29561	only	_
150-24	29561-29562	,	_
150-25	29563-29568	where	_
150-26	29569-29572	the	_
150-27	29573-29578	minor	_
150-28	29579-29585	allele	_
150-29	29586-29587	T	_
150-30	29588-29596	appeared	_
150-31	29597-29599	to	_
150-32	29600-29604	have	_
150-33	29605-29606	a	_
150-34	29607-29617	protective	_
150-35	29618-29624	effect	_
150-36	29624-29625	.	_

#Text=A replication attempt using the larger SAGE Sample (n = 3838) failed to replicate this association, suggesting that the effect size of the risk variant in AD is relatively small.
151-1	29626-29627	A	_
151-2	29628-29639	replication	_
151-3	29640-29647	attempt	_
151-4	29648-29653	using	_
151-5	29654-29657	the	_
151-6	29658-29664	larger	_
151-7	29665-29669	SAGE	_
151-8	29670-29676	Sample	_
151-9	29677-29678	(	_
151-10	29678-29679	n	_
151-11	29680-29681	=	_
151-12	29682-29686	3838	_
151-13	29686-29687	)	_
151-14	29688-29694	failed	_
151-15	29695-29697	to	_
151-16	29698-29707	replicate	_
151-17	29708-29712	this	_
151-18	29713-29724	association	_
151-19	29724-29725	,	_
151-20	29726-29736	suggesting	_
151-21	29737-29741	that	_
151-22	29742-29745	the	_
151-23	29746-29752	effect	_
151-24	29753-29757	size	_
151-25	29758-29760	of	_
151-26	29761-29764	the	_
151-27	29765-29769	risk	_
151-28	29770-29777	variant	_
151-29	29778-29780	in	_
151-30	29781-29783	AD	_
151-31	29784-29786	is	_
151-32	29787-29797	relatively	_
151-33	29798-29803	small	_
151-34	29803-29804	.	_

#Text=This is consistent with the prior GWAS in MDD of 300,000 samples, which reported a rather small effect size (OR = 1.05).
152-1	29805-29809	This	_
152-2	29810-29812	is	_
152-3	29813-29823	consistent	_
152-4	29824-29828	with	_
152-5	29829-29832	the	_
152-6	29833-29838	prior	_
152-7	29839-29843	GWAS	_
152-8	29844-29846	in	_
152-9	29847-29850	MDD	_
152-10	29851-29853	of	_
152-11	29854-29861	300,000	_
152-12	29862-29869	samples	_
152-13	29869-29870	,	_
152-14	29871-29876	which	_
152-15	29877-29885	reported	_
152-16	29886-29887	a	_
152-17	29888-29894	rather	_
152-18	29895-29900	small	_
152-19	29901-29907	effect	_
152-20	29908-29912	size	_
152-21	29913-29914	(	_
152-22	29914-29916	OR	_
152-23	29917-29918	=	_
152-24	29919-29923	1.05	_
152-25	29923-29924	)	_
152-26	29924-29925	.	_

#Text=Other potential reasons for the lack of replication are presence of confounding factors, such as clinical heterogeneity as individuals with a lifetime diagnosis of AD are more likely to present with comorbid psychiatric diagnoses and other substance use disorders.
153-1	29926-29931	Other	_
153-2	29932-29941	potential	_
153-3	29942-29949	reasons	_
153-4	29950-29953	for	_
153-5	29954-29957	the	_
153-6	29958-29962	lack	_
153-7	29963-29965	of	_
153-8	29966-29977	replication	_
153-9	29978-29981	are	_
153-10	29982-29990	presence	_
153-11	29991-29993	of	_
153-12	29994-30005	confounding	_
153-13	30006-30013	factors	_
153-14	30013-30014	,	_
153-15	30015-30019	such	_
153-16	30020-30022	as	_
153-17	30023-30031	clinical	_
153-18	30032-30045	heterogeneity	_
153-19	30046-30048	as	_
153-20	30049-30060	individuals	_
153-21	30061-30065	with	_
153-22	30066-30067	a	_
153-23	30068-30076	lifetime	_
153-24	30077-30086	diagnosis	_
153-25	30087-30089	of	_
153-26	30090-30092	AD	_
153-27	30093-30096	are	_
153-28	30097-30101	more	_
153-29	30102-30108	likely	_
153-30	30109-30111	to	_
153-31	30112-30119	present	_
153-32	30120-30124	with	_
153-33	30125-30133	comorbid	_
153-34	30134-30145	psychiatric	_
153-35	30146-30155	diagnoses	_
153-36	30156-30159	and	_
153-37	30160-30165	other	_
153-38	30166-30175	substance	_
153-39	30176-30179	use	_
153-40	30180-30189	disorders	_
153-41	30189-30190	.	_

#Text=Interestingly, our data showed a marginally significant protective effect of rs10514299 for AD, while Hyde et al. identified the minor allele T as conferring risk for MDD.
154-1	30191-30204	Interestingly	_
154-2	30204-30205	,	_
154-3	30206-30209	our	_
154-4	30210-30214	data	_
154-5	30215-30221	showed	_
154-6	30222-30223	a	_
154-7	30224-30234	marginally	_
154-8	30235-30246	significant	_
154-9	30247-30257	protective	_
154-10	30258-30264	effect	_
154-11	30265-30267	of	_
154-12	30268-30278	rs10514299	_
154-13	30279-30282	for	_
154-14	30283-30285	AD	_
154-15	30285-30286	,	_
154-16	30287-30292	while	_
154-17	30293-30297	Hyde	_
154-18	30298-30300	et	_
154-19	30301-30303	al	_
154-20	30303-30304	.	_
154-21	30305-30315	identified	_
154-22	30316-30319	the	_
154-23	30320-30325	minor	_
154-24	30326-30332	allele	_
154-25	30333-30334	T	_
154-26	30335-30337	as	_
154-27	30338-30348	conferring	_
154-28	30349-30353	risk	_
154-29	30354-30357	for	_
154-30	30358-30361	MDD	_
154-31	30361-30362	.	_

#Text=It is possible that the T allele is a risk allele for MDD and a protective allele for AD, especially given the fact that both disorders present with highly heterogeneous clinical phenotypes.
155-1	30363-30365	It	_
155-2	30366-30368	is	_
155-3	30369-30377	possible	_
155-4	30378-30382	that	_
155-5	30383-30386	the	_
155-6	30387-30388	T	_
155-7	30389-30395	allele	_
155-8	30396-30398	is	_
155-9	30399-30400	a	_
155-10	30401-30405	risk	_
155-11	30406-30412	allele	_
155-12	30413-30416	for	_
155-13	30417-30420	MDD	_
155-14	30421-30424	and	_
155-15	30425-30426	a	_
155-16	30427-30437	protective	_
155-17	30438-30444	allele	_
155-18	30445-30448	for	_
155-19	30449-30451	AD	_
155-20	30451-30452	,	_
155-21	30453-30463	especially	_
155-22	30464-30469	given	_
155-23	30470-30473	the	_
155-24	30474-30478	fact	_
155-25	30479-30483	that	_
155-26	30484-30488	both	_
155-27	30489-30498	disorders	_
155-28	30499-30506	present	_
155-29	30507-30511	with	_
155-30	30512-30518	highly	_
155-31	30519-30532	heterogeneous	_
155-32	30533-30541	clinical	_
155-33	30542-30552	phenotypes	_
155-34	30552-30553	.	_

#Text=However, it should be noted that a more recent GWAS of 130, 664 MDD cases and 330, 470 HCs did not replicate rs10514299 as a risk variant for MDD, suggesting the possibility that the signal may depend on the presence of other variants or may be driven by other SNPs altogether.
156-1	30554-30561	However	_
156-2	30561-30562	,	_
156-3	30563-30565	it	_
156-4	30566-30572	should	_
156-5	30573-30575	be	_
156-6	30576-30581	noted	_
156-7	30582-30586	that	_
156-8	30587-30588	a	_
156-9	30589-30593	more	_
156-10	30594-30600	recent	_
156-11	30601-30605	GWAS	_
156-12	30606-30608	of	_
156-13	30609-30612	130	_
156-14	30612-30613	,	_
156-15	30614-30617	664	_
156-16	30618-30621	MDD	_
156-17	30622-30627	cases	_
156-18	30628-30631	and	_
156-19	30632-30635	330	_
156-20	30635-30636	,	_
156-21	30637-30640	470	_
156-22	30641-30644	HCs	_
156-23	30645-30648	did	_
156-24	30649-30652	not	_
156-25	30653-30662	replicate	_
156-26	30663-30673	rs10514299	_
156-27	30674-30676	as	_
156-28	30677-30678	a	_
156-29	30679-30683	risk	_
156-30	30684-30691	variant	_
156-31	30692-30695	for	_
156-32	30696-30699	MDD	_
156-33	30699-30700	,	_
156-34	30701-30711	suggesting	_
156-35	30712-30715	the	_
156-36	30716-30727	possibility	_
156-37	30728-30732	that	_
156-38	30733-30736	the	_
156-39	30737-30743	signal	_
156-40	30744-30747	may	_
156-41	30748-30754	depend	_
156-42	30755-30757	on	_
156-43	30758-30761	the	_
156-44	30762-30770	presence	_
156-45	30771-30773	of	_
156-46	30774-30779	other	_
156-47	30780-30788	variants	_
156-48	30789-30791	or	_
156-49	30792-30795	may	_
156-50	30796-30798	be	_
156-51	30799-30805	driven	_
156-52	30806-30808	by	_
156-53	30809-30814	other	_
156-54	30815-30819	SNPs	_
156-55	30820-30830	altogether	_
156-56	30830-30831	.	_

#Text=Future GWAS with large sample sizes are needed to further elucidate the relevance of rs10514299 and proximal SNPs for an increased or reduced risk for MDD and AD.
157-1	30832-30838	Future	_
157-2	30839-30843	GWAS	_
157-3	30844-30848	with	_
157-4	30849-30854	large	_
157-5	30855-30861	sample	_
157-6	30862-30867	sizes	_
157-7	30868-30871	are	_
157-8	30872-30878	needed	_
157-9	30879-30881	to	_
157-10	30882-30889	further	_
157-11	30890-30899	elucidate	_
157-12	30900-30903	the	_
157-13	30904-30913	relevance	_
157-14	30914-30916	of	_
157-15	30917-30927	rs10514299	_
157-16	30928-30931	and	_
157-17	30932-30940	proximal	_
157-18	30941-30945	SNPs	_
157-19	30946-30949	for	_
157-20	30950-30952	an	_
157-21	30953-30962	increased	_
157-22	30963-30965	or	_
157-23	30966-30973	reduced	_
157-24	30974-30978	risk	_
157-25	30979-30982	for	_
157-26	30983-30986	MDD	_
157-27	30987-30990	and	_
157-28	30991-30993	AD	_
157-29	30993-30994	.	_

#Text=To investigate the effect of this SNP on depressive symptoms in AD, we looked at the MADRS in a subsample of the NIAAA Sample.
158-1	30995-30997	To	_
158-2	30998-31009	investigate	_
158-3	31010-31013	the	_
158-4	31014-31020	effect	_
158-5	31021-31023	of	_
158-6	31024-31028	this	_
158-7	31029-31032	SNP	_
158-8	31033-31035	on	_
158-9	31036-31046	depressive	_
158-10	31047-31055	symptoms	_
158-11	31056-31058	in	_
158-12	31059-31061	AD	_
158-13	31061-31062	,	_
158-14	31063-31065	we	_
158-15	31066-31072	looked	_
158-16	31073-31075	at	_
158-17	31076-31079	the	_
158-18	31080-31085	MADRS	_
158-19	31086-31088	in	_
158-20	31089-31090	a	_
158-21	31091-31100	subsample	_
158-22	31101-31103	of	_
158-23	31104-31107	the	_
158-24	31108-31113	NIAAA	_
158-25	31114-31120	Sample	_
158-26	31120-31121	.	_

#Text=Our data showed that the minor allele T of rs10514299 was significantly associated with greater severity of depressive symptoms in individuals with a lifetime AD diagnosis (Table 4).
159-1	31122-31125	Our	_
159-2	31126-31130	data	_
159-3	31131-31137	showed	_
159-4	31138-31142	that	_
159-5	31143-31146	the	_
159-6	31147-31152	minor	_
159-7	31153-31159	allele	_
159-8	31160-31161	T	_
159-9	31162-31164	of	_
159-10	31165-31175	rs10514299	_
159-11	31176-31179	was	_
159-12	31180-31193	significantly	_
159-13	31194-31204	associated	_
159-14	31205-31209	with	_
159-15	31210-31217	greater	_
159-16	31218-31226	severity	_
159-17	31227-31229	of	_
159-18	31230-31240	depressive	_
159-19	31241-31249	symptoms	_
159-20	31250-31252	in	_
159-21	31253-31264	individuals	_
159-22	31265-31269	with	_
159-23	31270-31271	a	_
159-24	31272-31280	lifetime	_
159-25	31281-31283	AD	_
159-26	31284-31293	diagnosis	_
159-27	31294-31295	(	_
159-28	31295-31300	Table	_
159-29	31301-31302	4	_
159-30	31302-31303	)	_
159-31	31303-31304	.	_

#Text=This association was mainly driven by cases of AA ancestry; however, our sample might have been too small to detect effects across ethnic backgrounds.
160-1	31305-31309	This	_
160-2	31310-31321	association	_
160-3	31322-31325	was	_
160-4	31326-31332	mainly	_
160-5	31333-31339	driven	_
160-6	31340-31342	by	_
160-7	31343-31348	cases	_
160-8	31349-31351	of	_
160-9	31352-31354	AA	_
160-10	31355-31363	ancestry	_
160-11	31363-31364	;	_
160-12	31365-31372	however	_
160-13	31372-31373	,	_
160-14	31374-31377	our	_
160-15	31378-31384	sample	_
160-16	31385-31390	might	_
160-17	31391-31395	have	_
160-18	31396-31400	been	_
160-19	31401-31404	too	_
160-20	31405-31410	small	_
160-21	31411-31413	to	_
160-22	31414-31420	detect	_
160-23	31421-31428	effects	_
160-24	31429-31435	across	_
160-25	31436-31442	ethnic	_
160-26	31443-31454	backgrounds	_
160-27	31454-31455	.	_

#Text=Furthermore, it should be noted that the medication status for this sample was not available.
161-1	31456-31467	Furthermore	_
161-2	31467-31468	,	_
161-3	31469-31471	it	_
161-4	31472-31478	should	_
161-5	31479-31481	be	_
161-6	31482-31487	noted	_
161-7	31488-31492	that	_
161-8	31493-31496	the	_
161-9	31497-31507	medication	_
161-10	31508-31514	status	_
161-11	31515-31518	for	_
161-12	31519-31523	this	_
161-13	31524-31530	sample	_
161-14	31531-31534	was	_
161-15	31535-31538	not	_
161-16	31539-31548	available	_
161-17	31548-31549	.	_

#Text=Given that antidepressant medication may influence the relationship between rs10514299 and depressive symptoms, this finding should be replicated in future studies that assess and control for psychotropic medication status.
162-1	31550-31555	Given	_
162-2	31556-31560	that	_
162-3	31561-31575	antidepressant	_
162-4	31576-31586	medication	_
162-5	31587-31590	may	_
162-6	31591-31600	influence	_
162-7	31601-31604	the	_
162-8	31605-31617	relationship	_
162-9	31618-31625	between	_
162-10	31626-31636	rs10514299	_
162-11	31637-31640	and	_
162-12	31641-31651	depressive	_
162-13	31652-31660	symptoms	_
162-14	31660-31661	,	_
162-15	31662-31666	this	_
162-16	31667-31674	finding	_
162-17	31675-31681	should	_
162-18	31682-31684	be	_
162-19	31685-31695	replicated	_
162-20	31696-31698	in	_
162-21	31699-31705	future	_
162-22	31706-31713	studies	_
162-23	31714-31718	that	_
162-24	31719-31725	assess	_
162-25	31726-31729	and	_
162-26	31730-31737	control	_
162-27	31738-31741	for	_
162-28	31742-31754	psychotropic	_
162-29	31755-31765	medication	_
162-30	31766-31772	status	_
162-31	31772-31773	.	_

#Text=Importantly, future studies are needed to further investigate this relationship and to examine whether minor allele T carrying individuals with AD might particularly benefit from treatments that focus on negative affect relief, such as mindfulness-based interventions, or antidepressant medications.
163-1	31774-31785	Importantly	_
163-2	31785-31786	,	_
163-3	31787-31793	future	_
163-4	31794-31801	studies	_
163-5	31802-31805	are	_
163-6	31806-31812	needed	_
163-7	31813-31815	to	_
163-8	31816-31823	further	_
163-9	31824-31835	investigate	_
163-10	31836-31840	this	_
163-11	31841-31853	relationship	_
163-12	31854-31857	and	_
163-13	31858-31860	to	_
163-14	31861-31868	examine	_
163-15	31869-31876	whether	_
163-16	31877-31882	minor	_
163-17	31883-31889	allele	_
163-18	31890-31891	T	_
163-19	31892-31900	carrying	_
163-20	31901-31912	individuals	_
163-21	31913-31917	with	_
163-22	31918-31920	AD	_
163-23	31921-31926	might	_
163-24	31927-31939	particularly	_
163-25	31940-31947	benefit	_
163-26	31948-31952	from	_
163-27	31953-31963	treatments	_
163-28	31964-31968	that	_
163-29	31969-31974	focus	_
163-30	31975-31977	on	_
163-31	31978-31986	negative	_
163-32	31987-31993	affect	_
163-33	31994-32000	relief	_
163-34	32000-32001	,	_
163-35	32002-32006	such	_
163-36	32007-32009	as	_
163-37	32010-32027	mindfulness-based	_
163-38	32028-32041	interventions	_
163-39	32041-32042	,	_
163-40	32043-32045	or	_
163-41	32046-32060	antidepressant	_
163-42	32061-32072	medications	_
163-43	32072-32073	.	_

#Text=If future research confirms this variant as a biomarker of an increased risk for depressive symptomatology in individuals with AD, it may be used by clinicians for the selection of more individualized interventions.
164-1	32074-32076	If	_
164-2	32077-32083	future	_
164-3	32084-32092	research	_
164-4	32093-32101	confirms	_
164-5	32102-32106	this	_
164-6	32107-32114	variant	_
164-7	32115-32117	as	_
164-8	32118-32119	a	_
164-9	32120-32129	biomarker	_
164-10	32130-32132	of	_
164-11	32133-32135	an	_
164-12	32136-32145	increased	_
164-13	32146-32150	risk	_
164-14	32151-32154	for	_
164-15	32155-32165	depressive	_
164-16	32166-32180	symptomatology	_
164-17	32181-32183	in	_
164-18	32184-32195	individuals	_
164-19	32196-32200	with	_
164-20	32201-32203	AD	_
164-21	32203-32204	,	_
164-22	32205-32207	it	_
164-23	32208-32211	may	_
164-24	32212-32214	be	_
164-25	32215-32219	used	_
164-26	32220-32222	by	_
164-27	32223-32233	clinicians	_
164-28	32234-32237	for	_
164-29	32238-32241	the	_
164-30	32242-32251	selection	_
164-31	32252-32254	of	_
164-32	32255-32259	more	_
164-33	32260-32274	individualized	_
164-34	32275-32288	interventions	_
164-35	32288-32289	.	_

#Text=When interpreting the findings from the Neuroimaging Sample, the following limitations should be considered.
165-1	32290-32294	When	_
165-2	32295-32307	interpreting	_
165-3	32308-32311	the	_
165-4	32312-32320	findings	_
165-5	32321-32325	from	_
165-6	32326-32329	the	_
165-7	32330-32342	Neuroimaging	_
165-8	32343-32349	Sample	_
165-9	32349-32350	,	_
165-10	32351-32354	the	_
165-11	32355-32364	following	_
165-12	32365-32376	limitations	_
165-13	32377-32383	should	_
165-14	32384-32386	be	_
165-15	32387-32397	considered	_
165-16	32397-32398	.	_

#Text=This was a discovery study that aimed to explore genetic variation in rs10514299 as a possible biomarker for interindividual differences in reward-related neuronal activation in individuals with AD.
166-1	32399-32403	This	_
166-2	32404-32407	was	_
166-3	32408-32409	a	_
166-4	32410-32419	discovery	_
166-5	32420-32425	study	_
166-6	32426-32430	that	_
166-7	32431-32436	aimed	_
166-8	32437-32439	to	_
166-9	32440-32447	explore	_
166-10	32448-32455	genetic	_
166-11	32456-32465	variation	_
166-12	32466-32468	in	_
166-13	32469-32479	rs10514299	_
166-14	32480-32482	as	_
166-15	32483-32484	a	_
166-16	32485-32493	possible	_
166-17	32494-32503	biomarker	_
166-18	32504-32507	for	_
166-19	32508-32523	interindividual	_
166-20	32524-32535	differences	_
166-21	32536-32538	in	_
166-22	32539-32553	reward-related	_
166-23	32554-32562	neuronal	_
166-24	32563-32573	activation	_
166-25	32574-32576	in	_
166-26	32577-32588	individuals	_
166-27	32589-32593	with	_
166-28	32594-32596	AD	_
166-29	32596-32597	.	_

#Text=Therefore, we did not correct for multiple comparisons.
167-1	32598-32607	Therefore	_
167-2	32607-32608	,	_
167-3	32609-32611	we	_
167-4	32612-32615	did	_
167-5	32616-32619	not	_
167-6	32620-32627	correct	_
167-7	32628-32631	for	_
167-8	32632-32640	multiple	_
167-9	32641-32652	comparisons	_
167-10	32652-32653	.	_

#Text=However, future confirmatory analyses will be done to validate the functional relevance of rs10514299 in neuroimaging phenotypes in alcohol-dependent populations.
168-1	32654-32661	However	_
168-2	32661-32662	,	_
168-3	32663-32669	future	_
168-4	32670-32682	confirmatory	_
168-5	32683-32691	analyses	_
168-6	32692-32696	will	_
168-7	32697-32699	be	_
168-8	32700-32704	done	_
168-9	32705-32707	to	_
168-10	32708-32716	validate	_
168-11	32717-32720	the	_
168-12	32721-32731	functional	_
168-13	32732-32741	relevance	_
168-14	32742-32744	of	_
168-15	32745-32755	rs10514299	_
168-16	32756-32758	in	_
168-17	32759-32771	neuroimaging	_
168-18	32772-32782	phenotypes	_
168-19	32783-32785	in	_
168-20	32786-32803	alcohol-dependent	_
168-21	32804-32815	populations	_
168-22	32815-32816	.	_

#Text=Additionally, cases and controls were not well matched for age and gender, therefore, these variables were included as covariates in all analyses.
169-1	32817-32829	Additionally	_
169-2	32829-32830	,	_
169-3	32831-32836	cases	_
169-4	32837-32840	and	_
169-5	32841-32849	controls	_
169-6	32850-32854	were	_
169-7	32855-32858	not	_
169-8	32859-32863	well	_
169-9	32864-32871	matched	_
169-10	32872-32875	for	_
169-11	32876-32879	age	_
169-12	32880-32883	and	_
169-13	32884-32890	gender	_
169-14	32890-32891	,	_
169-15	32892-32901	therefore	_
169-16	32901-32902	,	_
169-17	32903-32908	these	_
169-18	32909-32918	variables	_
169-19	32919-32923	were	_
169-20	32924-32932	included	_
169-21	32933-32935	as	_
169-22	32936-32946	covariates	_
169-23	32947-32949	in	_
169-24	32950-32953	all	_
169-25	32954-32962	analyses	_
169-26	32962-32963	.	_

#Text=Cases and controls differed significantly in smoking status, however, all results remained significant when analyses were repeated while controlling for smoking status.
170-1	32964-32969	Cases	_
170-2	32970-32973	and	_
170-3	32974-32982	controls	_
170-4	32983-32991	differed	_
170-5	32992-33005	significantly	_
170-6	33006-33008	in	_
170-7	33009-33016	smoking	_
170-8	33017-33023	status	_
170-9	33023-33024	,	_
170-10	33025-33032	however	_
170-11	33032-33033	,	_
170-12	33034-33037	all	_
170-13	33038-33045	results	_
170-14	33046-33054	remained	_
170-15	33055-33066	significant	_
170-16	33067-33071	when	_
170-17	33072-33080	analyses	_
170-18	33081-33085	were	_
170-19	33086-33094	repeated	_
170-20	33095-33100	while	_
170-21	33101-33112	controlling	_
170-22	33113-33116	for	_
170-23	33117-33124	smoking	_
170-24	33125-33131	status	_
170-25	33131-33132	.	_

#Text=Limiting factors for the case-control association analyses include small sample sizes and thus a lack of statistical power to detect the likely small effect size of this SNP as discussed above.
171-1	33133-33141	Limiting	_
171-2	33142-33149	factors	_
171-3	33150-33153	for	_
171-4	33154-33157	the	_
171-5	33158-33170	case-control	_
171-6	33171-33182	association	_
171-7	33183-33191	analyses	_
171-8	33192-33199	include	_
171-9	33200-33205	small	_
171-10	33206-33212	sample	_
171-11	33213-33218	sizes	_
171-12	33219-33222	and	_
171-13	33223-33227	thus	_
171-14	33228-33229	a	_
171-15	33230-33234	lack	_
171-16	33235-33237	of	_
171-17	33238-33249	statistical	_
171-18	33250-33255	power	_
171-19	33256-33258	to	_
171-20	33259-33265	detect	_
171-21	33266-33269	the	_
171-22	33270-33276	likely	_
171-23	33277-33282	small	_
171-24	33283-33289	effect	_
171-25	33290-33294	size	_
171-26	33295-33297	of	_
171-27	33298-33302	this	_
171-28	33303-33306	SNP	_
171-29	33307-33309	as	_
171-30	33310-33319	discussed	_
171-31	33320-33325	above	_
171-32	33325-33326	.	_

#Text=We only focused on one variant but this variant was initially identified in a cluster of SNPs.
172-1	33327-33329	We	_
172-2	33330-33334	only	_
172-3	33335-33342	focused	_
172-4	33343-33345	on	_
172-5	33346-33349	one	_
172-6	33350-33357	variant	_
172-7	33358-33361	but	_
172-8	33362-33366	this	_
172-9	33367-33374	variant	_
172-10	33375-33378	was	_
172-11	33379-33388	initially	_
172-12	33389-33399	identified	_
172-13	33400-33402	in	_
172-14	33403-33404	a	_
172-15	33405-33412	cluster	_
172-16	33413-33415	of	_
172-17	33416-33420	SNPs	_
172-18	33420-33421	.	_

#Text=Future studies should investigate possible other important functional variants, such as nearby SNPs with strong linkage disequilibrium by sequencing all promising regions.
173-1	33422-33428	Future	_
173-2	33429-33436	studies	_
173-3	33437-33443	should	_
173-4	33444-33455	investigate	_
173-5	33456-33464	possible	_
173-6	33465-33470	other	_
173-7	33471-33480	important	_
173-8	33481-33491	functional	_
173-9	33492-33500	variants	_
173-10	33500-33501	,	_
173-11	33502-33506	such	_
173-12	33507-33509	as	_
173-13	33510-33516	nearby	_
173-14	33517-33521	SNPs	_
173-15	33522-33526	with	_
173-16	33527-33533	strong	_
173-17	33534-33541	linkage	_
173-18	33542-33556	disequilibrium	_
173-19	33557-33559	by	_
173-20	33560-33570	sequencing	_
173-21	33571-33574	all	_
173-22	33575-33584	promising	_
173-23	33585-33592	regions	_
173-24	33592-33593	.	_

#Text=Both AD and MDD are highly heritable and influenced by polygenic effects associated with many genetic variants, and therefore genetic interaction among the many genes related to the single variant on the same pathways should be examined functionally.
174-1	33594-33598	Both	_
174-2	33599-33601	AD	_
174-3	33602-33605	and	_
174-4	33606-33609	MDD	_
174-5	33610-33613	are	_
174-6	33614-33620	highly	_
174-7	33621-33630	heritable	_
174-8	33631-33634	and	_
174-9	33635-33645	influenced	_
174-10	33646-33648	by	_
174-11	33649-33658	polygenic	_
174-12	33659-33666	effects	_
174-13	33667-33677	associated	_
174-14	33678-33682	with	_
174-15	33683-33687	many	_
174-16	33688-33695	genetic	_
174-17	33696-33704	variants	_
174-18	33704-33705	,	_
174-19	33706-33709	and	_
174-20	33710-33719	therefore	_
174-21	33720-33727	genetic	_
174-22	33728-33739	interaction	_
174-23	33740-33745	among	_
174-24	33746-33749	the	_
174-25	33750-33754	many	_
174-26	33755-33760	genes	_
174-27	33761-33768	related	_
174-28	33769-33771	to	_
174-29	33772-33775	the	_
174-30	33776-33782	single	_
174-31	33783-33790	variant	_
174-32	33791-33793	on	_
174-33	33794-33797	the	_
174-34	33798-33802	same	_
174-35	33803-33811	pathways	_
174-36	33812-33818	should	_
174-37	33819-33821	be	_
174-38	33822-33830	examined	_
174-39	33831-33843	functionally	_
174-40	33843-33844	.	_

#Text=In summary, our data suggest an association between rs10514299 and BOLD activation in the putamen during reward and loss anticipation in individuals with AD.
175-1	33845-33847	In	_
175-2	33848-33855	summary	_
175-3	33855-33856	,	_
175-4	33857-33860	our	_
175-5	33861-33865	data	_
175-6	33866-33873	suggest	_
175-7	33874-33876	an	_
175-8	33877-33888	association	_
175-9	33889-33896	between	_
175-10	33897-33907	rs10514299	_
175-11	33908-33911	and	_
175-12	33912-33916	BOLD	_
175-13	33917-33927	activation	_
175-14	33928-33930	in	_
175-15	33931-33934	the	_
175-16	33935-33942	putamen	_
175-17	33943-33949	during	_
175-18	33950-33956	reward	_
175-19	33957-33960	and	_
175-20	33961-33965	loss	_
175-21	33966-33978	anticipation	_
175-22	33979-33981	in	_
175-23	33982-33993	individuals	_
175-24	33994-33998	with	_
175-25	33999-34001	AD	_
175-26	34001-34002	.	_

#Text=Carrying the minor allele T differentially affects putamen activation during reward/loss anticipation in individuals with AD compared to HCs, indicating that genetic variation in rs10514299 may be a clinical biomarker for a neuronal phenotype in AD.
176-1	34003-34011	Carrying	_
176-2	34012-34015	the	_
176-3	34016-34021	minor	_
176-4	34022-34028	allele	_
176-5	34029-34030	T	_
176-6	34031-34045	differentially	_
176-7	34046-34053	affects	_
176-8	34054-34061	putamen	_
176-9	34062-34072	activation	_
176-10	34073-34079	during	_
176-11	34080-34086	reward	_
176-12	34086-34087	/	_
176-13	34087-34091	loss	_
176-14	34092-34104	anticipation	_
176-15	34105-34107	in	_
176-16	34108-34119	individuals	_
176-17	34120-34124	with	_
176-18	34125-34127	AD	_
176-19	34128-34136	compared	_
176-20	34137-34139	to	_
176-21	34140-34143	HCs	_
176-22	34143-34144	,	_
176-23	34145-34155	indicating	_
176-24	34156-34160	that	_
176-25	34161-34168	genetic	_
176-26	34169-34178	variation	_
176-27	34179-34181	in	_
176-28	34182-34192	rs10514299	_
176-29	34193-34196	may	_
176-30	34197-34199	be	_
176-31	34200-34201	a	_
176-32	34202-34210	clinical	_
176-33	34211-34220	biomarker	_
176-34	34221-34224	for	_
176-35	34225-34226	a	_
176-36	34227-34235	neuronal	_
176-37	34236-34245	phenotype	_
176-38	34246-34248	in	_
176-39	34249-34251	AD	_
176-40	34251-34252	.	_

#Text=Furthermore, the minor allele T was significantly associated with greater levels of depressive symptoms in individuals with a lifetime diagnosis of AD, a finding that was driven by individuals of African American ancestry.
177-1	34253-34264	Furthermore	_
177-2	34264-34265	,	_
177-3	34266-34269	the	_
177-4	34270-34275	minor	_
177-5	34276-34282	allele	_
177-6	34283-34284	T	_
177-7	34285-34288	was	_
177-8	34289-34302	significantly	_
177-9	34303-34313	associated	_
177-10	34314-34318	with	_
177-11	34319-34326	greater	_
177-12	34327-34333	levels	_
177-13	34334-34336	of	_
177-14	34337-34347	depressive	_
177-15	34348-34356	symptoms	_
177-16	34357-34359	in	_
177-17	34360-34371	individuals	_
177-18	34372-34376	with	_
177-19	34377-34378	a	_
177-20	34379-34387	lifetime	_
177-21	34388-34397	diagnosis	_
177-22	34398-34400	of	_
177-23	34401-34403	AD	_
177-24	34403-34404	,	_
177-25	34405-34406	a	_
177-26	34407-34414	finding	_
177-27	34415-34419	that	_
177-28	34420-34423	was	_
177-29	34424-34430	driven	_
177-30	34431-34433	by	_
177-31	34434-34445	individuals	_
177-32	34446-34448	of	_
177-33	34449-34456	African	_
177-34	34457-34465	American	_
177-35	34466-34474	ancestry	_
177-36	34474-34475	.	_

#Text=Finally, association analyses showed a relationship at trend-level between rs10514299 and a lifetime diagnosis of AD in European Americans in the NIAAA Sample but not in the SAGE Sample.
178-1	34476-34483	Finally	_
178-2	34483-34484	,	_
178-3	34485-34496	association	_
178-4	34497-34505	analyses	_
178-5	34506-34512	showed	_
178-6	34513-34514	a	_
178-7	34515-34527	relationship	_
178-8	34528-34530	at	_
178-9	34531-34542	trend-level	_
178-10	34543-34550	between	_
178-11	34551-34561	rs10514299	_
178-12	34562-34565	and	_
178-13	34566-34567	a	_
178-14	34568-34576	lifetime	_
178-15	34577-34586	diagnosis	_
178-16	34587-34589	of	_
178-17	34590-34592	AD	_
178-18	34593-34595	in	_
178-19	34596-34604	European	_
178-20	34605-34614	Americans	_
178-21	34615-34617	in	_
178-22	34618-34621	the	_
178-23	34622-34627	NIAAA	_
178-24	34628-34634	Sample	_
178-25	34635-34638	but	_
178-26	34639-34642	not	_
178-27	34643-34645	in	_
178-28	34646-34649	the	_
178-29	34650-34654	SAGE	_
178-30	34655-34661	Sample	_
178-31	34661-34662	.	_

#Text=This is the first study to show functional relevance of rs10514299 for an imaging phenotype in individuals with AD, as well as its relevance for depressive symptom severity in individuals with a lifetime diagnosis of AD.
179-1	34663-34667	This	_
179-2	34668-34670	is	_
179-3	34671-34674	the	_
179-4	34675-34680	first	_
179-5	34681-34686	study	_
179-6	34687-34689	to	_
179-7	34690-34694	show	_
179-8	34695-34705	functional	_
179-9	34706-34715	relevance	_
179-10	34716-34718	of	_
179-11	34719-34729	rs10514299	_
179-12	34730-34733	for	_
179-13	34734-34736	an	_
179-14	34737-34744	imaging	_
179-15	34745-34754	phenotype	_
179-16	34755-34757	in	_
179-17	34758-34769	individuals	_
179-18	34770-34774	with	_
179-19	34775-34777	AD	_
179-20	34777-34778	,	_
179-21	34779-34781	as	_
179-22	34782-34786	well	_
179-23	34787-34789	as	_
179-24	34790-34793	its	_
179-25	34794-34803	relevance	_
179-26	34804-34807	for	_
179-27	34808-34818	depressive	_
179-28	34819-34826	symptom	_
179-29	34827-34835	severity	_
179-30	34836-34838	in	_
179-31	34839-34850	individuals	_
179-32	34851-34855	with	_
179-33	34856-34857	a	_
179-34	34858-34866	lifetime	_
179-35	34867-34876	diagnosis	_
179-36	34877-34879	of	_
179-37	34880-34882	AD	_
179-38	34882-34883	.	_

#Text=Taken together, our findings indicate rs10514299 as a promising target for future study in populations with AD and MDD.
180-1	34884-34889	Taken	_
180-2	34890-34898	together	_
180-3	34898-34899	,	_
180-4	34900-34903	our	_
180-5	34904-34912	findings	_
180-6	34913-34921	indicate	_
180-7	34922-34932	rs10514299	_
180-8	34933-34935	as	_
180-9	34936-34937	a	_
180-10	34938-34947	promising	_
180-11	34948-34954	target	_
180-12	34955-34958	for	_
180-13	34959-34965	future	_
180-14	34966-34971	study	_
180-15	34972-34974	in	_
180-16	34975-34986	populations	_
180-17	34987-34991	with	_
180-18	34992-34994	AD	_
180-19	34995-34998	and	_
180-20	34999-35002	MDD	_
180-21	35002-35003	.	_

#Text=Identifying genetic risk variants may serve to guide the selection of treatment options, as well as reveal novel treatment targets, while neuronal phenotypes may serve as markers of treatment response to cognitive, behavioral, or pharmacological interventions.
181-1	35004-35015	Identifying	_
181-2	35016-35023	genetic	_
181-3	35024-35028	risk	_
181-4	35029-35037	variants	_
181-5	35038-35041	may	_
181-6	35042-35047	serve	_
181-7	35048-35050	to	_
181-8	35051-35056	guide	_
181-9	35057-35060	the	_
181-10	35061-35070	selection	_
181-11	35071-35073	of	_
181-12	35074-35083	treatment	_
181-13	35084-35091	options	_
181-14	35091-35092	,	_
181-15	35093-35095	as	_
181-16	35096-35100	well	_
181-17	35101-35103	as	_
181-18	35104-35110	reveal	_
181-19	35111-35116	novel	_
181-20	35117-35126	treatment	_
181-21	35127-35134	targets	_
181-22	35134-35135	,	_
181-23	35136-35141	while	_
181-24	35142-35150	neuronal	_
181-25	35151-35161	phenotypes	_
181-26	35162-35165	may	_
181-27	35166-35171	serve	_
181-28	35172-35174	as	_
181-29	35175-35182	markers	_
181-30	35183-35185	of	_
181-31	35186-35195	treatment	_
181-32	35196-35204	response	_
181-33	35205-35207	to	_
181-34	35208-35217	cognitive	_
181-35	35217-35218	,	_
181-36	35219-35229	behavioral	_
181-37	35229-35230	,	_
181-38	35231-35233	or	_
181-39	35234-35249	pharmacological	_
181-40	35250-35263	interventions	_
181-41	35263-35264	.	_

#Text=Ultimately, the identification of objective biomarkers of disease-related mechanisms will contribute to the development of individualized treatments.
182-1	35265-35275	Ultimately	_
182-2	35275-35276	,	_
182-3	35277-35280	the	_
182-4	35281-35295	identification	_
182-5	35296-35298	of	_
182-6	35299-35308	objective	_
182-7	35309-35319	biomarkers	_
182-8	35320-35322	of	_
182-9	35323-35338	disease-related	_
182-10	35339-35349	mechanisms	_
182-11	35350-35354	will	_
182-12	35355-35365	contribute	_
182-13	35366-35368	to	_
182-14	35369-35372	the	_
182-15	35373-35384	development	_
182-16	35385-35387	of	_
182-17	35388-35402	individualized	_
182-18	35403-35413	treatments	_
182-19	35413-35414	.	_

#Text=Electronic supplementary material
#Text=Electronic supplementary material
#Text=Supplementary Information accompanies this paper at (10.1038/s41398-018-0184-9).
183-1	35415-35425	Electronic	_
183-2	35426-35439	supplementary	_
183-3	35440-35448	material	_
183-4	35449-35459	Electronic	_
183-5	35460-35473	supplementary	_
183-6	35474-35482	material	_
183-7	35483-35496	Supplementary	_
183-8	35497-35508	Information	_
183-9	35509-35520	accompanies	_
183-10	35521-35525	this	_
183-11	35526-35531	paper	_
183-12	35532-35534	at	_
183-13	35535-35536	(	_
183-14	35536-35543	10.1038	_
183-15	35543-35544	/	_
183-16	35544-35550	s41398	_
183-17	35550-35551	-	_
183-18	35551-35554	018	_
183-19	35554-35555	-	_
183-20	35555-35559	0184	_
183-21	35559-35560	-	_
183-22	35560-35561	9	_
183-23	35561-35562	)	_
183-24	35562-35563	.	_

#Text=Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
184-1	35564-35575	Publisher's	_
184-2	35576-35580	note	_
184-3	35580-35581	:	_
184-4	35582-35590	Springer	_
184-5	35591-35597	Nature	_
184-6	35598-35605	remains	_
184-7	35606-35613	neutral	_
184-8	35614-35618	with	_
184-9	35619-35625	regard	_
184-10	35626-35628	to	_
184-11	35629-35643	jurisdictional	_
184-12	35644-35650	claims	_
184-13	35651-35653	in	_
184-14	35654-35663	published	_
184-15	35664-35668	maps	_
184-16	35669-35672	and	_
184-17	35673-35686	institutional	_
184-18	35687-35699	affiliations	_
184-19	35699-35700	.	_

#Text=Conflict of interest
#Text=The authors declare that they have no conflict of interest.
185-1	35701-35709	Conflict	_
185-2	35710-35712	of	_
185-3	35713-35721	interest	_
185-4	35722-35725	The	_
185-5	35726-35733	authors	_
185-6	35734-35741	declare	_
185-7	35742-35746	that	_
185-8	35747-35751	they	_
185-9	35752-35756	have	_
185-10	35757-35759	no	_
185-11	35760-35768	conflict	_
185-12	35769-35771	of	_
185-13	35772-35780	interest	_
185-14	35780-35781	.	_

#Text=References
#Text=The surgeon general’s facing addiction report: an historic document for health care
#Text=Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on alcohol and related conditions
#Text=Focus on: comorbid mental health disorders
#Text=Comorbidity and disease burden in the national comorbidity survey replication (NCS‐R)
#Text=Genomic priorities and public health
#Text=Overview of the genetics of alcohol use disorder
#Text=A Swedish national twin study of lifetime major depression
#Text=Overview of the genetics of major depressive disorder
#Text=Genetic risk variants associated with comorbid alcohol dependence and major depression
#Text=Identification of 15 genetic loci associated with risk of major depression in individuals of European descent
#Text=MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and/or cerebral malformations
#Text=MEF2C haploinsufficiency features consistent hyperkinesis, variable epilepsy, and has a role in dorsal and ventral neuronal developmental pathways
#Text=Depression, stress, and anhedonia: toward a synthesis and integrated model
#Text=Anhedonia in substance use disorders: a systematic review of its nature, course and clinical correlates
#Text=Reward and punishment processing in depression
#Text=Disruption of reward processing in addiction: an image-based meta-analysis of functional magnetic resonance imaging studies
#Text=Different neural correlates of reward expectation and reward expectation error in the putamen and caudate nucleus during stimulus-action-reward association learning
#Text=Reward-related responses in the human striatum
#Text=Dissociable roles of ventral and dorsal striatum in instrumental conditioning
#Text=Ventral striatal activation during reward anticipation correlates with impulsivity in alcoholics
#Text=Dysfunction of reward processing correlates with alcohol craving in detoxified alcoholics
#Text=Reduced caudate and nucleus accumbens response to rewards in unmedicated individuals with major depressive disorder
#Text=Altered neural reward and loss processing and prediction error signalling in depression
#Text=Nosologic comparisons of DSM-IV and DSM-5 alcohol and drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III
#Text=FMRI visualization of brain activity during a monetary incentive delay task
#Text=AFNI: software for analysis and visualization of functional magnetic resonance neuroimages
#Text=
#Text=A region of mesial prefrontal cortex tracks monetarily rewarding outcomes: characterization with rapid event-related fMRI
#Text=Anticipation of increasing monetary reward selectively recruits nucleus accumbens
#Text=Addictions biology: haplotype-based analysis for 130 candidate genes on a single array
#Text=A genome-wide association study of alcohol dependence
#Text=Enhanced striatal responses during expectancy coding in alcohol dependence
#Text=Parallel neural networks for learning sequential procedures
#Text=Discovering imaging endophenotypes for major depression
#Text=MEF2C, a transcription factor that facilitates learning and memory by negative regulation of synapse numbers and function
#Text=Severe mental retardation, seizures, and hypotonia due to deletions of MEF2C
#Text=Mutations in MEF2C from the 5q14.3q15 microdeletion syndrome region are a frequent cause of severe mental retardation and diminish MECP2 and CDKL5 expression
#Text=Refining the phenotype associated with MEF2C point mutations
#Text=A novel microdeletion syndrome involving 5q14. 3-q15: clinical and molecular cytogenetic characterization of three patients
#Text=Wray N.
186-1	35782-35792	References	_
186-2	35793-35796	The	_
186-3	35797-35804	surgeon	_
186-4	35805-35812	general	_
186-5	35812-35813	’	_
186-6	35813-35814	s	_
186-7	35815-35821	facing	_
186-8	35822-35831	addiction	_
186-9	35832-35838	report	_
186-10	35838-35839	:	_
186-11	35840-35842	an	_
186-12	35843-35851	historic	_
186-13	35852-35860	document	_
186-14	35861-35864	for	_
186-15	35865-35871	health	_
186-16	35872-35876	care	_
186-17	35877-35887	Prevalence	_
186-18	35888-35891	and	_
186-19	35892-35905	co-occurrence	_
186-20	35906-35908	of	_
186-21	35909-35918	substance	_
186-22	35919-35922	use	_
186-23	35923-35932	disorders	_
186-24	35933-35936	and	_
186-25	35937-35948	independent	_
186-26	35949-35953	mood	_
186-27	35954-35957	and	_
186-28	35958-35965	anxiety	_
186-29	35966-35975	disorders	_
186-30	35975-35976	:	_
186-31	35977-35984	results	_
186-32	35985-35989	from	_
186-33	35990-35993	the	_
186-34	35994-36002	National	_
186-35	36003-36016	Epidemiologic	_
186-36	36017-36023	Survey	_
186-37	36024-36026	on	_
186-38	36027-36034	alcohol	_
186-39	36035-36038	and	_
186-40	36039-36046	related	_
186-41	36047-36057	conditions	_
186-42	36058-36063	Focus	_
186-43	36064-36066	on	_
186-44	36066-36067	:	_
186-45	36068-36076	comorbid	_
186-46	36077-36083	mental	_
186-47	36084-36090	health	_
186-48	36091-36100	disorders	_
186-49	36101-36112	Comorbidity	_
186-50	36113-36116	and	_
186-51	36117-36124	disease	_
186-52	36125-36131	burden	_
186-53	36132-36134	in	_
186-54	36135-36138	the	_
186-55	36139-36147	national	_
186-56	36148-36159	comorbidity	_
186-57	36160-36166	survey	_
186-58	36167-36178	replication	_
186-59	36179-36180	(	_
186-60	36180-36185	NCS‐R	_
186-61	36185-36186	)	_
186-62	36187-36194	Genomic	_
186-63	36195-36205	priorities	_
186-64	36206-36209	and	_
186-65	36210-36216	public	_
186-66	36217-36223	health	_
186-67	36224-36232	Overview	_
186-68	36233-36235	of	_
186-69	36236-36239	the	_
186-70	36240-36248	genetics	_
186-71	36249-36251	of	_
186-72	36252-36259	alcohol	_
186-73	36260-36263	use	_
186-74	36264-36272	disorder	_
186-75	36273-36274	A	_
186-76	36275-36282	Swedish	_
186-77	36283-36291	national	_
186-78	36292-36296	twin	_
186-79	36297-36302	study	_
186-80	36303-36305	of	_
186-81	36306-36314	lifetime	_
186-82	36315-36320	major	_
186-83	36321-36331	depression	_
186-84	36332-36340	Overview	_
186-85	36341-36343	of	_
186-86	36344-36347	the	_
186-87	36348-36356	genetics	_
186-88	36357-36359	of	_
186-89	36360-36365	major	_
186-90	36366-36376	depressive	_
186-91	36377-36385	disorder	_
186-92	36386-36393	Genetic	_
186-93	36394-36398	risk	_
186-94	36399-36407	variants	_
186-95	36408-36418	associated	_
186-96	36419-36423	with	_
186-97	36424-36432	comorbid	_
186-98	36433-36440	alcohol	_
186-99	36441-36451	dependence	_
186-100	36452-36455	and	_
186-101	36456-36461	major	_
186-102	36462-36472	depression	_
186-103	36473-36487	Identification	_
186-104	36488-36490	of	_
186-105	36491-36493	15	_
186-106	36494-36501	genetic	_
186-107	36502-36506	loci	_
186-108	36507-36517	associated	_
186-109	36518-36522	with	_
186-110	36523-36527	risk	_
186-111	36528-36530	of	_
186-112	36531-36536	major	_
186-113	36537-36547	depression	_
186-114	36548-36550	in	_
186-115	36551-36562	individuals	_
186-116	36563-36565	of	_
186-117	36566-36574	European	_
186-118	36575-36582	descent	_
186-119	36583-36588	MEF2C	_
186-120	36589-36607	haploinsufficiency	_
186-121	36608-36614	caused	_
186-122	36615-36617	by	_
186-123	36618-36624	either	_
186-124	36625-36638	microdeletion	_
186-125	36639-36641	of	_
186-126	36642-36645	the	_
186-127	36646-36652	5q14.3	_
186-128	36653-36659	region	_
186-129	36660-36662	or	_
186-130	36663-36671	mutation	_
186-131	36672-36674	is	_
186-132	36675-36686	responsible	_
186-133	36687-36690	for	_
186-134	36691-36697	severe	_
186-135	36698-36704	mental	_
186-136	36705-36716	retardation	_
186-137	36717-36721	with	_
186-138	36722-36733	stereotypic	_
186-139	36734-36743	movements	_
186-140	36743-36744	,	_
186-141	36745-36753	epilepsy	_
186-142	36754-36757	and	_
186-143	36757-36758	/	_
186-144	36758-36760	or	_
186-145	36761-36769	cerebral	_
186-146	36770-36783	malformations	_
186-147	36784-36789	MEF2C	_
186-148	36790-36808	haploinsufficiency	_
186-149	36809-36817	features	_
186-150	36818-36828	consistent	_
186-151	36829-36841	hyperkinesis	_
186-152	36841-36842	,	_
186-153	36843-36851	variable	_
186-154	36852-36860	epilepsy	_
186-155	36860-36861	,	_
186-156	36862-36865	and	_
186-157	36866-36869	has	_
186-158	36870-36871	a	_
186-159	36872-36876	role	_
186-160	36877-36879	in	_
186-161	36880-36886	dorsal	_
186-162	36887-36890	and	_
186-163	36891-36898	ventral	_
186-164	36899-36907	neuronal	_
186-165	36908-36921	developmental	_
186-166	36922-36930	pathways	_
186-167	36931-36941	Depression	_
186-168	36941-36942	,	_
186-169	36943-36949	stress	_
186-170	36949-36950	,	_
186-171	36951-36954	and	_
186-172	36955-36964	anhedonia	_
186-173	36964-36965	:	_
186-174	36966-36972	toward	_
186-175	36973-36974	a	_
186-176	36975-36984	synthesis	_
186-177	36985-36988	and	_
186-178	36989-36999	integrated	_
186-179	37000-37005	model	_
186-180	37006-37015	Anhedonia	_
186-181	37016-37018	in	_
186-182	37019-37028	substance	_
186-183	37029-37032	use	_
186-184	37033-37042	disorders	_
186-185	37042-37043	:	_
186-186	37044-37045	a	_
186-187	37046-37056	systematic	_
186-188	37057-37063	review	_
186-189	37064-37066	of	_
186-190	37067-37070	its	_
186-191	37071-37077	nature	_
186-192	37077-37078	,	_
186-193	37079-37085	course	_
186-194	37086-37089	and	_
186-195	37090-37098	clinical	_
186-196	37099-37109	correlates	_
186-197	37110-37116	Reward	_
186-198	37117-37120	and	_
186-199	37121-37131	punishment	_
186-200	37132-37142	processing	_
186-201	37143-37145	in	_
186-202	37146-37156	depression	_
186-203	37157-37167	Disruption	_
186-204	37168-37170	of	_
186-205	37171-37177	reward	_
186-206	37178-37188	processing	_
186-207	37189-37191	in	_
186-208	37192-37201	addiction	_
186-209	37201-37202	:	_
186-210	37203-37205	an	_
186-211	37206-37217	image-based	_
186-212	37218-37231	meta-analysis	_
186-213	37232-37234	of	_
186-214	37235-37245	functional	_
186-215	37246-37254	magnetic	_
186-216	37255-37264	resonance	_
186-217	37265-37272	imaging	_
186-218	37273-37280	studies	_
186-219	37281-37290	Different	_
186-220	37291-37297	neural	_
186-221	37298-37308	correlates	_
186-222	37309-37311	of	_
186-223	37312-37318	reward	_
186-224	37319-37330	expectation	_
186-225	37331-37334	and	_
186-226	37335-37341	reward	_
186-227	37342-37353	expectation	_
186-228	37354-37359	error	_
186-229	37360-37362	in	_
186-230	37363-37366	the	_
186-231	37367-37374	putamen	_
186-232	37375-37378	and	_
186-233	37379-37386	caudate	_
186-234	37387-37394	nucleus	_
186-235	37395-37401	during	_
186-236	37402-37424	stimulus-action-reward	_
186-237	37425-37436	association	_
186-238	37437-37445	learning	_
186-239	37446-37460	Reward-related	_
186-240	37461-37470	responses	_
186-241	37471-37473	in	_
186-242	37474-37477	the	_
186-243	37478-37483	human	_
186-244	37484-37492	striatum	_
186-245	37493-37504	Dissociable	_
186-246	37505-37510	roles	_
186-247	37511-37513	of	_
186-248	37514-37521	ventral	_
186-249	37522-37525	and	_
186-250	37526-37532	dorsal	_
186-251	37533-37541	striatum	_
186-252	37542-37544	in	_
186-253	37545-37557	instrumental	_
186-254	37558-37570	conditioning	_
186-255	37571-37578	Ventral	_
186-256	37579-37587	striatal	_
186-257	37588-37598	activation	_
186-258	37599-37605	during	_
186-259	37606-37612	reward	_
186-260	37613-37625	anticipation	_
186-261	37626-37636	correlates	_
186-262	37637-37641	with	_
186-263	37642-37653	impulsivity	_
186-264	37654-37656	in	_
186-265	37657-37667	alcoholics	_
186-266	37668-37679	Dysfunction	_
186-267	37680-37682	of	_
186-268	37683-37689	reward	_
186-269	37690-37700	processing	_
186-270	37701-37711	correlates	_
186-271	37712-37716	with	_
186-272	37717-37724	alcohol	_
186-273	37725-37732	craving	_
186-274	37733-37735	in	_
186-275	37736-37746	detoxified	_
186-276	37747-37757	alcoholics	_
186-277	37758-37765	Reduced	_
186-278	37766-37773	caudate	_
186-279	37774-37777	and	_
186-280	37778-37785	nucleus	_
186-281	37786-37795	accumbens	_
186-282	37796-37804	response	_
186-283	37805-37807	to	_
186-284	37808-37815	rewards	_
186-285	37816-37818	in	_
186-286	37819-37830	unmedicated	_
186-287	37831-37842	individuals	_
186-288	37843-37847	with	_
186-289	37848-37853	major	_
186-290	37854-37864	depressive	_
186-291	37865-37873	disorder	_
186-292	37874-37881	Altered	_
186-293	37882-37888	neural	_
186-294	37889-37895	reward	_
186-295	37896-37899	and	_
186-296	37900-37904	loss	_
186-297	37905-37915	processing	_
186-298	37916-37919	and	_
186-299	37920-37930	prediction	_
186-300	37931-37936	error	_
186-301	37937-37947	signalling	_
186-302	37948-37950	in	_
186-303	37951-37961	depression	_
186-304	37962-37971	Nosologic	_
186-305	37972-37983	comparisons	_
186-306	37984-37986	of	_
186-307	37987-37993	DSM-IV	_
186-308	37994-37997	and	_
186-309	37998-38001	DSM	_
186-310	38001-38002	-	_
186-311	38002-38003	5	_
186-312	38004-38011	alcohol	_
186-313	38012-38015	and	_
186-314	38016-38020	drug	_
186-315	38021-38024	use	_
186-316	38025-38034	disorders	_
186-317	38034-38035	:	_
186-318	38036-38043	results	_
186-319	38044-38048	from	_
186-320	38049-38052	the	_
186-321	38053-38061	National	_
186-322	38062-38075	Epidemiologic	_
186-323	38076-38082	Survey	_
186-324	38083-38085	on	_
186-325	38086-38093	Alcohol	_
186-326	38094-38097	and	_
186-327	38098-38105	Related	_
186-328	38106-38120	Conditions-III	_
186-329	38121-38125	FMRI	_
186-330	38126-38139	visualization	_
186-331	38140-38142	of	_
186-332	38143-38148	brain	_
186-333	38149-38157	activity	_
186-334	38158-38164	during	_
186-335	38165-38166	a	_
186-336	38167-38175	monetary	_
186-337	38176-38185	incentive	_
186-338	38186-38191	delay	_
186-339	38192-38196	task	_
186-340	38197-38201	AFNI	_
186-341	38201-38202	:	_
186-342	38203-38211	software	_
186-343	38212-38215	for	_
186-344	38216-38224	analysis	_
186-345	38225-38228	and	_
186-346	38229-38242	visualization	_
186-347	38243-38245	of	_
186-348	38246-38256	functional	_
186-349	38257-38265	magnetic	_
186-350	38266-38275	resonance	_
186-351	38276-38287	neuroimages	_
186-352	38289-38290	A	_
186-353	38291-38297	region	_
186-354	38298-38300	of	_
186-355	38301-38307	mesial	_
186-356	38308-38318	prefrontal	_
186-357	38319-38325	cortex	_
186-358	38326-38332	tracks	_
186-359	38333-38343	monetarily	_
186-360	38344-38353	rewarding	_
186-361	38354-38362	outcomes	_
186-362	38362-38363	:	_
186-363	38364-38380	characterization	_
186-364	38381-38385	with	_
186-365	38386-38391	rapid	_
186-366	38392-38405	event-related	_
186-367	38406-38410	fMRI	_
186-368	38411-38423	Anticipation	_
186-369	38424-38426	of	_
186-370	38427-38437	increasing	_
186-371	38438-38446	monetary	_
186-372	38447-38453	reward	_
186-373	38454-38465	selectively	_
186-374	38466-38474	recruits	_
186-375	38475-38482	nucleus	_
186-376	38483-38492	accumbens	_
186-377	38493-38503	Addictions	_
186-378	38504-38511	biology	_
186-379	38511-38512	:	_
186-380	38513-38528	haplotype-based	_
186-381	38529-38537	analysis	_
186-382	38538-38541	for	_
186-383	38542-38545	130	_
186-384	38546-38555	candidate	_
186-385	38556-38561	genes	_
186-386	38562-38564	on	_
186-387	38565-38566	a	_
186-388	38567-38573	single	_
186-389	38574-38579	array	_
186-390	38580-38581	A	_
186-391	38582-38593	genome-wide	_
186-392	38594-38605	association	_
186-393	38606-38611	study	_
186-394	38612-38614	of	_
186-395	38615-38622	alcohol	_
186-396	38623-38633	dependence	_
186-397	38634-38642	Enhanced	_
186-398	38643-38651	striatal	_
186-399	38652-38661	responses	_
186-400	38662-38668	during	_
186-401	38669-38679	expectancy	_
186-402	38680-38686	coding	_
186-403	38687-38689	in	_
186-404	38690-38697	alcohol	_
186-405	38698-38708	dependence	_
186-406	38709-38717	Parallel	_
186-407	38718-38724	neural	_
186-408	38725-38733	networks	_
186-409	38734-38737	for	_
186-410	38738-38746	learning	_
186-411	38747-38757	sequential	_
186-412	38758-38768	procedures	_
186-413	38769-38780	Discovering	_
186-414	38781-38788	imaging	_
186-415	38789-38803	endophenotypes	_
186-416	38804-38807	for	_
186-417	38808-38813	major	_
186-418	38814-38824	depression	_
186-419	38825-38830	MEF2C	_
186-420	38830-38831	,	_
186-421	38832-38833	a	_
186-422	38834-38847	transcription	_
186-423	38848-38854	factor	_
186-424	38855-38859	that	_
186-425	38860-38871	facilitates	_
186-426	38872-38880	learning	_
186-427	38881-38884	and	_
186-428	38885-38891	memory	_
186-429	38892-38894	by	_
186-430	38895-38903	negative	_
186-431	38904-38914	regulation	_
186-432	38915-38917	of	_
186-433	38918-38925	synapse	_
186-434	38926-38933	numbers	_
186-435	38934-38937	and	_
186-436	38938-38946	function	_
186-437	38947-38953	Severe	_
186-438	38954-38960	mental	_
186-439	38961-38972	retardation	_
186-440	38972-38973	,	_
186-441	38974-38982	seizures	_
186-442	38982-38983	,	_
186-443	38984-38987	and	_
186-444	38988-38997	hypotonia	_
186-445	38998-39001	due	_
186-446	39002-39004	to	_
186-447	39005-39014	deletions	_
186-448	39015-39017	of	_
186-449	39018-39023	MEF2C	_
186-450	39024-39033	Mutations	_
186-451	39034-39036	in	_
186-452	39037-39042	MEF2C	_
186-453	39043-39047	from	_
186-454	39048-39051	the	_
186-455	39052-39061	5q14.3q15	_
186-456	39062-39075	microdeletion	_
186-457	39076-39084	syndrome	_
186-458	39085-39091	region	_
186-459	39092-39095	are	_
186-460	39096-39097	a	_
186-461	39098-39106	frequent	_
186-462	39107-39112	cause	_
186-463	39113-39115	of	_
186-464	39116-39122	severe	_
186-465	39123-39129	mental	_
186-466	39130-39141	retardation	_
186-467	39142-39145	and	_
186-468	39146-39154	diminish	_
186-469	39155-39160	MECP2	_
186-470	39161-39164	and	_
186-471	39165-39170	CDKL5	_
186-472	39171-39181	expression	_
186-473	39182-39190	Refining	_
186-474	39191-39194	the	_
186-475	39195-39204	phenotype	_
186-476	39205-39215	associated	_
186-477	39216-39220	with	_
186-478	39221-39226	MEF2C	_
186-479	39227-39232	point	_
186-480	39233-39242	mutations	_
186-481	39243-39244	A	_
186-482	39245-39250	novel	_
186-483	39251-39264	microdeletion	_
186-484	39265-39273	syndrome	_
186-485	39274-39283	involving	_
186-486	39284-39288	5q14	_
186-487	39288-39289	.	_
186-488	39290-39291	3	_
186-489	39291-39292	-	_
186-490	39292-39295	q15	_
186-491	39295-39296	:	_
186-492	39297-39305	clinical	_
186-493	39306-39309	and	_
186-494	39310-39319	molecular	_
186-495	39320-39331	cytogenetic	_
186-496	39332-39348	characterization	_
186-497	39349-39351	of	_
186-498	39352-39357	three	_
186-499	39358-39366	patients	_
186-500	39367-39371	Wray	_
186-501	39372-39373	N	_
186-502	39373-39374	.	_

#Text=R., et al.
187-1	39375-39376	R	_
187-2	39376-39377	.	_
187-3	39377-39378	,	_
187-4	39379-39381	et	_
187-5	39382-39384	al	_
187-6	39384-39385	.	_

#Text=Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression.
188-1	39386-39397	Genome-wide	_
188-2	39398-39409	association	_
188-3	39410-39418	analyses	_
188-4	39419-39427	identify	_
188-5	39428-39430	44	_
188-6	39431-39435	risk	_
188-7	39436-39444	variants	_
188-8	39445-39448	and	_
188-9	39449-39455	refine	_
188-10	39456-39459	the	_
188-11	39460-39467	genetic	_
188-12	39468-39480	architecture	_
188-13	39481-39483	of	_
188-14	39484-39489	major	_
188-15	39490-39500	depression	_
188-16	39500-39501	.	_

#Text=Nat Genet. 50, 668 (2018).
189-1	39502-39505	Nat	_
189-2	39506-39511	Genet	_
189-3	39511-39512	.	_
189-4	39513-39515	50	_
189-5	39515-39516	,	_
189-6	39517-39520	668	_
189-7	39521-39522	(	_
189-8	39522-39526	2018	_
189-9	39526-39527	)	_
189-10	39527-39528	.	_

#Text=Research review: polygenic methods and their application to psychiatric traits
190-1	39529-39537	Research	_
190-2	39538-39544	review	_
190-3	39544-39545	:	_
190-4	39546-39555	polygenic	_
190-5	39556-39563	methods	_
190-6	39564-39567	and	_
190-7	39568-39573	their	_
190-8	39574-39585	application	_
190-9	39586-39588	to	_
190-10	39589-39600	psychiatric	_
190-11	39601-39607	traits	_
